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ABSTRACT
Over-expression of parathyroid hormone-related protein (PTHrP) is commonly
described in a number of different forms of cancer and it has been suggested that this
over-expression leads to tissue-specific metastasis whereby primary tumours have a
propensity to metastasise to one particular organ e.g. breast tumours metastasise to
bone whereas gastrointestinal tumours favour the liver. The aim of my PhD was to
examine the role PTHrP plays in cancer cell adhesion to the extracellular matrix
(ECM), to explore a mechanism of action and to elucidate any tissue-specific
differences to explain the apparent partiality during metastasis.
In order to do this a small interfering RNA was used to silence PTHrP gene
expression and expression vectors containing cDNA for PTHrP were used to create
several stable PTHrP over-expressing cell lines. Analysis of cell adhesion revealed
that regulating PTHrP expression caused changes in adhesion to the ECM proteins
collagen type I, fibronectin and laminin in breast cancer cell lines. However
although cell adhesion of gastrointestinal cancer cell lines to collagen type I and
fibronectin was similarly affected, adhesion to laminin was unchanged by variations
in PTHrP expression.
The cell adhesion molecules integrins were subsequently investigated for their role
LQ37+U3PHGLDWHGFHOODGKHVLRQ,QWHJULQVDUHKHWHURGLPHUVFRPSRVHGRIDQĮDQGȕ
subunit and to date 24 different subunits have been identified. Each unique
combination of subunits results in a different ligand specificity, which includes
collagens, fibronectin and laminin. Analysis of integrin gene and protein expression
in over-expressing cell lines and in cells where PTHrP had been silenced it was
xv
possible to demonstrate a link between expression of PTHrP and a number of
different integrin subunits. One of the more significant findings was the observation
WKDW WKH LQWHJULQ VXEXQLW Į6 changed in parallel with PTHrP in breast but not
gastrointestinal cancer cell lines. As laminin is a ligand for this subunit these results
correlate with the results previously described regarding this ECM protein.
The effects of PTHrP appeared to be mediated at the transcriptional rather than the
translational level so integrin transcriptional activity was investigated using a
reporter vector containing the coding region for firefly luciferase. The integrin
VXEXQLWĮ5 had shown a link to PTHrP expression in both breast and gastrointestinal
cell lines so the promoter region for this subunit was inserted into the reporter vector,
which was then transiently transfected into PTHrP over-expressing cell lines.
Subsequent examination of luciferase activity revealed a significant increase in
promoter activity compared with control thus implicating PTHrP as a key factor in
integrin gene transcription.
The results described here suggest that PTHrP increases cell adhesion by inducing
integrin gene transcription and is able to regulate expression of different subunits in
different tissues thereby encouraging tissue-specific metastasis.
Chapter 1:
Introduction
21.1 PARATHYROID HORMONE-RELATED PROTEIN
Malignancy associated hypercalcemia, which is characterised by a life threatening
increase in serum calcium, can be subdivided into humoral hypercalcemia of
malignancy (HHM) and local osteolytic hypercalcemia (LOH). LOH is the result of
a local paracrine factor and is the product of bone invasion and destruction by
tumour cells. HHM on the other hand is the product of a circulating hormone which
induces osteoclastic bone resorption (Broadus, Goltzman et al. 1985).
Parathyroid hormone (PTH) is a circulating hormone and was originally thought to
be the cause of HHM due to its ability to induce bone resorption; however
radioimmunoassay tests on patient sera did not show evidence of an increase in PTH
expression (Powell, Singer et al. 1973). The real culprit was identified in 1987 by a
group at the University of Melbourne.
Using a cell line established from a hypercalcemic patient with a squamous cell
carcinoma of the bronchus, Moseley et al purified an 18kDa protein from the cell
medium with “PTH-like activity”, which the authors defined as an ability to
stimulate cAMP production. Due to its biological similarities with PTH it was
named PTH-related protein (PTHrP). When they subsequently analysed the amino
acid sequence they found a high degree of homology with the human PTH sequence,
with 8 out of the first 13 residues being identical. Using PTH antagonists they were
also able to inhibit the cAMP production induced by the conditioned media
(Moseley, Kubota et al. 1987).
3Around the same time, PTHrP was also isolated from breast and renal carcinomas
(Burtis, Wu et al. 1987; Strewler, Stern et al. 1987) and in the studies that followed it
was confirmed that PTHrP was not only responsible for HHM but also played a
paracrine role in causing LOH.
HHM is an important health issue in patients with cancer as it develops suddenly and
reduces a patient’s survival rate; Coleman and Rubens reported that patients with
breast carcinoma, bone metastases and hypercalcemia had a median survival time of
three months survival compared with 24 months for patients with bone metastases
alone. Similarly the development of hypercalcemia in colon cancer reduces patient
median survival to only 35 days (Coleman and Rubens 1987; Lortholary, Cadeau et
al. 1999).
HHM is most commonly found in breast cancer patients with bone metastases as the
majority of these are osteolytic (Sloan and Anderson 2002). Although rare, HHM
has been identified in other forms of cancer such as colon cancer, as described by
Lortholary et al who reported two cases of HHM in colorectal carcinoma patients
and also reviewed the literature and found only nine other reported cases, the first of
which was described in 1963. In both of their reported cases Lorthorlary et al found
an increase in serum PTHrP along with PTHrP immunoreactivity in the primary
tumour however there were no detectable bone metastases. Likewise Sidler et al
showed that the gene for PTHrP was amplified in colon cancer and coincided with
the appearance of hypercalcemia (Sidler, Alpert et al. 1996; Lortholary, Cadeau et al.
1999).
4Other reported cases of HHM associated with PTHrP include a germ cell tumour
(Sorscher 2004), a pancreatic tumour (Miraliakbari, Asa et al. 1992) and cancer of
the penis (Akashi, Fuse et al. 2002).
It can thus be seen that an increase in PTHrP expression brings about additional
complications in cancer patients and as such should be taken into account when
considering patient prognosis.
1.1.1 PTHrP Gene Structure
PTHrP was cloned by several groups shortly after it had been isolated (Suva,
Winslow et al. 1987; Mangin, Webb et al. 1988). The PTHrP gene can be found on
the short arm of chromosome 12 and consists of over 15 kilobases of genomic DNA
(Yasuda T, Banville D et al. 1989); it is comprised of nine exons, includes three
different promoters and alternative splicing allows the production of three different
isoforms. Splicing of exon VI to VII produces an isoform 139 amino acids (aa) in
length, splicing of exon VI to IX produces a 141aa isoform and VI to VIII a 173aa
isoform. Exon V encodes the pre-pro region of PTHrP and consequently products of
exons V and VI can be found in all three PTHrP transcripts (Wysolmerski and
Broadus 1994). The structure of PTHrP can be seen in Figure 1.1.
PTHrP has three promoters which suggests a degree of transcriptional control; P1 is
an upstream TATA promoter (5’ to exon I), P2 is a GC-rich promoter (5’ to exon III)
while P3 is a downstream TATA promoter (5’ to exon IV) (Southby J, O'Keeffe LM
et al. 1995). It is believed that any of the three different isoforms can use any of
these three promoters and to date there has been no evidence to suggest otherwise.
5Figure 1.1 – Diagrammatic representation of PTHrP gene structure (Southby,
O'Keeffe et al. 1995)
1.1.2 Regulation of PTHrP Gene Expression
PTHrP mRNA is unstable, with a half-life between 30 and 120 minutes. A number
of factors have been shown to regulate PTHrP expression, including epidermal
JURZWKIDFWRU(*)+HDWK6RXWKE\HWDODQGWUDQVIRUPLQJJURZWKIDFWRUȕ
7*)ȕ+HDWK6RXWKE\HWDO6HOOHUV&DSHQHWDO
An increase in EGF receptor expression has been shown in a number of solid
tumours, including breast, head-and-neck, non-small-cell lung (NSCLC), renal,
ovarian and colon. This increase has been linked to an increase in cell growth and
tumour invasion; in NSCLC, over-expression of the EGF receptor correlates with a
high level of metastasis and tumour growth. As such it has been linked with poor
prognosis (Herbst 2004).
Heath et al identified a role for EGF in regulating PTHrP expression using an
immortalised keratinocyte cell line which constitutively produces PTHrP. EGF
stimulation caused a dose-dependent increase in PTHrP protein and gene expression,
which the authors went on to show was mediated via an increase in PTHrP
transcription (Heath, Southby et al. 1995).
P1 P2 P3 +1 ATG 139 aa 173 aa 141aa
Coding Region Untranslated Region
6Heath et al also examined PTHrP mRNA stability using the transcriptional inhibitors
actinomycin D and 5,6-dichlororibofuranosyl benzimidazole (DRB) to demonstrate
that EGF causes a post-transcriptional increase in mRNA stability and proposed that
these effects were mediated by post-translational modifications such as
phosphorylation or intracellular translocation. In addition they examined expression
of the three different PTHrP isoforms and showed that while EGF increased the
stability of PTHrP (1-139) and (1-173), PTHrP (1-141) was unaffected.
Tovar Sepulveda and Falzon also used EGF to induce a dose-dependent increase in
PTHrP mRNA and secretion rate in a prostate cancer cell line. They went on to
demonstrate that the active metabolite of vitamin D (1,25(OH)2D3) is able to produce
a dose-dependent decrease in PTHrP mRNA and secretion in prostate tumour cells
but not in normal prostate epithelial cells. Further analysis revealed that both EGF
and 1,25(OH)2D3 were able to induce their responses at the transcriptional level
(Tovar Sepulveda and Falzon 2002).
7*)ȕKDVEHHQGHVFULEHGDVDWXPRXUVXSSUHVVRULQHDUO\VWDJHVRIFDQFHUKRZHYHU
its over-expression has also been identified in a number of cancers including breast,
FRORQSURVWDWHJDVWULFOXQJDQGOLYHU $VZLWK(*)7*)ȕKDVEHHQOLQNHGZLWK
DQ LQFUHDVH LQ PHWDVWDVLV IROORZLQJ VWXGLHV GHPRQVWUDWLQJ DQ LQFUHDVH LQ 7*)ȕ
H[SUHVVLRQ FRPSDUHG ZLWK WKH SULPDU\ WXPRXU  7*)ȕ KDV WKXV EHHQ OLQNHG ZLWK
poor prognosis (Glick 2004).
7Sellers et alXVHG7*)ȕWRLQFUHDVHWKHKDOIOLIHRI37+U3LQVTXDPRXVFDUFLQRPD
cells and using DRB demonstrated that, as with EGF, this increase in mRNA half-
life appears to be mediated post-transcriptionally. (Sellers, Capen et al. 2002).
The same group expanded this study to include a human lung cancer cell line, a
human keratinocyte cell line and a canine oral squamous carcinoma cell line and
demonstrated a significant increase in PTHrP mRNA levels and PTHrP secretion
IROORZLQJ7*)ȕWUHDWPHQW:KHQWKHLQGLYLGXDOLVRIRUPVZHUHH[DPLQHGWKHUHZDV
an increase in the half-life of PTHrP (1-141) but no change in the half-lives of (1-
139) or (1-173) (Sellers, Luchin et al. 2004).
Heath et al demonstrated that EGF increased stability of PTHrP (1-139) but not (1-
141) and Sellers et al VKRZHG WKDW 7*)ȕ KDG WKH RSSRVLWH HIIHFW ZKHUHE\ LW
increased stability of PTHrP (1-141) but not (1-139). Although the coding regions
of these two isoforms are very similar, differing by only two amino acids, the 3’
untranslated regions (UTR) of their mRNAs are very different thus allowing
different proteins to regulate their expression. Sellers et al (2004) carried out a U.V.
cross-linking assay and found that different proteins bind to the two 3’-UTRs: the
proteins bound to the 3’-UTR (1-141) had a mobility of 64, 80 and 100 kDa whereas
those bound to (1-139) had a mobility of 45 and 55kDa. Although Sellers et al were
unable to identify the proteins they hypothesised that they were involved in mRNA
GHJUDGDWLRQDQGWKDW7*)ȕDQG(*)DUHDEOHWRUHJXODWHGLIIHUHQW¶875ELQGLQJ
proteins, thereby affecting the stability of the different isoforms.
81.1.3 Post-Translational Products
Once PTHrP has been translated, its pre-pro sequence directs the mature protein to
the endoplasmic reticulum where it undergoes endoproteolytic processing. Figure
1.2 shows that this post-translational processing results in the generation of a number
of daughter peptides, which are believed to have a variety of functions in normal
homeostasis (see Section 1.2) (Orloff, Reddy et al. 1994).
Figure 1.2 The post-translational products of PTHrP and the known cellular
functions of the various daughter peptides (Sourbier and Massfelder 2006)
These daughter peptides can either enter transport vesicles (constitutive pathway) or
secretory granules (regulated secretory pathway) depending on the cell type
(Plawner, Philbrick et al. 1995). It has been shown that the secretory peptides are
more predominant than the intact unprocessed peptide (Philbrick, Wysolmerski et al.
1996) and it is thought that each has a separate physiological function mediated
through individual receptors; a distinct receptor for PTHrP (37-106) was proposed in
91990 (Ellis, Adam et al. 1990) but to date no such receptor has been isolated and at
present only one receptor has been shown to respond to PTHrP.
1.1.4 A Receptor for PTHrP
The type I PTH/PTHrP receptor, or PTH1R, is a class II G-protein coupled receptor
(Gardella and Juppner 2001). Following agonist binding there is a rapid
desensitisation of PTH1R before internalisation of the agonist-receptor complex
(Huang, Chen et al. 1995). As can be seen in Figure 1.3, PTH1R is coupled to Gs,
Gq/G11 and Gi which allows it to increase cAMP, IP3 and Ca
2+
(Guo, Chung et al.
2002).
Figure 1.3 – Diagrammatic representation of the signalling pathways of PTH1R
following ligand binding
pAdenylate
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PTH and PTHrP exhibit 70% homology within their first 13 amino acids and this
allows them to share PTH1R, with only the first 34 amino acids of PTHrP being
necessary for activation (Wysolmerski and Stewart 1998).
1.2 FUNCTIONS OF PTHrP IN NORMAL HOMEOSTASIS
Although initially discovered as a tumour product, PTHrP has subsequently been
linked with a number of normal physiological functions in a variety of organ systems
and these can be divided into three main roles: growth & development, calcium
transport and homeostasis, and smooth muscle regulation.
1.2.1 Growth & Development
Studies by Kronenberg et al using knockout mice have shown that the PTHrP gene is
necessary for foetal development. Their study showed that PTHrP (-/-) mice survive
until birth but die soon after, which prompted Kronenberg et al to suggest that the
mother is able to provide enough PTHrP for the foetus by way of the placenta in
order to complete gestation, but unable to produce its own supply the offspring
quickly dies (Kronenberg, Lanske et al. 1998).
Amling et al found that PTHrP is able to increase expression of the anti-apoptotic
protein Bcl-2 in growth plate chondrocytes, which results in slowed differentiation
thereby allowing bone to grow and elongate normally (Amling, Neff et al. 1997).
PTHrP has also been linked to mammary development and branching morphogenesis
of the tubes comprising the mammary gland (Wysolmerski, Philbrick et al. 1998).
11
Furthermore, it has been found in the pregnant and lactating breast along with the
milk which is subsequently generated (Lam, Thomas et al. 2000).
In addition, PTHrP has been shown to affect the development of skin, teeth,
cartilage, extraembryonic endoderm, smooth muscle, the central nervous system and
the placenta (Nissenson 2000).
1.2.2 Calcium Transport & Homeostasis
Expression of PTH1R is high in both the bone and kidney where it is utilised by
PTH and PTHrP to maintain calcium homeostasis (Wysolmerski and Stewart 1998).
In bone this is achieved through the stimulation of the cytokine RANKL, which in
turn binds to its receptor RANK located on osteoclast progenitor cells. This results
in the differentiation of these cells into mature osteoclasts, which then go on to cause
bone resorption and calcium release (Mannstadt, Juppner et al. 1999). In the kidney
PTH1R activation results in a decrease in calcium excretion in the distal tubule, an
increase in phosphorus excretion and an increase in cAMP production and excretion
(Martin, Allan et al. 1989).
As only the first 34 amino acids of PTHrP are necessary for activation of PTH1R the
amino-terminal peptide is generally believed to be responsible for maintaining
calcium homeostasis however it is thought that the mid-region peptide is responsible
for stimulating trans-placental calcium transport. Using PTHrP and PTH1R
knockout mice, Kovacs et al demonstrated that the PTHrP gene is necessary for
maintaining calcium transport across the placenta and consequently maintaining
calcium concentration in the foetus. Using exogenous PTHrP the authors were able
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to reverse the impaired calcium transport using PTHrP (1-86) and (67-86). As
PTHrP (1-34) was unable to affect calcium transport across the placenta it was
subsequently suggested that the mid-region peptide is responsible for transplacental
calcium transport. Also, as PTHrP (1-34) is necessary for activation of PTH1R, this
study suggests that another receptor specific to the mid-region may be involved
(Kovacs, Lanske et al. 1996).
While PTHrP (1-34) appears to stimulate osteoclast activation and bone resorption,
the carboxyl-terminal of PTHrP appears to have the opposite effect. Fenton et al
initially described the use of PTHrP (107-139) as an inhibitor of resorption in rat
ostoclasts but went on to isolate this inhibitory activity to the (107-111) region and
labelled it osteostatin (Fenton, Kemp et al. 1991).
1.2.3 Smooth Muscle and Endothelial Cells
Expression of the PTHrP gene has been shown in every smooth muscle cell and
mechanical stretch stimulates PTHrP expression in the stomach, uterus and bladder
where, by acting in a paracrine fashion, it can induce smooth muscle relaxation
(Macica and Broadus 2003).
Kalinowski et al used PTHrP (1-34) to demonstrate that PTHrP was able to induce
smooth muscle relaxation by stimulating nitric oxide (NO) production in endothelial
cells. Using PTH (1-34) and PTHrP (1-34) antagonists, they were able to reduce NO
release, which led the authors to propose that NO release was mediated via PTH1R
activation. This theory was further supported when cAMP/protein kinase A
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blockade reduced PTH (1-34) and PTHrP (1-34) stimulated NO release
(Kalkinowski, Dobrucki et al. 2001).
PTHrP was identified as a neuroprotective vascular peptide when Funk et al showed
for the first time that PTHrP is able to act within the central nervous system. The
authors demonstrated an increase in PTHrP gene expression in the brain subsequent
to focal ischemia. Prior to this increase there was an increase in TNF-D and IL-1E;
two cytokines which are able to generate an increase in PTHrP expression during
inflammation. The authors suggested that the increase in PTHrP expression resulted
in an increase in cerebral blood flow by acting in a vasodilatory manner (Funk,
Migliati et al. 2003).
PTHrP expression has also been shown in coronary endothelial cells where it appears
to reduce coronary resistance. Not only have Grohe et al shown this to be the case
but they were also able to show that this occurs in a sex-specific manner: they
demonstrated that ventricular expression of PTHrP is higher in female rats than
males, which results in a greater reduction in coronary resistance in the females. The
authors proposed that this may explain the sex-specific differences observed in
cardiovascular disease (Grohe, van Eickels et al. 2004).
1.3 A ROLE FOR PTHrP DURING CANCER
Since its initial discovery PTHrP has been associated with cancer. Following its
initial identification as the key factor in HHM it is now frequently associated with
increased metastasis and tumour cell proliferation. PTHrP has been linked with
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numerous cancers however to date it is still most commonly associated with breast
cancer.
1.3.1 Breast Cancer
Breast cancer is the most commonly diagnosed cancer among women and is the
second leading cause of cancer death after lung cancer. It has previously been
discussed that PTHrP plays a role in normal breast development and physiology (see
Section 1.2); however it also appears to be involved in breast cancer metastasis to
bone.
Southby et al examined the immunohistochemical localisation of PTHrP in 102
breast tumour samples and 60% of these samples stained positively for PTHrP (1-
34). The authors also described stronger staining in the invasive element of the
tumour compared with the intraductal component whilst there was no expression of
PTHrP in normal epithelium. Furthermore, during follow up studies Southby et al
found that five of the seven patients who had developed bone metastases exhibited
positive PTHrP staining in the primary tumours. Additionally, all four patients who
had developed nonosseous metastases showed no PTHrP staining in their primary
tumours. In spite of this the authors observed that positive PTHrP staining did
actually correlate with a favourable prognostic index (Southby, Kissin et al. 1990).
The same group expanded this study and considered not only bone metastases from
breast cancer but metastases in the lung, skin, liver, brain and pericardium. 31
secondary tumours were analysed for PTHrP expression and in 13 bone metastases,
12 stained positively for PTHrP. There were a limited number of samples for the
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other metastases, for example only four lung samples were obtained, two of which
stained positively, and only one liver sample, which did not appear to express
PTHrP. From this study it is not possible to make any general conclusions regarding
the role of PTHrP in metastasis overall, however it is possible to conclude from this
study that breast cancer does have a penchant to metastasise to bone and this appears
to be linked with PTHrP expression (Powell, Southby et al. 1991). Furthermore,
Southby and colleague’s studies have led them to suggest that PTHrP could be used
as a guide to predict which patients may develop bone metastases and in doing so
highlight which patients may benefit from an anti-bone metastasis treatment.
Bundred et al also demonstrated a link between PTHrP and hypercalcaemia in breast
cancer using an antibody raised against PTHrP (37-67) to examine PTHrP
cytoplasmic staining in patients with breast cancer. In early breast cancer patients,
who were normocalcaemic and exhibited no signs of metastasis, positive PTHrP
staining was shown in 52% (55/106) of patients. In normocalcaemic patients who
developed metastases primarily in the bone, 65% (47/72) exhibited positive PTHrP
staining in the primary tumours. Despite being normocalcaemic at the outset of the
study, 25 of the patients in this latter group developed hypercalcaemia; 88% (22/25)
of these tumours stained positively for PTHrP whereas only 53% (25/47) of the
remaining normocalcaemic patients did so (p=0.004). This study also examined
plasma levels of PTHrP: the protein was detectable in only 9% (5/57) of patients
who were diagnosed with early breast cancer and had no discernible metastases,
whereas it was detected in 36% (10/28) of the patients who did have identifiable
bone metastases. Further analysis showed that PTHrP was detected in 92% (12/13)
of patients with hypercalcaemia and that the observed concentrations were
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significantly greater than in those with early breast cancer (p<0.01) or who were
normocalcaemic but had developed bone metastases (p<0.001). The results from
this study clearly demonstrates a link between PTHrP, hypercalcaemia and
metastases (Bundred, Ratcliffe et al. 1991).
However the premise that PTHrP aids tumour progression was challenged in a study
by Henderson et al who examined PTHrP expression as well as patient prognosis
and found that the presence of PTHrP actually improves survival in breast cancer
patients. Using 367 samples from patients with operable invasive primary breast
cancer, PTHrP was detected in 72% of samples. When they compared the 5-year
survival rate of patients with PTHrP positive and negative tumours, there was an
87% survival rate in patients with PTHrP positive tumours compared with 73% in
patients with PTHrP negative tumours (p=0.002). They also found that the presence
of PTHrP in the primary tumour resulted in a reduced likelihood of the development
of bone metastases after surgery with 27% of PTHrP negative patients developing
bone metastases compared with only 12% of PTHrP positive patients (p=0.001).
Similarly the PTHrP negative patients had an increased likelihood to develop lung
metastases with 22% developing metastases compared with only 8% of PTHrP
positive patients (p<0.001) (Henderson, Danks et al. 2001).
A number of studies have also examined PTH1R expression in breast cancer. For
example, Linforth and colleagues examined co-expression of PTHrP and PTH1R and
related it to patient survival in breast cancer patients. Using samples of malignant
breast carcinoma tissue and bone metastases, receptor expression was examined
using two different techniques. Using RT-PCR, 51% of early breast cancer tissue
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and 84% of bone metastases were shown to express PTH1R. These results
correlated well with those obtained by in situ hybridisation where 49% of breast
cancer tissue and 80% of bone metastases exhibited PTH1R expression. When they
examined PTHrP using immunohistochemistry they showed expression in 68% of
breast carcinoma samples and 100% of bone metastases. Co-expression of the
protein and receptor were found in 32% of breast carcinoma and 81% of bone
metastases. When they looked at patient survival they showed that positive
expression of either PTH1R and PTHrP was linked to a decrease in disease-free
survival and that positive expression of PTH1R was linked with a significant
decrease in overall survival. Examination of the 5-year mortality rates in patients
with primary breast cancer who demonstrated either positive or negative PTH1R
expression was 29% and 12%, respectively and this was a significant decrease in
survival for the PTH1R positive patients (p=0.003). PTHrP expression alone did not
appear to significantly affect overall survival however co-expression with PTH1R
resulted in a 5-year mortality rate of 32%, which was greater than positive PTH1R
expression alone. The 5-year mortality for patients who were both PTH1R and
PTHrP negative was shown to be 6% (Linforth, Anderson et al. 2002).
Hoey et al also linked over-expression of the PTHrP receptor with breast cancer
bone metastases. Their study found that PTH1R was evident in 58% of primary
breast cancers compared with 85% of bone metastases. Their study included only 67
primary tumour samples and 13 bone metastases; as such their results were not
statistically significant however they do suggest a link between receptor expression
and bone metastases. The authors postulated that receptor over-expression might
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provide a growth advantage by aiding autocrine PTHrP signalling (Hoey, Sanderson
et al. 2003).
Most studies examining the role of PTHrP in breast cancer have examined
expression of PTHrP (1-34) and the majority have demonstrated an increase in
proliferation and metastasis. Luparello et al however examined the mid-region of
PTHrP and demonstrated the ability of PTHrP (38-94)-amide to inhibit growth and
invasion in several breast cancer cell lines by slowing cell proliferation and
enhancing cell death. Luparello et al have also shown that PTHrP (67-86)-amide is
able to inhibit breast cancer cell growth and invasion through matrigel as well as
reducing tumorigenesis in vivo. These opposing effects may be the result of
activation of separate receptors however until a mid-region receptor is cloned it will
not be possible to verify this hypothesis (Luparello, Romanotto et al. 2001;
Luparello, Sirchia et al. 2003).
An increase in PTHrP expression in breast cancer cells metastasising to bone
explains the increase in bone resorption mediated by osteoclast activation which
would lead to an increase in serum calcium and may possibly aid tumour cells in
their ability to form metastases by allowing them to be substituted for bone; however
it does not explain the apparent preferential ability of these cells to form the initial
metastases.
1.3.2 Gastrointestinal (GI) Cancer
GI cancer encompasses cancer of the stomach, colon and pancreas. Colorectal
cancer is the second most common cause of death from cancer in both males and
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females, whilst pancreatic and gastric cancer are the sixth and seventh causes of
death from cancer, respectively
(http://info.cancerresearchuk.org/cancerstats/mortality/cancerdeaths/).
Shortly after its discovery, PTHrP expression was demonstrated in a wide variety of
normal and neoplastic endocrine tissues, including endocrine tumours within the GI
tract and pancreas (Asa, Henderson et al. 1990). Nishihara et al looked at PTHrP
expression in human colorectal tumours and found elevated PTHrP mRNA and
protein expression in the majority of patients. Similarly the intensity of PTHrP
staining correlated with increasing grades of Dukes’ classification; however neither
PTHrP gene or protein expression was detected in either adenomas or adjacent non-
neoplastic mucosae of the colon. (Nishihara, Ito et al. 1999).
Abdeen et al looked at 14 cases of gastric adenocarinoma and stained tumour
specimens with antibodies directed towards both PTHrP (1-34) and (109-141). 13 of
the 14 cases stained positively using an antibody directed against the carboxyl-
terminal, where it was localised to the cytoplasm, whilst none of the cases stained
positively using the antibody directed towards the amino-terminal. Significantly,
PTHrP expression was not detected in ten control cases of normal gastric tissue
using either antibody, which led the authors to suggest that PTHrP plays a role in
growth regulation of gastric adenocarcinoma (Abdeen, Pandol et al. 1995).
In a larger study Alipov et al examined 92 cases of gastric carcinoma and using an
antibody raised against PTHrP (38-64) showed positive staining in 77.2% of cases,
which was again localised to the cytoplasm. This study also showed that cases
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exhibiting deeper invasion along with poorly differentiated adenocarcinomas stained
stronger for PTHrP expression than early invasive or well-differentiated
adenocarcinomas. Furthermore, cases with lymph node metastasis showed stronger
staining at both the primary site as well as in metastatic cells, compared with cases
with no evidence of metastasis (Alipov, Ito et al. 1997).
The same group investigated a case of gastric cancer with multiple metastases
including bone, kidney, liver, lung, spleen, peritioneum, retro-peritoneum and lymph
nodes. Using an antibody raised against the (38-64) region of PTHrP, they found
PTHrP present in the tumour cells of the metastases but not in the cells of the
primary tumour thus providing further evidence for a role of PTHrP in GI tumour
progression (Ito, Nakashima et al. 1997).
As mentioned earlier, PTHrP has also been found within the pancreas with
expression often described in a number of cell lines derived from pancreatic tumours
as well as in the tumours themselves (Drucker, Asa et al. 1989; Miraliakbari, Asa et
al. 1992; Bouvet, Nardin et al. 2001). Furthermore it has been shown that exogenous
PTHrP (1-34) is able to stimulate DNA synthesis in isolated rat pancreatic islets,
which express PTHrP and PTH1R, whereas exogenous mid-region and carboxyl-
terminal PTHrP had no effect on DNA synthesis (Villaneuva-Penacarrillo, Cancelas
et al. 1999).
As with other cell types several studies have described the induction of PTHrP over-
expression resulting in an increase in the resistance of pancreatic E cells to apoptosis
(Cebrian, Garcia-Ocana et al. 2002; Hastings, Quintana et al. 2003).
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1.3.3 Other Forms of Cancer
There are several examples of increased PTHrP expression in a variety of other
cancers, where it is commonly discovered in association with hypercalcemia.
For example PTHrP over-expression is often demonstrated in prostate cancer cells
when compared with normal cells and this over-expression has been linked to a
propensity to metastasise to bone (Deftos 2000).
Iddon et al examined PTHrP expression in benign and malignant prostate tumours;
PTHrP (1-34) expression was detected in 68% of benign prostate tumours compared
with 95% of the malignant tumours (p=0.04). The authors also examined bone
metastases and only 50% of the bone metastases from prostate cancer produced
PTHrP (1-34) compared with 100% of bone metastases from other primary cancers.
There was no apparent correlation between the Gleason grade and the intensity of
staining and there appeared to be greater PTHrP expression in the primary tumours
rather than in the metastases. These results suggest that PTHrP may not be linked to
prostate tumour progression directly but rather facilitates metastases through some
other means. However, of the metastases that did not stain for PTHrP (1-34), two
out of seven did stain for PTHrP (37-67), which suggests that these results may in
fact underestimate PTHrP expression in the metastases (Iddon, Bundred et al. 2000).
Another study examining the role of PTHrP in prostate cancer again used paired
primary tumours and metastases. Not only was PTHrP gene expression shown in 13
out of the 14 primary tumours and in all 14 metastases but there was also an increase
in PTHrP expression in the metastases. These results contradict the findings by
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Iddon et al however as this study examined gene expression and Iddon et al protein
expression, no direct comparison can be made (Bryden, Hoyland et al. 2002).
Studies by Asadi et al using a human prostate adenocarcinoma cell line showed that
exogenous PTHrP (1-34) produced an increase in ornithine decarboxylase (ODC)
mRNA expresson. ODC is the rate-limiting enzyme in polyamine biosynthesis and
cell cycle progression and these results suggest that by increasing ODC PTHrP
mediates its effects on cell growth by playing an indirect role in cell cycle
progression (Asadi, Faraj et al. 2001).
Brandt et al examined PTHrP expression in each of the major lung cancer cell types,
including cell lines derived from lung tumours and each one expressed and secreted
PTHrP. Furthermore, Richard et al found a 131-fold increase in PTHrP gene
expression in lung carcinoma compared with normal adjacent tissue (Brandt, Burton
et al. 1991; Richard, Luchin et al. 2003).
Hastings and colleagues also examined the role of PTHrP in lung cancer and they
published several reports in close succession. In one study they used exogenous
PTHrP (1-34) and (67-86) to reveal a pro-apoptotic role in type II pneumocytes
whilst in subsequent studies they have demonstrated that PTHrP (1-34) and (140-
173) are able to protect lung cancer cells from apoptosis (Hastings, Araiza et al.
2003; Hastings, Quintana et al. 2003).
In the first study Hastings et al used alveolar type II epithelial cells isolated from
healthy rats. Apoptosis was induced by ultraviolet exposure and treatment with
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PTHrP (1-34) or (67-86) caused a further increase in apoptosis. In an ensuing study
they used a squamous bronchial lung carcinoma cell line and again induced
apoptosis by ultraviolet radiation. In this study the authors showed that pre-
treatment with PTHrP (1-34) and (140-173) protected the lung cancer cells against
apoptosis by causing a dose-dependent decrease in caspase-3, -8 and -9 activity as
well as loss of cell mass and nuclear condensation. PTHrP (38-64), (67-86) and
(107-139) meanwhile had no effect on caspase-3 activity. The results from these two
studies appear to suggest that in normal cells PTHrP is pro-apoptotic whereas in
tumour cells it switches to an anti-apoptotic factor.
The wide-spread actions of PTHrP are once again demonstrated by a report of
increased PTHrP expression in penile cancer with bone metastases and
hypercalcemia (Akashi, Fuse et al. 2002) and a reported case of a gallbladder
carcinoma with liver metastasis where the patient not only exhibited increased serum
PTHrP levels but also hypercalcemia (Ebinuma, Imaeda et al. 2002).
By considering all of these studies, which are summarised in Table 1.1, it appears
that PTHrP is not only over-expressed in a variety of different tumours but that in
doing so it is able to increase tumour cell proliferation and possibly plays a role in
tumour progression. Despite the numerous studies investigating such a role, a
mechanism of action has yet to be elucidated.
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Table 1.1 Summary of PTHrPs links with tumour metastasis
Site of Primary
Tumour
Site of Metastasis Study
Breast Bone
Southby, Kissin et al. 1990
Powell, Southby et al. 1991
Bundred, Ratcliffe et al. 1991
Linforth, Anderson et al. 2002
GI
Lymph Node Alipov, Ito et al. 1997
Bone, Kidney, Liver, Lung,
Spleen, Peritoneum, Retro-
peritoneum, Lymph Node
Ito, Nakashima et al. 1997
Prostate Bone
Deftos 2000
Iddon, Bundred et al. 2000
Bryden, Hoyland et al. 2002
Penile Bone Akashi, Fuse et al. 2002
Gallbladder Liver Ebinuma, Imaeda et al. 2002
1.4 NUCLEAR ACTIONS OF PTHrP
Under normal conditions PTHrP does not enter the circulation but acts either in an
autocrine, paracrine or intracine manner. This is demonstrated by the low serum
level of PTHrP as well as the close association of the protein and receptor mRNA in
breast and colon tumours (Carron, Fraser et al. 1997). The exact intracrine functions
of PTHrP are unknown however they appear to be dependent on its presence within
the cell nucleus.
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1.4.1 Nuclear Transport
PTHrP is directed to the nucleus by a bipartite nuclear localisation sequence (NLS)
within its mid-region. Figure 1.4 demonstrates the location of the two multibasic
clusters at residues (88-91) and (102-106) (Nguyen and Karaplis 1998).
Figure 1.4 –Mid-region section of PTHrP, including the bipartite nuclear
localisation sequence and the threonine which when phosphorylated prevents
nuclear entry
Most proteins require a carrier in order to enter the nucleus and PTHrP is no
exception; the NLS of PTHrP binds to the nucleo-cytoplasmic transport factor
importin E. Importin E in turn docks to the nuclear pore complex, which makes a
hole in the double membrane of the nucleus and facilitates entry of PTHrP-importin
E. Following RanGTP binding, PTHrP dissociates from importin E and is free to act
within the nucleus (Lam, Thomas et al. 2000).
Lam et al were able to localise PTHrP expression to the cytoplasm by deleting amino
acids (67-94), the residues which bind to importin E. However although PTHrP (1-
87) does not contain a functional NLS it has been identified within the nucleus.
Furthermore, using fluorescently labelled PTHrP it has been shown that exogenous
61
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PTHrP is also able to localise to the nucleus in a PTH1R dependent manner: Watson
et al demonstrated nuclear localisation of PTH1R in a number of rat tissues
including the liver, kidney, gut, uterus and ovaries which led them to propose the
presence of a bipartite NLS in the carboxyl-terminal tail of PTH1R which could bind
to importin D. It is known that ligand binding results in internalisation of the
PTHrP/PTH1R complex and if the receptor does indeed contain an NLS this may
offer a mechanism by which amino-terminal PTHrP can enter the nucleus
independent of the mid-region. However if this is indeed the case, deletion of amino
acids (67-94) shouldn’t confine PTHrP to the cytoplasm. Further investigation will
be necessary to establish the precise mechanism of PTHrP’s nuclear translocation
(Watson, Fraher et al. 2000; Lam, Thomas et al. 2002).
1.4.2 Actions of Nuclear PTHrP
Once in the nucleus it has been shown that PTHrP can affect the cell cycle and also
inhibit apoptosis. For example, Tovar Sepulveda and Falzon used plasmids
encoding for either intact PTHrP or PTHrP without the bipartite NLS to examine the
actions of nuclear PTHrP. Over-expression of intact PTHrP in prostate cancer cells
caused a two to three fold increase in proliferation compared with vector control
containing cells, however where the NLS had been removed cell growth was slower
compared with vector control. When the cell-cycle profile of the transfected cells
was examined, the vector-control containing cells were mainly in the G1 phase whilst
over-expression of intact PTHrP resulted in an increase in the number of cells within
the G2+M phase, correlating with the apparent increase in cell growth. In cells over-
expressing PTHrP minus the NLS there was an increase in the number of cells
within the G2+M phase compared with vector control, however this number was
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significantly lower compared with cells where PTHrP was able to enter the nucleus
and conflicts with their cell growth results (Tovar Sepulveda and Falzon 2002).
Lam et al also demonstrated that PTHrP localises to the nucleus in a cell-cycle
dependent manner. Using a keratinocyte cell line, they demonstrated that PTHrP
expression was greatest during the G2+M phase of the cell cycle and showed that
during mitosis PTHrP moves from the nucleolus to the cytoplasm. By
phosphorylating PTHrP at Thr
85
(Figure 1.4) the cyclin-dependent kinases cdc2 and
cdk2 prevent nuclear entry and the mutation of Thr
85
results in cytoplasmic
accumulation. Lam and colleagues have shown that this phosphorylation activity
begins during S phase and peaks during G2+M, resulting in localisation of PTHrP to
the cytoplasm during these phases. They went on to show the presence of PTHrP
within the nucleus during G1 and therefore suggested that once PTHrP has
stimulated cell growth it is no longer required within the nucleus and is consequently
exported to the cytoplasm (Lam, Olsen et al. 1997; Lam, House et al. 1999).
Henderson et al examined the effect of a functional NLS on the survival of
chondrocytes during apoptotic conditions. Using plasmids encoding either intact
PTHrP or PTHrP where the NLS had been deleted, the authors were able to
demonstrate that the ability of PTHrP to translocate to the nucleus leads to an
increase in the resistance of chondrocytic cells to serum deprivation. They also
showed the presence of endogenous PTHrP in the nucleolus, an area of the nucleus
where transcription and processing of ribosomal RNA occurs (Henderson, Amizuka
et al. 1995).
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In a similar study Aarts et al also showed that chondrocytes expressing PTHrP with
an intact NLS were protected from serum deprivation. They showed that PTHrP (1-
34) is insufficient to protect cells from apoptosis and consequently suggested that
protection from apoptosis is unrelated to the cellular responses produced via PTH1R
and may be mediated through a separate mechanism such as a mid-region receptor
(Aarts, Davidson et al. 2001).
In an earlier study Aarts et al demonstrated that PTHrP can bind to poly(G)
homopolymeric RNA, GC-rich double-stranded RNA and total cellular RNA located
in the nucleus. Again using expression vectors encoding either full-length PTHrP or
PTHrP without the NLS the authors were able to show that transient transfection of
these vectors resulted in binding of PTHrP to cellular RNA and homopolymeric
RNA only in the vector containing the NLS. Not only did they demonstrate that this
interaction is of high relative affinity but they identified a core motif within PTHrP
which is necessary for the binding: GxKKxxK. This motif is conserved among other
RNA-binding proteins, adding further weight to the suggestion that PTHrP interacts
with RNA (Aarts, Levy et al. 1999).
When Tovar Sepulveda et al expanded their earlier study to examine the effect of
PTHrP on apoptosis they used breast cancer cells to demonstrate that the removal of
the NLS leads to an increase in apoptosis in serum-deprived cells, which is
consistent with Henderson et al’s study. The ratio of anti-apoptotic to pro-apoptotic
proteins determines whether or not a cell will undergo apoptosis and Tovar
Sepulveda et al were able to demonstrate that by entering the nucleus PTHrP
increases the ratio of the anti-apoptotic proteins Bcl-2 and Bcl-xL to the pro-
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apoptotic protein Bax, thus leading to a decrease in apoptosis. Tovar Sepulveda et
al’s results are consistent with Amling et al’s study which demonstrated that PTHrP
is upstream of Bcl-2 in chondrocytes (Tovar Sepulveda, Shen et al. 2002).
The effect of nuclear PTHrP appears to be distinct from extracellular PTHrP. For
example in vascular smooth muscle cells (VSMC) nuclear PTHrP promotes cell
proliferation whereas extracellular PTHrP inhibits cell proliferation (Massfelder,
Dann et al. 1997). These results led the authors to suggest that by translocating to
the nucleus, PTHrP does not affect cell proliferation directly but rather decreases the
amount of PTHrP available for secretion, thereby reducing the levels of extracellular
PTHrP and diminishing its inhibitory effects.
Each of these studies has shown a role for PTHrP as a mitogen or as an anti-
apoptotic protein. However, PTHrP’s NLS is homologous to the NLS of
transcription factors such as c-jun, c-fos and p53, which has led to the suggestion
that PTHrP may also be a transcription factor (Fiaschi-Taesch and Stewart 2003). It
has also been hypothesised that intracrine PTHrP may be related to the ability of
cells to adhere to the extracellular matrix.
1.5 TUMOUR PROGRESSION
1.5.1 Metastasis
Metastasis is a key element in tumour progression and as such it is a complex, highly
regulated process which begins with a cancer cell dissociating from the primary
tumour and entering the blood system, Figure 1.5.
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Figure 1.5 Diagrammatic representation of metastasis including dissociation
from the primary tumour, migration to a distant organ resulting in metastasis
formation (Yoneda and Hiraga 2005)
However, once a tumour cell has entered the blood system, it is not simply a case of
forming a secondary tumour in the nearest available organ; Paget’s ‘seed and soil’
hypothesis suggests that a cancer cell (the ‘seed’) is only able to metastasise to an
area (the ‘soil’) which has an advantageous microenvironment in which the cell may
grow (Paget 1889).
The lung is the most common organ for metastasis, followed by the liver and bone
(Mollabashy and Scarborough 2000). Melanoma and osteosarcoma tend to
metastasise to the lung, while the liver is the most common site for colorectal cancer
metastases. Breast cancer cells meanwhile metastasise predominantly to bone, as do
tumour cells from the prostate, thyroid and kidney.
Bone metastasis is characterised by osteolysis, diffuse osteopenia and osteoblastic
lesions (Mundy 1997). Bone metastases are a serious complication, not only due to
the pain, nerve compression and ease of bone fracturing, but because the cancer can
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no longer be cured and palliative therapy is the only option available. It is common
for patients dying from lung and breast cancer to have bone metastases and as
previously mentioned these are commonly associated with an increase in PTHrP
expression.
1.5.2 The Extracellular Matrix
Tumour invasion into the extracellular matrix (ECM), including cell attachment to
and penetration of the ECM, is a crucial step during metastasis. The ECM provides
a structural framework around the cell and cellular interaction with the ECM also
provides signals for cell growth and differentiation. There are many components of
the ECM including collagens, fibronectin and laminin.
Collagenous proteins comprise the major component of the ECM. There are many
types of collagen, however collagen type I is the most abundant type isolated from
connective tissues such as skin, bone, tendon and liver. It is found in the interstitial
matrix and provides these tissues with tensile strength, for example collagen type I
makes up >95% of the bone matrix (Kiefer and Farach-Carson 2001).
Fibronectin is expressed in the basement membrane and plays a role in cell adhesion,
embryonic cell migration and wound healing. Laminin is also expressed in the
basement membrane and plays an important role in development, differentiation and
migration. Both fibronectin and laminin are able to bind to cell surface receptors
such as integrins and other extracellular molecules (Hay 1991).
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In addition to growth and differentiation, binding to the ECM also aids cell
migration. Changes in cell-cell adhesion and cell-matrix adhesion play an important
role in the development of metastases with tumour cells using integrin-ECM
interactions as a foothold during migration. Additionally several studies have shown
that the ECM appears to stimulate tumour cell proliferation (Adams and Watt 1993;
Ohtaka, Watanabe et al. 1996; Stupack and Cheresh 2002).
For example Kiefer and Farach-Carson examined the effect of collagen type I on
proliferation of PC3 prostate carcinoma cells. After 24 hours of growth cells grown
on collagen type I demonstrated a >50% increase in proliferation compared with
cells grown in uncoated wells (Kiefer and Farach-Carson 2001).
Binding of cells to the ECM is mediated by cell surface receptors, the most abundant
group being the transmembrane cell adhesion receptors, integrins.
1.5.3 Integrins
Integrins were first discovered in 1987 by Richard Hynes and have since been shown
to have universal expression where they play a key role in cell-cell, cell-ECM and
cell-soluble ligand interaction (Hynes 1987; Brakebusch, Bouvard et al. 2002).
These receptors are heterodimers composed of non-covalently linked D and E
subunits. To date 18 D and eight E subunits have been discovered and these can
form 24 different DE heterodimers with each different D and E subunit combination
creating a different integrin-ligand interaction (Hynes 2002). Figure 1.6 shows the
different combinations of the D and E subunits which have been identified to date.
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Figure 1.6 Diagrammatic representation of the different D and E subunit
interactions
Table 1.2 also shows the different DE heterodimers along with their integrin/ligand
interactions and demonstrates that each ECM not only has multiple receptors but that
each integrin receptor can bind to multiple ligands.
E3
E5
E6 E8
DIIb
D6
D5
D7
D8
D9
D4D3
D11
DV
D10
D1
D2
E7
DE
E4
E2
DXDM
DL Dd
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Table 1.2 Integrin-Ligand Interactions
Beta Subunit Alpha Subunit Ligand
E1
D1 Collagens, Laminin
D2 Collagens, Laminin
D3 Collagens, Laminin, Fibronectins
D5 Fibronectin
D7 Laminin
D8 Fibronectin
D10 Collagens
D11 Collagens
E1 & E7 D4 Fibronectin
E1 & E4 D6 Laminin
E1, E3 & E6 DV Fibronectin
E3 DIIb Collagens, Fibronectin
E8 DV Collagens, Laminin, Fibronectin
Integrins have a large extracellular domain, a membrane spanning domain and a
short cytoplasmic tail. The extracellular domain mediates cell-matrix and cell-cell
interaction while the cytoplasmic tails interact with the cytoskeleton, consequently
integrin signal transduction is bidirectional and provides a link between the
cytoskeleton and ECM (Brakebusch, Bouvard et al. 2002).
Integrins are involved in multiple cellular functions including migration, cell cycle
progression and programmed cell death. For example, during migration integrins
interact with the actin cytoskeleton to stimulate cell contraction, integrin inactivation
allows cell detachment from the substratum and integrins are also able to activate
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extracellular matrix-degrading enzymes. It has been suggested that lower levels of
integrin expression may protect against invasion and metastasis while a threshold
level of integrin expression is required for cell invasion (Brakebusch, Bouvard et al.
2002).
Stallmach et al demonstrated a reduction in expression of a number of integrin
subunits in colorectal carcinoma samples compared with normal, including D2, D3,
D5, D6, E1 and E4. They also found that D3 and D5 expression was reduced in
adenomas and absent in most colonic carcinoma suggesting a link between a
reduction in integrin expression and tumour progression. In another study Stallmach
et al showed D5 expression in normal colonic epithelial cells but no expression in
adenomas and carcinomas. Using HT29 clones which were positive and negative for
this integrin, the authors were able to show that the ability of the positive cells to
form tumours in nude mice was reduced compared with the negative cells. They
proposed that expression of D5E1 mediates the deposit of fibronectin at the epithelial-
mesenchymal interface, thus providing a line of defence between the tumour cells
and the host tissue and concluded that loss of D5E1is part of tumour progression
(Stallmach, von Lampe et al. 1992; Stallmach, Von Lampe et al. 1994).
However, Stallmach et al’s studies conflict with a number of other studies which
have linked an increase in D5E1 expression to cancer progression. For example
Koretz examined integrin expression in a number of colon cancer cell lines and
found D5 expression in each of the five cell lines examined. Furthermore, Gong et al
demonstrated a positive correlation between D5E1 expression and the level of
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invasiveness in a number of colon cancer cell lines (Koretz, Bruderlein et al. 1994;
Gong, Want et al. 1997).
A number of studies have induced D5E1 over-expression and linked expression of
this receptor to cell death. For example, Lee and Juliano used human colon
carcinoma cells to show that over-expression of D5E1 results in an increased
resistance to apoptosis induced by serum deprivation, aspirin, staurosporine and
etoposide. Further analysis revealed that this effect was mediated via an increase in
PKB/Akt activity (Lee and Juliano 2000).
Zhang et al also demonstrated a role for D5E1 expression in cell survival. Using the
Chinese hamster ovary cell line they induced over-expression of D5E1 and DVE1.
When they subsequently examined cell growth on fibronectin in the absence of
serum, fewer than 25% of cells over-expressing D5E1 became apoptotic whereas
nearly 100% of cells over-expressing DVE1 displayed evidence of apoptosis. Both
cell lines became apoptotic when grown on poly(lysine)-coated dishes or uncoated
cell culture dishes. The authors concluded that the D5E1 interaction with fibronectin
protected the cells from apoptosis and went on to show an increase in the ratio of
Bcl-2/Bax gene expression in D5E1 over-expressing cells (Zhang, Vuori et al. 1995).
A number of integrins are also thought to aid breast cancer progression. For
example the DVE3 heterodimer has frequently been shown to play an important role
during breast cancer metastasis to bone as it is highly expressed by both osteoclasts
and the metastasising tumour cells. Expression of this integrin has also been linked
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to the aggressiveness of breast cancer and as such has been used as a prognostic
marker (Gasparini, Brooks et al. 1998). In addition, Pecheur et al demonstrated that
breast cancer cells over-expressing DVE3 exhibited an increase in the incidence and
number of osteolytic lesions compared with control cells, with bone metastases
visible at day 21 in all of the mice inoculated with DVE3 cells, compared with 60-
66% of control animals (Pecheur, Peyruchaud et al. 2002).
Expression of the integrin subunit D6 has also been linked with breast cancer. For
example, one study compared patient survival with D6 expression in 119 patients
where there was evidence of cell invasion into the basement membrane. These
patients were classified into four groups based on whether they had low (grade I and
II), intermediate (grade III) or high (grade IV) D6 expressing tumours and
examination of patient survival time revealed a link between increased D6 expression
and decreased patient survival time. All of the patients classified as having low D6
expression survived whilst mortality increased to 11% in patients with intermediate
expression and to 19% in patients with a high percentage of D6 expressing cells.
Furthermore, in 34 cases where distant metastases were observed 30 were shown to
express high levels of D6 (the other four were classified as having low D6
expression), which led the authors to conclude that D6 expression was linked to
metastasis and patient survival. They also suggested that D6 expression could be
used as a prognostic marker (Friedrichs, Ruiz et al. 1995).
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In a similar study Wewer et al examined the role of D6E1 expression in tumour
progression by eliminating expression of D6E1 in a breast cancer cell line. The
authors then used these cells to induce breast tumours in mice and found that the
tumours formed by cells lacking D6E1 demonstrated reduced growth and an increase
in apoptosis compared with mice given D6E1-expressing cells. Similarly these
control cells formed lung metastases which the D6E1-null cells were unable to do.
The authors concluded that D6E1 plays an important role in tumorigenesis and
tumour cell survival in distant organs (Wewer, Shaw et al. 1997).
It is not only breast and colorectal cancer where integrin expression has been shown
to be increased; Liu et al used a cDNA microarray to examine expression of 17
integrin genes and demonstrated an up-regulation of all 17 in hepatocellular
carcinoma (HCC) compared with adjacent normal liver tissue. Similarly Masumoto
et al investigated the relationship between E1 integrin activity and HCC invasion and
showed that cells with high E1 integrin activity are more invasive than cells with
lower activity (Liu, Jiang et al. 2002; Masumoto, Arao et al. 1999).
Secondary tumours increase the number of complications in cancer and are the
leading cause of cancer related morbidity and mortality. The studies described here
demonstrate the importance of integrins in tumour progression and as a result several
groups have attempted to block integrin activity in an effort to inhibit tumour
progression. For example an inhibitor of D5E1 has been used in conjunction with
continuous 5-FU infusion to reduce colorectal-liver metastases in mice (Stoeltzing,
Liu et al. 2003). Reinmuth et al also examined colorectal metastasis in mice
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however they used an antagonist of DVE3 and not only reduced metastasis but also
produced an increase in survival. Similarly another group used another antagonist of
DVE3 (S247) to suppress metastasis in a mouse model of breast cancer metastasis to
bone. Following a pre-injection of S247, Harms et al demonstrated a significant
reduction in the incidence and number of bone metastasis (p=0.002) following an
intracardiac injection of MDA-MB-435 breast cancer cells. When they administered
S247 after tumour cell inoculation they found only a small decrease in the incidence
of bone metastases compared with vehicle control. This led the authors to suggest
that DVE3was involved in the early steps of metastasis rather than the later stages i.e.
adherence and colonisation rather than proliferation and osteolysis, respectively.
(Reinmuth, Liu et al. 2003; Harms, Welch et al. 2004).
1.5.4 PTHrP and Cell Adhesion
Several studies have shown a relationship between PTHrP and integrin expression.
For example, a study by Ye et al using human colon cancer cells over-expressing
PTHrP demonstrated not only an increase in PTHrP secretion in these cells
compared with vector-control, but also a two-fold increase in adhesion to collagen
type I. However PTHrP over-expression had no effect on adhesion to either laminin
or fibronectin. Ye et al examined the effect of exogenous PTHrP on adhesion and
found that neither PTHrP (1-136) nor a PTH1R receptor antagonist affected cell
adhesion to collagen type I, laminin or fibronectin (Ye, Seitz et al. 2001).
It has previously been discussed that certain tumours appear to have a predisposition
to metastasise to certain organs and from these results Ye et al suggested that when
entering the blood system, tumour cells over-expressing PTHrP may promote organ-
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specific metastasis through their increased capacity to adhere to certain ECM
components.
Another group at the University of Texas have shown a similar effect in a number of
tumour derived cell lines. Using expression vectors containing PTHrP they showed
that PTHrP over-expression in PC-3 prostate cancer cells causes an increase in
adhesion to collagen type I, fibronectin and laminin (Shen and Falzon 2003).
Subsequent studies showed an increase in adhesion to laminin in breast cancer cells
over-expressing PTHrP (Shen, Qian et al. 2004), while in a colonic cell line they
demonstrated an increase in adhesion to collagen type I, fibronectin and laminin
(Shen and Falzon 2005).
When Shen and Falzon subsequently examined integrin expression in their over-
expressing cell lines they found an increase in expression of the integrin subunits D1,
D5, D6 and E4LQWKHSURVWDWHFDQFHUFHOOOLQHDQLQFUHDVHLQWKHH[SUHVVLRQRIĮ6 and
ȕ4LQWKHEUHDVWFDQFHUFHOOOLQHDQGDQLQFUHDVHLQĮ2Į5ȕ1ȕ4 DQGȕ6 expression in
the colonic cell line. They also used an expression vector containing PTHrP without
the NLS to negate not only the increase in ECM adhesion but also the increase in
integrin expression. Different subunits were increased in the three cell lines
suggesting that PTHrP-induced up-regulation is not random but provides a more
direct system of control which is tissue-specific.
It is known that PTHrP is over-expressed in a number of tumours and this has been
linked to tumour progression. Integrin expression has also been described in
association with tumour progression and Shen and Falzon’s results point towards a
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possible link between the two. A number of PTHrP’s functions are similar to actions
of certain integrins, for example an increase in cell growth and an increased
resistance to apoptosis. It is therefore possible that PTHrP mediates some of its
effects via an increase in integrin expression, an idea explored during the course of
this thesis.
1.6 CURRENT PTHrP RELATED THERAPEUTICS
Shortly after PTHrP had been isolated and linked with hypercalcemia, Kukreja et al
used an antibody directed against PTHrP to lower serum calcium in a mouse model
of malignancy associated hypercalcemia. The anti-sera were directed against PTHrP
(1-34) and (1-16) and both were able to reduce the biological activity of PTHrP (1-
34) resulting in a decrease in serum calcium, urine calcium and urine cAMP
(Kukreja, Shrevin et al. 1988).
This has been confirmed in several other studies where a PTHrP neutralising
antibody has been used to treat various aspects of malignancy associated with
PTHrP.
Following the suggestion that there was a link between PTHrP expression in breast
cancer cells and bone metastasis, Guise et al used a PTHrP neutralising antibody in a
mouse model of human breast cancer metastasis to bone. The present treatment for
metastatic breast cancer involves the use of the osteoclast inhibitors,
bisphosphonates. However their low absorption often necessitates high doses and
they are often poorly tolerated resulting in significant GI side effects (Body 2002).
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When Guise et al induced osteolytic lesions in mice they were unable to detect an
increase in Ca
2+
or plasma PTHrP levels. However they did detect an increase in
bone marrow plasma PTHrP levels in mice with osteolytic lesions compared with
control mice. When mice were subcutaneously treated with a PTHrP (1-34)
neutralising antibody or IgG control seven days prior to tumour inoculation and
treated twice a week during the course of the study, there was a significant reduction
in both the number and area of metastatic lesions in mice receiving the antibody.
There was also a significant reduction in the number of osteoclasts and while
calcium concentration was unaltered, mice receiving IgG control rather than PTHrP
antibody experienced significant weight loss (Guise, Yin et al. 1996).
Guise et al’s study not only indicated that antibodies directed against PTHrP could
be used in the prevention of bone metastases but also suggested that PTHrP plays a
role in weight loss in cancer patients. This hypothesis was given additional support
by Iguchi et al who suggested that PTHrP was able to affect weight loss by acting on
the hypothalamus and subsequently used a PTHrP neutralising antibody to bring
about weight gain in mice suffering from cancer induced cachexia (Iguchi, Onuma et
al. 2001).
Massfelder et al used a PTHrP neutralising antibody to examine the role of PTHrP in
renal cell carcinoma. They demonstrated a decrease in cell proliferation with the
antibody as well as a PTH1R antagonist and a parallel increase in apoptosis. When
they then utilised a xenograft athymic mouse model they found that tumour-bearing
mice treated with either the PTHrP (1-36) antibody or the PTH1R antagonist
exhibited a significant decrease in tumour growth. With increased antibody dosage,
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tumour regression was observed with the disappearance of 7/10 tumours and a 50-
80% regression in three others. The antagonist was unable to bring about tumour
regression however it was able to prevent tumour growth, with two out of ten
tumours demonstrating a 90% and 60% regression. Due to the disappearance of the
tumours the authors were unable to conduct histopathological analysis on antibody
treated tumours however, when antagonist-treated tumours were subsequently
examined there was an increase in apoptosis in antagonist-treated mice compared
with control animals (Massfelder, Lang et al. 2004).
The successful use of PTHrP neutralising antibodies both in vitro and in vivo led the
pharmaceutical company Chugai to develop an anti-PTHrP antibody called CAL for
use in the treatment of metastatic breast cancer. This was successfully used to
inhibit osteolytic bone metastases in mice and although Chugai began enrolment for
a Phase I/II trial, at the time of writing development on this antibody has been
suspended.
Immunotherapy is based upon neutralisation of the protein however PTHrP gene
expression has also been targeted. After successfully using a PTHrP neutralising
antibody, Teresa Guise went on to use nucleotide analogues of guanine to induce a
70% reduction in PTHrP promoter activity leading to a decrease in PTHrP mRNA
concentration and PTHrP production. In mice bearing osteolytic bone lesions, the
guanine analogues were able to significantly reduce the tumour lesion area from 3.97
r 1.48mm2 in untreated mice to 0.74 r 0.14mm2 in mice treated with 6-thioguanine
(p<0.05). Similarly the number of osteoclasts per mm of tumour-bone interace was
reduced from 15.62 r 0.93 to 2.81 r 1.74 (p<0.05). This led to an increase in
44
survival: all of the untreated mice had died by day 35 whereas 80% of the analogue
treated mice were still alive (p<0.05). The analogues were also able to significantly
decrease whole blood ionized calcium concentration and reduce mean serum PTHrP
concentrations (p<0.05) (Gallwitz, Guise et al. 2002).
Other approaches have included the use of anti-sense oligodeoxynucleotides targeted
against PTHrP to decrease translation of PTHrP mRNA in rat chondrocytes.
Similarly Falzon and Du used anti-sense oligodeoxynucleotides to inhibit PTHrP
production in a human breast cancer cell line and induced a decrease in cell
proliferation (Tsukazaki, Ohtsuru et al. 1996; Falzon and Du 2000).
The active form of vitamin D (1,25(OH)2D3) has been shown to decrease PTHrP
gene transcription as well as decreasing PTH1R expression in mouse osteoblasts
(Goltzman, White et al. 2001). In a similar study Tovar Sepulveda and Falzon used
1,25(OH)2D3 to decrease PTHrP expression in prostate cancer cells and suggested
that it could be used in the prevention and treatment of prostate cancer (Tovar
Sepulveda and Falzon 2002).
Francini et al also explored chemoprevention when they used PTHrP peptides to
vaccinate mice against PTHrP and in doing so were able to stimulate an immune
response against PTHrP (Francini, Kosmatopoulos et al. 2002).
Each of these studies describes systems whereby PTHrP could be targeted, but they
also emphasise the number of cancer related complaints which could be treated by
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doing so. These include hypercalcemia, tumour metastasis and cachexia. It can
therefore be seen that PTHrP provides a key target in cancer therapy.
1.7 AIMS & HYPOTHESIS
PTHrP is commonly over-expressed in a number of cancers; it has been shown to be
a growth and anti-apoptotic factor and there is evidence to suggest that it is also
involved in cell adhesion. As PTHrP is also linked to tumour progression it is clear
that it presents an ideal therapeutic target.
The principle aim of this work is to examine the role of PTHrP in cell adhesion.
Specifically, it aims to investigate the mechanism by which this protein mediates cell
adhesion, utilising a variety of methods including over-expression and RNAi of
PTHrP.
Chapter 2:
Materials & Methods
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2.1 CELL CULTURE
2.1.1 Cell Line Maintenance
The origin of the cell lines used in this study are shown in Table 2.1. They were
cultured in Roswell Park Memorial Institute (RMPI) 1640 media (Sigma Aldrich,
Dorset, UK) supplemented with 2mM glutamine (Sigma Aldrich) and 10% v/v heat
inactivated foetal bovine serum (FBS, Sigma Aldrich). Genetically modified cell
lines were cultured with the addition of 200Pg/mL geneticin (Sigma Aldrich) in
order to ensure transfection maintenance. Cells were housed in a humidified 5%
CO2 incubator at 37°C. Passage numbers were not recorded for the cell lines used
during the course of this study.
2.1.2 Sub-culture
When harvesting cells for propagation or for assay purposes, growth media was
removed and cells detached using 2mLs/75cm
2
of either 0.025%
ethylenediaminetetracetic acid (EDTA) in phosphate buffered saline (PBS, pH 7.37,
Oxoid, Basingstoke, UK) or 0.25% trypsin-EDTA (Sigma Aldrich). Cells were
incubated for approximately five minutes or until cells detached, then pelleted by
centrifugation at 1500rpm for five minutes using a Sanyo MSE Harrier 15/80
centrifuge.
A Neubauer haemocytometer was used in conjunction with trypan blue (Sigma
Aldrich), which excludes live cells, in order to determine viable cell number. The
haemocytometer contains a central platform with a ruled counting area 0.1mm under
the coverslip. The counting area is divided into 25 squares with a total volume of
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liquid encompassed by the primary square being 0.1mm
3
. A 0.2% stock of trypan
blue was first diluted 3:1 with 4.25% saline solution (sodium chloride in distilled
water, Sigma Aldrich) and then mixed 1:1 with cell suspension. Clear cells were
deemed viable and blue cells non-viable. The number of viable cells contained
within the squares of the hemocytometer were counted and the number of cells per
mL calculated by multiplying the cell count by two (to allow for the 1:1 dilution) and
1x10
4
(to allow for the volume underneath the coverslip).
Table 2.1 Cell lines used, including their tissue of origin and transfected
variants.
Cell Line Tissue of Origin Transfected Variants
AGS
a
Gastric adenocarcinoma
C170HM2
a
Colonic carcinoma
COLO205
a
Colonic adenocarcinoma
HT29
b
Colonic adenocarcinoma
PTHrP (1-139), PTHrP (1-
139+NLS Mutation), Vector
Control
MDAMB231
a
Breast adenocarcinoma
PTHrP (1-141)
d
, PTHrP (1-139),
PTHrP (1-139+NLS Mutation),
Vector Control
MGLVA1 ascites
c
Gastric adenocarcinoma
PAN1
a
Pancreatic carcinoma
PANC1
c
Pancreatic carcinoma
a - supplied by European Collection of Cell Cultures, Porton Down, Salisbury, UK
b - supplied by American Type Culture Collection, available from LGC Prochem, Middlesex, UK
c - derived within the Academic Unit of Cancer Studies, University of Nottingham, Nottingham, UK
d - provided by Dr Teresa Guise, Division of Endocrinology, University of Texas, USA
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2.2 SMALL INTERFERING RNA
2.2.1 siRNA Design
Small interfering RNAs (siRNA) were used to induce post-transcriptional gene
silencing of PTHrP and the integrin subunits D5 and D6. The PTHrP siRNAs were
designed using Ambion’s siRNA target finder
(www.ambion.com/techlib/misc/siRNA_finder.html) while the integrin siRNAs
were designed using a similar programme provided by Dharmacon
(www.dharmacon.com/sidesign). While Dharmacon’s design programme
automatically eliminates siRNAs with high homology to other targets, Ambion’s
does not. Accordingly the potential PTHrP siRNAs were checked for homology
with other genes using the web based tool BLAST (www.ncbi.nlm.nih.gov/BLAST)
and three siRNAs targeted against different regions of the PTHrP gene subsequently
chosen for investigation. The scrambled siRNAs were generated using another web
based tool, RANDSEQ, which is available via workbench.sdsc.edu. Table 2.2 shows
that target sequence of each siRNA investigated.
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Table 2.2 siRNA Target Sequences
siRNA Target Sequence
PTHrP
Target 4 AAGGGGAAGTCCATCCAAGAT
Target 19 AAGACACCTGGGAAGAAAAAG
Target 28 AAGAAAAAACGGCGAACTCGC
Scrambled PTHrP Target 19 AAGCACAAAGAGATGGAGAAC
Integrin D5
D5A AAGAATCTCAACAACTCGCAAAGCGAC
D5B AAGAATCTCAACAACTCGCAA
Scrambled Integrin D5 A AACCCTCGGACCTTAAGCAGAAACAAA
Integrin D6
D6A AAACATGGACCTTGATCGAAA
D6A (27nt) AAACATGGACCTTGATCGAAATTCCTA
D6B AACAGCAACCTTAAACTAGAA
D6 C AACAACAAGCAATCAAGATAA
2.2.2 Construction of siRNA
Sense and anti-sense oligonucleotide primers complementary to the siRNA target
sequences were purchased from Eurogentec (Southampton, UK) and the siRNA
constructed using the reagents provided with the Silencer siRNA Construction kit
(Ambion, Huntingdon, UK).
This kit uses T7 RNA polymerase to transcribe the RNA; in order to do utilise this
enzyme however it is necessary to first hybridise the oliognucleotide primers to T7
promoter primers. This is achieved by adding several nucleotides complementary to
the T7 promoter (CCTGTCTC) onto the end of each oligonucleotide primer at the
time of purchase.
A five minute incubation of the template oligonucleotides with the T7 promoter
primer and DNA hybridisation buffer at 70ºC encourages hybridisation of the primer
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with the template. A further 30 minute incubation at 37ºC with Klenow reaction
buffer, dNTP mix and Exo-Klenow enzyme promotes 3’ extension of the hybridised
oligonucleotide by the Klenow fragment of DNA polymerase.
The sense and anti-sense templates were then incubated at 37ºC with T7 RNA
polymerase, T7 Reaction buffer and NTP mix to produce RNA transcripts. For
fluorescent siRNA construction an NTP mix containing fluorescein-12-UTP (Roche,
East Sussex, UK) was included in this reaction mix.
The sense and anti-sense transcripts were then combined and incubated at 37ºC
overnight to allow hybridisation and the creation of double-stranded RNA.
Incubation at 37ºC for a further two hours with a single-strand specific ribonuclease
removed the leader sequence, while a deoxyribonuclease removed the DNA
template. The siRNA were then purified by glass fibre filter binding in conjunction
with an ethanol containing wash buffer to remove excess nucleotides, short
oligomers, proteins, and salts. siRNAs were then eluted in nuclease-free water
preheated to 75ºC. The resultant double-stranded 21-mer siRNAs were then ready
for transfection into mammalian cells. A diagrammatic representation of siRNA
construction can be seen in Figure 2.1.
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Figure 2.1 siRNA construction using Silencer siRNA Construction kit (taken
from instruction manual).
2.3 VECTOR CONSTRUCTION
2.3.1 PTHrP Plasmids
In order to examine the effects of PTHrP over-expression, mammalian expression
vectors were used to create several stable cell lines. Three pcDNA3.1(+)vectors
containing the coding regions for PTHrP were kindly donated by Professor Miriam
Falzon at the University of Texas. The vectors contained either full-length PTHrP (-
5 to +139) or PTHrP (-5 to +139) without the NLS. An empty vector control was
also provided.
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Figure 2.2 pcDNA3.1 vector with ligation sites for PTHrP (1-136) highlighted.
The nuclear localisation sequence is also represented and highlights the deleted
regions
The cDNA encoding for PTHrP had been cloned into pcDNA3.1(+) by digesting the
vector with the restriction enzymes EcoRI and HindIII (Figure 2.2). The deletion of
the NLS had been carried out using a Transformer Site-Directed Mutagenesis Kit
(Clontech Laboratories, Palo Alto, CA), which resulted in the deletion of residues
(88-91) and (102-106) and confirmed by DNA sequencing (Shen and Falzon 2003).
A small volume of plasmid was initially obtained, so plasmid preparations were
carried out to generate a greater working stock (see Sections 2.3.7 and 2.3.8).
2.3.2 Integrin Promoter Plasmids
The pGL3-Basic Vector (Promega, Southampton, UK) contains a coding region for
firefly luciferase; by coupling this region to the coding region for a reporter gene it is
possible to explore changes in promoter activity through changes in luciferase
expression. For example by coupling the coding region for an integrin promoter it
85T P G K K K K A K P G K R K E Q E K K K R R T R 108
NLS
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was possible to examine the effects of PTHrP on the transcriptional activity of an
integrin subunit.
Figure 2.3 pGL3-Basic vector circle map, containing coding region for firefly
luciferase and with multiple cloning sites.
The sequence for each integrin promoter region was amplified by PCR as described
in Section 2.7.5, using the primers noted in Table 2.3. Restriction enzyme sites were
included to allow insertion of the promoter regions into the pGL3-Basic vector.
Table 2.3 Primers for amplifying integrin promoter sequences (restriction
enzyme sequences are underlined).
Integrin
Subunit
Primer Sequence 5’o 3’
D2 FCGACGCGTTTCAGCAATGTGCTGGAAAT (Mlu I)R CGGGATCCCCCATCCTGGGTCTGACG (Bam HI)
D5
F CGACGCGTGTTTACACCGATTAGGAGCTGAAGGT (Mlu I)
F CGGGTACCGTTTACACCGATTAGGAGCTGAAGGT (Kpn I)
R GAGAGATCTTCCTAAACCTCCCAGAGGCG (Bgl II)
D6
F CGACGCGTCAGGAGCCTTCATGCCACCTACACA (Mlu I)
R GAGAGATCTGAATGAGCCCGTTGTTCTCTGGAG (Bgl II)
R GGCGACTTACTCGGGCAACAAGAG (from Lim, Lee et al. 2001)
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2.3.3 Restriction Digest
Restriction digests of plasmids or amplified DNA were performed using restriction
endonucleases. These enzymes each have a specific recognition sequence and cleave
DNA at the sugar-phosphate backbone. Each enzyme was mixed with a specific
enzyme buffer (New England Biolabs, Hertfordshire, UK) and RNase- and DNase-
free water (Sigma Aldrich) to produce a 1:10 working concentration. The DNA and
enzyme were incubated between four and 20 hours at 37qC and the subsequent
digestion products mixed with 10x Blue Juice loading buffer (Invitrogen, Paisley,
UK) and visualised using a 2% agarose gel containing 0.005% ethidium bromide
(Sigma Aldrich), which intercalates between DNA base pairs then fluoresces when
exposed to UV light. Buffers and incubation times can be seen in Table 2.4 and
varied between the enzymes used and depending on whether these were used alone
or in conjunction with another enzyme.
Table 2.4 Restriction enzymes used, including requisite buffers and incubation
times
Restriction Enzyme
New England Biolab
Buffer Used
Incubation Time (h)
Bam HI 2 2
Bgl II 3 20
Kpn I 1 2
Mlu I 3 20
Mlu I & Bgl II 3 20
Mlu I & Bam HI 3 20
Kpn I & Bgl II 2 20
A 100 base pair or 2-log DNA Molecular Weight Marker (New England Biolabs)
was loaded onto each agarose gel and used for band size comparison. Digested
products were visualised using GeneSnap software in conjunction with a Chemi
Genius
2
BioImaging System (Syngene, Cambridge, UK).
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2.3.4 Ethanol Precipitation of DNA
Ethanol precipitation was used to concentrate DNA and was performed as follows.
Two volumes of 100% ethanol (Sigma Aldrich) along with 1/10
th
volume of 3M
sodium acetate (Sigma Aldrich) were added to the DNA and incubated at -20°C for
one hour. Following centrifugation
1
, the DNA was washed twice with four volumes
of 70% ethanol. After the final wash the supernatant was removed and the plasmid
pellet allowed to air dry before being re-suspended in RNase- and DNase-free water
(Sigma Aldrich).
2.3.5 Agarose Gel Purification
Following gel electrophoresis the desired DNA fragment was excised from the
agarose gel using a clean scalpel and gel purified using reagents provided with the
QIAquick Gel Extraction Kit (Qiagen, Crawley, UK).
The agarose gel fragment was weighed and three volumes of Buffer QG used to
solubilise the agarose gel at 50qC, where one volume is equivalent to 100mg of gel.
In order to aid solubilisation the tube was vortexed every two to three minutes for
approximately ten minutes until the gel fragment fully dissolved. In order to
increase the yield of DNA, one gel volume of isopropanol was then mixed with the
sample before it was transferred to a QIAquick column and centrifuged for one
minute. The bound DNA was washed with a further 0.5mL of Buffer QG in order to
remove all traces of agarose from the column before the DNA was washed with
0.75mL of Buffer PE. The column was dried by a further one-minute centrifugation
before being placed in a clean tube and the DNA eluted using 30PL water. DNA
1
Unless otherwise stated all centrifugations were carried out using a Hettich Mikro 20 bench top centrifuge
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was quantified using a NanoDrop ND-1000 spectrophotometer (Labtech, East
Sussex, UK).
2.3.6 Ligation of Vector and DNA Insert
The restriction endonucleases generated overhanging cohesive ends in the vector and
DNA which allowed them to be ligated together. In order to join the vector and
DNA together 100ng of pGL3-Basic vector was used alongside an appropriate
amount of DNA to give a molar ratio of 1:3 (vector:insert) taking into account the
base pair size of the vector and the DNA insert.
The vector and DNA insert were then ligated together at 4°C using T4 ligase (New
England Biolabs), which creates a phosphodiester bond between the 3’ hydroxyl of
one nucleotide and the 5’ phosphate of another. The vector, DNA insert and enzyme
were also incubated with 10xbuffer and ATP to aid ligation (New England Biolabs).
Following an overnight incubation the ligated vector and insert were ready for
bacterial transformation.
2.3.7 Bacterial Transformation
Both the PTHrP and integrin containing plasmids were transformed into bacteria
which are able to replicate the vector DNA and consequently generate additional
plasmid stocks.
In a pre-cooled 15-mL falcon tube, 100PL of XL1-Blue MR Supercompetent Cells
(Stratagene, La Jolla, CA USA) were mixed with 1.7PL E-mercaptoethanol, which
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has been shown to increase the efficiency of the transformation. The sample was
then incubated on ice for ten minutes, and mixed gently every two minutes.
Between 1 and 50ng of plasmid DNA was then mixed with the supercompetent cells
and incubated for a further 30 minutes on ice. A tube containing supercompetent
cells only was also included as a control. The DNA was then incorporated into the
supercompetent cells via heat-shock; the tubes containing cells and DNA were
immersed in a 42°C waterbath for 45 seconds before being cooled on ice for a
further two minutes.
The mixture was diluted with 900µL of SOC medium (Sigma Aldrich), preheated to
42°C, and shaken for one hour at 37ºC to encourage bacterial growth. The
transformed bacteria were then plated out on an LB agar plate containing 50µg/mL
of the antibiotic ampicillin (Sigma Aldrich) and incubated overnight at 37ºC. [Each
of the vectors used in this study contained an ampicillin resistance gene which
enables selection of transformed bacteria.]
The agar plates were prepared by diluting the contents of one packet of FastMedia
LB Agar Amp (Fermentas, Sunderland, UK), which is supplemented with 50µg/mL
of ampicillin, with 200mL of distilled water. The mixture was then heated in a
microwave for two to three minutes until the appearance of bubbles. The solution
was then swirled gently and heated for a further 30-seconds or until the medium
completely dissolved. The agar was left to cool before being aliquoted into petri
dishes and allowed to set.
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Multiple colonies were then selected for each plasmid and incubated in 2mL NZY
media (0.5% NaCl, 0.2% MgSO4, 0.5% yeast extract, 1% NZ Amine, pH 7.5 (Sigma
Aldrich)) again supplemented with 50µg/mL ampicillin and shaken at 37ºC
overnight to promote bacterial growth. The plasmid DNA was then extracted from
the overnight culture.
2.3.8 Plasmid DNA Extraction
Plasmid DNA was extracted using reagents supplied with the GenElute Plasmid
Mini-prep kit (Sigma Aldrich), which is based on the alkaline lysis method.
The overnight culture was pelleted by centrifugation for one minute and the
supernatant discarded. The cell pellet was re-suspended in 200PL Resuspension
Solution containing RNase A, before the addition of 200PL of Lysis Solution. This
alkali solution denatures the bacterial chromosomal DNA however, the circular
plasmid DNA is covalently closed thus allowing it to remain double-stranded and
intact. The sample was mixed by inversion and in order to ensure complete bacterial
lysis the sample was incubated at room temperature for five minutes. 350PL of
Neutralisation Solution was subsequently used to induce precipitation and the
resultant bacterial debris pelleted by a ten-minute centrifugation. The supernatant
(containing the plasmid DNA) was transferred to a Mini Spin Column and
centrifuged for one minute. The column contains a silica-gel membrane which
allows adsorption of the plasmid DNA in a high-salt buffer and elution in a low salt
buffer. As RNA, cellular proteins and metabolites are not adsorbed by the
membrane they are discarded in the flow-through.
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The DNA was washed with 750PL of Wash Solution which contained ethanol, the
column centrifuged and the flow-through discarded. The column was dried by
another one-minute centrifugation before being transferred to a clean tube and the
DNA eluted in 50PL of RNase and DNase free water. Eluted DNA was quantified
using a NanoDrop ND-1000 spectrophotometer and either used immediately for cell
transfection or stored at -20qC.
2.3.9 Sequencing of DNA Insert
Following PCR amplification of the integrin promoter regions (See sections 2.3.2)
the sequence of the DNA was verified using the chain termination method, which
was carried out by the School of Biomedical Sciences at the University of
Nottingham.
The DNA being sequenced was used as a template in the synthesis of new DNA,
which was initiated using the specific primers used for PCR amplification (See Table
2.3). The sequencing reaction consisted of an initial incubation at 94qC which
induced the separation of the DNA into single strands. A further incubation at 50qC
allowed the oligonucleotide primers to anneal to the template before the temperature
was increased to 60qC in order to allow a DNA polymerase to extend the primers
and produce a new copy of DNA.
Included in the reaction mix was a pool of single deoxynucleotide (dNTP) bases as
well as fluorescently labelled dideoxynucleotide (ddNTP) bases. ddNTPs contain a
hydrogen atom at the 3' carbon instead of the hydoxyl group found in dNTPs,
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consequently when a ddNTPs is incorporated rather than a dNTP it brings about the
termination of the growing DNA chain. Also as this incorporation occurs randomly,
not only will chains of assorted lengths be produced but these will contain each of
the four bases.
The resultant assorted truncated strands can then separated by size on a
polyacrylamide gel. When the fragments migrate through the gel the fluorescently
labelled ddNTPs are excited by a laser beam at the bottom, triggering the emission of
light by the fluorescent molecules; this allows the complete DNA sequence to be
reconstructed by matching the order of the bands with the ddNTP. Furthermore
using different dye labels for the four ddNTPs allows the reaction to be performed in
a single tube and analysed on a single gel.
5PL of gel purified PCR product was sent for analysis, which was performed using
an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Warrington, UK).
2.4 TRANSFECTION PROTOCOLS
2.4.1 siRNA Transfection
Cells were either forward transfected using siPORT Neofx (Ambion) or reverse
transfected using siPORT Amine (Ambion). siPORT Neofx is a lipid-based
formulation while siPORT Amine is a blend of polyamines.
When forward transfected, cells were harvested and counted as described in Section
2.1.2 then re-suspended in growth medium at a concentration of 1x10
5
cells/mL and
incubated at 37°C until required. For each well that was transfected 2µL of siPORT
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Neofx was combined with 23µL of Opti-MEM I reduced serum media (Invitrogen)
and incubated at room temperature for ten minutes. siRNAs were diluted to their
working concentration using Opti-MEM I and then combined with the previously
diluted siPORT Neofx. The mixture was again incubated for ten minutes at room
temperature to allow the formation of transfection complexes, which were then
dispensed into the empty well of a 24-well plate. 450µL of cell suspension was then
added to each well and incubated at 37qC, 5% CO2 to promote transfection.
When cells were reverse transfected, it was necessary to plate 5x10
4
cells/mL 24
hours prior to transfection in a 24-well plate so that cells achieved a level of
confluence between 30-70% at the time of transfection. On the day of transfection
2µL of siPORT Amine was combined with 47µL of Opti-MEM I and incubated at
room temperature for between ten and 30 minutes. siRNA were sufficiently diluted
in RNase and DNase free water so that the addition of 1µL to the diluted siPORT
Amine would result in the requisite working concentration. In order to allow
formation of the siRNA/siPORT Amine complex, samples were incubated at room
temperature for 15-20 minutes. The media was removed from the previously seeded
cells and replaced with 200PL of fresh growth medium and the transfection reagents
added drop-wise onto the cells. The cells were then incubated at 37qC, 5% CO2 for
approximately four to six hours before a further 1mL of growth medium media was
added to the cells to prevent cytotoxicity.
2.4.2 Plasmid Transfection
Cells were harvested, counted and seeded in a 24-well plate 24 hours prior to
transfection in order to achieve a level of confluence between 90-95% at the time of
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transfection. For each well that was transfected 2µL of Lipofectamine 2000
(Invitrogen) was diluted in 50µL Opti-MEM I and incubated for five minutes at
room temperature. Plasmid DNA was diluted to 500ng in 50µL Opti-MEM I before
the DNA and Lipofectamine 2000 were combined and incubated for a further 20
minutes at room temperature to promote formation of transfection complexes. These
complexes were then added to the previously seeded cells and incubated at 37qC, 5%
CO2.
In order to produce stable transfectants, transfected cells were passaged at 1:10 and
re-seeded into a 6-well plate 24 hours later. The pcDNA3.1 vector contained a drug
restriction marker which allowed selection of transfected cells following incubation
of cells with 500µg/mL geneticin. Individual clones were selected in a 96-well plate
before expansion and analysis of gene expression.
When only transient transfection was required, transfected cells were lysed and
examined for luciferase expression one day after transfection, as described in Section
2.10.
2.5 CELL PROLIFERATION
2.5.1 PTHrP Stimulation Assay
Cells were harvested, counted and re-suspended in growth medium at a
concentration of 5x10
3
cells per well and 200PL of this cell suspension added to the
inner 60 wells of an opaque 96-well plate (Corning, Surrey, UK). The remaining
outer wells were filled with media only to prevent evaporation.
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Serum has been shown to induce the release of PTHrP into the media, consequently
following an overnight incubation, medium was aspirated from each well and
replaced with 200PL of serum-free medium containing 100nM of PTHrP peptide and
1µCi per mL of tritiated thymidine ([
3
H]-thymidine; Amersham Biosciences,
Buckinghamshire, UK). The peptides employed were PTHrP (1-34), (67-86) (107-
139), (140-173) and (67-101) (Bachem, St Helens, UK; Anaspec, Cambridge, UK),
which correspond to amino-terminal, mid-region (without NLS), osteostatin,
carboxyl-terminal and mid-region (with NLS) respectively. As a control, a (67-101)
peptide was used which contained a five amino acid scrambled sequence linked to
the PTHrP NLS sequence (Cambridge Research Biochemicals, Cleveland, UK).
Proliferation was assessed daily via thymidine incorporation, a nucleoside involved
in the biosynthesis of DNA. Using [
3
H]-thymidine it is possible to measure the
incorporation of thymidine into DNA, with an increase in radioactivity correlating
with an increase in cell proliferation.
At each time point, the medium containing [
3
H]-thymidine was removed and the
cells washed once with 100µL PBS before being lysed with 25µL of 1M sodium
hydroxide. Plates were shaken using a Heidolph Titramax 1000 to aid cell lysis
before the addition of 175µL of Opti-Phase ‘HiSafe’ 3 liquid scintillation cocktail
(Perkin Elmer, Buckinghamshire, UK) to each well. Again plates were shaken to aid
mixture of scintillant with cell lysates.
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Well radioactivity was counted using a Trilux Microbeta Liquid Scintillation
Counter for three minutes, with radioactivity reported in counts per minute (CPM).
The use of an opaque 96-well plate prevented radioactive cross-talk between wells.
2.5.2 Antibody Neutralisation Assay
Two different antibodies (one raised against PTHrP (1-34) and the other against (38-
64) were used to neutralise PTHrP and the effects on proliferation again assessed
using [
3
H]-thymidine incorporation. IgG1-N murine ascites (Sigma Aldrich) was
used as a control.
Cells were harvested and seeded into opaque 96-well plates as described previously.
The following day, medium was removed and replaced with serum free medium
containing 1µg/mL of antibody. At each time point, radioactivity was measured as
described in Section 2.5.1.
2.5.3 Assay of siRNA Transfection and Proliferation
Cells were transiently transfected with either the PTHrP siRNA or the scrambled
control siRNA, as described in Section 2.4.1. The following morning, the medium
was replaced with fresh growth medium to maintain the wellbeing of the transfected
cells and later the same day the cells were harvested, pelleted, re-suspended in
growth medium and re-plated in an opaque 96-well plate; approximately one well of
a 24-well plate provided enough cells for ten wells of a 96-well plate. The following
day the medium were replaced with serum-free medium containing 1µCi per mL of
[
3
H]-thymidine and proliferation assessed daily.
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2.5.4 Clonogenicity Assays
Clonagenicity assays were performed in order to compare the basal growth rate of
cells transfected to over-express PTHrP. Cells were seeded in growth medium at a
density of 5x10
3
cells per well in opaque 96-well plates. The following day the
medium was aspirated and replaced with serum-free medium containing 1µCi per
mL of [
3
H]-thymidine. The growth rate of different cell lines was compared by
examining proliferation on a daily basis for up to 72 hours.
2.6 EXTRACELLULARMATRIX ADHESION
2.6.1 ECM Preparation
The extracellular matrix (ECM) components rat-tail collagen type I (Sigma Aldrich),
human fibronectin and mouse laminin (BD Bioscience, Oxford, UK) were used to
investigate cell adhesion. Collagen type I was dissolved in 0.1M acetic acid (Sigma
Aldrich) at a stock concentration of 1mg/mL and stored at -20qC. Fibronectin was
dissolved in PBS and laminin in serum-free media, at a stock concentration of
100µg/mL. Fibronectin was stored at -20qC whilst laminin was stored at –80qC.
Collagen type I and fibronectin were diluted to a working concentration of 5µg/mL
in PBS; laminin was diluted in serum-free medium.
50Pl of 5µg/mL ECM was added to the inner 60 wells of a clear 96-well plate
(Corning) and incubated at room temperature for one hour, excess ECM was
removed and wells washed in distilled water. Plates were air dried at room
temperature then stored until required.
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Prior to use adventitious binding sites were blocked with 1mg/mL bovine serum
albumin (BSA; Sigma Aldrich) in PBS and left at room temperature for one hour.
Excess BSA was then removed and wells again washed with distilled water.
2.6.2 Effect of Peptide Stimulation on Cell Adhesion
Cells were seeded in six-well plates at 1x10
5
/mL, or 2x10
5
/well, and grown
overnight before the growth medium was removed and replaced with serum-free
medium containing 100nM of PTHrP peptide. This seeding density produced a sub-
confluent monolayer on the day of assay, 72 hours following PTHrP peptide
stimulation.
On the day of assay, cells were harvested, counted and re-suspended in growth
medium at a concentration of 5x10
5
/mL. 200Pl of cell suspension was then added to
an ECM coated plate and the outer wells filled with medium only. Cells were
incubated for one hour at 37qC, after which time each well was washed twice with
growth medium to remove any non-adherent cells and the number of viable, adherent
cells determined using MTT uptake.
MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; Sigma
Aldrich) is converted to the purple salt formazan by the mitochondrial enzyme
succinate dehydrogenase and consequently only viable cells will be able to convert
MTT (Mossman 1983).
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Following the addition of 50PL of 1mg/mL MTT, cells were incubated for four
hours at 37qC, 5% CO2 to promote MTT uptake and conversion to formazan. Excess
MTT was removed and the remaining formazan crystals, which are insoluble in
aqueous solution, were solubilised with 75PL of dimethyl sulfoxide (Sigma Aldrich).
The amount of solubilised formazan product was then photometrically quantified
using an MRX microplate reader at a wavelength of 550nm (ThermoLab Systems,
Chantilly, USA). An increase in the number of viable cells correlates with an
increase in total metabolic activity and consequently a larger amount of formazan.
Therefore an increase in absorbance can be taken as being proportional to an
increase in the number of viable cells and used as a measure of proliferation.
2.6.3 Effect of PTHrP Neutralisation on Cell Adhesion
Cells were grown in six-well plates prior to assay. The day after cells were seeded,
growth medium was removed and replaced with serum-free medium containing
1µg/mL of PTHrP neutralising antibody or IgG1-N murine ascites control.
Following a 72-hour incubation, cells were harvested, counted and re-suspended in
growth medium. 200µL of cell suspension was added to an ECM coated plate to
give a cell density of 1x10
4
cells per well. Outer wells were filled with media only.
Following a one-hour incubation at 37qC, non-adherent cells were washed off and
the number of viable, adherent cells determined by MTT uptake as described in
Section 2.6.3.
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2.6.4 Effect of Gene Silencing on Cell Adhesion
Cells were transfected with siRNA targeted against either PTHrP or the integrin
VXEXQLWVĮ5RUĮ6. At various time points cells were harvested and re-suspended in
growth medium before being added to an ECM-coated plate. Transfected cells were
incubated for one hour, non-adherent cells washed off and the number of viable cells
remaining assessed by MTT uptake.
2.6.5 PTHrP Over-expression and Adhesion
In order to aid reproducibility, cells were seeded at a density sufficient to achieve a
level of confluence of 80-90% on the day of assay. Cells were then harvested,
counted and plated at a concentration of 1x10
4
cells per well in growth medium.
Cells were incubated for one hour at 37qC, washed twice and viable cell number
determined using MTT uptake.
2.7 MOLECULAR BIOLOGY
2.7.1 RNA Isolation
RNA was isolated using either 1mL of RNA-Bee (Biogenesis, Poole, UK) to re-
suspend a pellet of approximately 1x10
6
cells or by using 500µL to lyse cells directly
in a 24-well plate. RNA-Bee is a monophase solution containing phenol, which
dissolves proteins and lipids, and guanidine thiocyanate, a protein denaturant. The
addition of 200µL of chloroform (Sigma Aldrich), a vigorous shake for 10-30
seconds followed by a 30-minute centrifugation at 13,000rpm, 4°C resulted in the
separation of the organic phase, containing DNA and proteins, and the aqueous
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phase, containing the desired RNA. The RNA was then precipitated by mixing the
aqueous layer with an equal volume of isopropranol (Sigma Aldrich) in a clean tube.
The sample was incubated at -20°C for at least 20 minutes before a 15-minute
centrifugation at 13,000rpm, 4°C. Once the supernatant had been discarded the
RNA pellet was washed with 1mL of 70% ethanol, followed by another five-minute
centrifugation. This wash was then repeated and as much of the remaining liquid as
possible removed. The tube was left open but covered in order to aid evaporation of
any remaining ethanol. Once dry, the RNA pellet was re-suspended in 50µL of
DNase and RNase free water and samples either stored at -80°C or used immediately
for reverse transcription.
2.7.2 Reverse Transcription
$ ȝ/ DOLTXRW RI 51$ ZDV PL[HG ZLWK ȝ/ RI HLWKHU UDQGRP 3G1 KH[DPHU
primer mix (Amersham Biosciences) or water to provide a cDNA positive and
negative sample, respectively. Both samples were incubated at 70qC, to aid the
unfolding of the RNA and allow primer access. At the end of this incubation the
samples were transferred onto ice to prevent re-folding of the RNA.
ȝ/ RI D UHYHUVH WUDQVFULSWLRQ UHDFWLRQ PL[ FRQWDLQLQJ '77 )LUVW6WUDQG %XIIHU
dNTP mix and SuperScript II RNase-H Reverse Transcriptase (Invitrogen) was then
added to the cDNA positive sample; the negative sample contained the same mix
with the exception of the reverse transcriptase.
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Reverse transcription was carried out by heating the samples to 25°C for ten
minutes, 42°C for one hour and finally 95°C for five minutes, which inactivated the
enzyme. This reaction protocol allows the transcriptase to elongate the PdN6
primers previously annealed to the RNA template, thus generating cDNA.
Samples were then diluted 1:5 with water and stored at -20°C or used immediately
for PCR.
2.7.3 Extraction of Genomic DNA
When amplifying the integrin promoter regions it was necessary to use genomic
DNA as cDNA reverse transcribed from RNA does not contain this region.
Gemomic DNA was thus obtained using the reagents provided with the DNeasy
tissue kit (Qiagen).
A cell pellet containing 1x10
6
PAN1 cells was re-suspended in 200µL of PBS before
20µL of proteinase K and 200µL of Buffer AL were added to the cell sample,
vortexted and incubated at 70qC to induce cell lysis. 200µL of 100% ethanol was
then added to the cell lysate which was again vortexted before being added to a
silica-gel containing mini-spin column. In order to promote binding of the DNA to
the membrane, the column was centrifuged at 8000rpm for one minute and the flow-
through discarded. The bound DNA was then washed using 500µL of Buffer AW2
and centrifuged for three minutes at maximum centrifugal speed in order to dry the
membrane. The spin column was then placed in a clean tube and 100µL of DNase
and RNase free water used to elute the DNA, which was then either used
immediately for PCR or stored at -20qC until required.
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2.7.4 Polymerase Chain Reaction (PCR)
PCR reactions were carried out in 0.2mL thin wall tubes (Sigma Aldrich) using
genomic DNA and a reaction mix containing the following: Reaction Buffer, Q
solution, dNTP mix, previously optimised primer pair and HotStarTaq enzyme
(Qiagen).
The samples were amplified using a PTC-200 Peltier Thermal Cycler (MJ Research,
Hertfordshire, UK) using the following reaction protocol: 15 minutes at 94qC
followed by 40 cycles of one minute at 94qC, 2.5 minutes at 55qC then 1.5 minutes
at 72qC. This allowed denaturation and separation of the DNA strands, annealing of
the oligonucleotide primers which were then extended by Taq DNA polymerase. By
using two opposing primers copies of the target DNA sequence are able to
accumulate at an exponential rate. A final ten minute incubation at 72qC allowed for
completion of any unfinished transcripts.
PCR products were visualised following mixture with 10x Blue Juice loading buffer
(Invitrogen) and separation using a 2% agarose gel (Sigma Aldrich) containing
0.005% ethidium bromide (Sigma Aldrich) for 45 minutes at 120V. A 100 base pair
DNA Molecular Weight Marker (New England Biolabs) was used for band size
comparison.
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2.7.5 Real time-PCR (RT-PCR)
Using RT-PCR it was possible to quantify levels of a specific template cDNA in cell
lysates and thereby examine gene expression levels. RT-PCR reactions were carried
out in 96-well optical reaction plates (Applied Biosystems) using 5PL of diluted
cDNA and 20PL of reaction mix which contained Reaction Buffer, SYBR green,
MgCl2, dNTP mix, previously optimised primer pair, UNG and HotGoldStar
(Eurogentec).
Corresponding cDNA positive and negative samples were analysed using a 7500
Real-time PCR System (Applied Biosystems) using the following reaction protocol:
2 minutes at 50qC, ten minutes at 95qC followed by 40 cycles of 15 seconds at 95qC
and one minute at 60qC. As with PCR this reaction involved denaturation, annealing
and extension. Again using two opposing primers copies of the target DNA
sequence are able to accumulate at an exponential rate and using the fluorescent
DNA binding dye, SYBR green, gene expression can be quantified.
SYBR green emits strong fluorescence upon binding to double-stranded DNA and
can thus be used to quantify expression of the target gene by monitoring the levels of
SYBR green fluoresence emitted at the end of each cycle; the greater the template at
the beginning of the reaction the fewer the number of cycles it takes to reach a point
at which the fluorescent signal is statistically significant above background, which is
defined as the threshold cycle (Ct). Gene expression was not deemed not detectable
if the Ct of the test gene was >35 when the Ct of HPRT was <25.
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In order to allow for differences in template concentration, gene expression of the
house-keeping gene hypoxanthine guanine phosphoribosyl transferase (HPRT) was
also measured and compared to expression of the test gene; this 'Ct was calculated
using Ct, target gene – Ct, HPRT. Relative quantification of gene expression was then
calculated using the following equation:
Relative gene expression = 2
-('Ct, test sample – 'Ct, control sample)
This comparative Ct model, also known as the 2
-''Ct
model, was derived by Livak
and Schmittgen. In order for the equation to be valid the amplification efficiencies
of the target and house-keeping gene must be approximately equal. To examine
whether this is the case, it is necessary to serially dilute a cDNA template and
examine the 'Ct for the target and reference genes. If the amplification efficiencies
are equal then a plot of cDNA dilution versus 'Ct is <0.1 (Livak and Schmittgen
2001).
The oligonucleotide primers used during PCR can be seen in Table 2.4. These were
purchased from Eurogentec and prior to use each primer pair was optimised to
prevent primer-dimer formation and the amplification efficiency for each primer pair
compared with that of the housekeeping gene, HPRT.
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Table 2.5 Oligonucleotide primer pairs used during PCR
Target Gene Primer Sequence 5’o 3’
Working
Concentration
(µM)
HPRT F GACCAGTCAACAGGGGACAT
R CGACCTTGACCATCTTTGGA
2.5
PTHrP F GCTCGGTGGAGGGTCTCA
R TTGTCATGGAGGAGCTGATGTT
2
Integrin D1
F GGAGAAAACGTGACCCATGA
R TGGATGACCTTCTTCAGTCG
5
Integrin D2
F AACATCCCAGACATCCCAAT
R CATCATGTGATTCACCGTCAG
5
Integrin D3
(Guidry, Bradley
et al. 2003)
F ACGAAGTCAGCAATGGCAAG
R CAGCCACAGCTCGATTTGG
3.33
Integrin D5
(Oki, Matsuo et
al. 2004)
F GGCAGCTATGGCGTCCCACTGTGG
R GGCATCAGAGGTGGCTGGAGGCTT
5
Integrin D6
F TCAATTGCTGGAAACATGGA
R GGCGGAGGTCAATTCTGTTA
3.33
Integrin E1
(Oki, Matsuo et
al. 2004)
F GTGGTTGCTGGAATTGTTCTTATT
R TTTTCCCTCATACTTCGGATTGAC
5
Integrin E3
(Schneider,
Whitson et al.
1999)
F CTACCTGATGGACCTCTCCCTG
R GTACTGCATCAAAGCCCCCCTC
3.33
Integrin E4
(Utermark,
Kaempchen et al.
2003)
F ATAGAGTCCCAGGATGGAGGA
R GTGGTGGAGATGCTGCTGTA
5
Where there is no reference given primers were designed using the web based
programme Primer3 (frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi), which
was developed by Steve Rozen and Helen Skaletsky. To avoid amplification of
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contaminating genomic DNA the primers were designed to span exon-exon junctions
in the cDNA sequence. Other criteria adhered to during design included limiting the
melting temperature to 50-60qC, using oligonucleotides between 15-30 bases and
with a G/C content between 30-80% (Rozen and Skaletsky 2000).
In addition, OAS, STAT and HPRT gene expression was examined using ABI
Taqman primer sets (Applied Biosystems) labelled with the fluorescent reporter dye
FAM, which negated the need for SYBR green.
2.8 PROTEIN BIOLOGY
2.8.1 Western Blotting
It is possible to detect a specific protein in a lysed cell sample using immunoblotting
(more commonly referred to as western blotting) in conjunction with specific
primary antibodies. The methods described here are based on the original protocol
developed by Towbin et al and involves the separation of charged molecules through
a polyacrylamide matrix via the application of an electrical field before the
electrophoretic transfer of these proteins from the polyacrylamide gel to a
nitrocellulose or PVDF membrane (Towbin, Staehelin et al. 1979; Burnette 1981).
2.8.1.1 Cell Lysate Preparation
In order to obtain both nuclear and cytoplasmic fractions ~5x10
6
cells were lysed
first with a a lysis buffer containing 20mM Tris-HCl at pH 7.6, 0.5% Triton X-100,
250mM NaCl, 3mM EDTA, 3mM EGTA, 1mM PMSF, 1mM DTT (Sigma Aldrich)
and 10PL/mL Protease Inhibitor Cocktail III (Calbiochem, Nottingham, UK).
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Following a ten-minute centrifugation at 13,000rpm, 4qC, the supernatant was
removed, stored separately and taken to represent the cytosolic fraction of the cell.
The cell pellet was then further lysed using RIPA buffer containing 20mM Tris
buffer, 137mM NaCl, 10% Glycerol, 1% Igepal, 0.1% SDS, 0.5% sodium
deoxycholate, 2mM EDTA, 1mM PMSF, 1mM DTT (Sigma Aldrich) and 10PL/mL
Protease Inhibitor Cocktail III. This was then taken to represent the nuclear fraction
of the cell.
To aid loading of the samples, 4x NuPAGE sample buffer (Invitrogen) was mixed
with the cell lysates and the samples then heated at 99qC for two minutes. When
heated, SDS coats the protein resulting in a uniform negative charge, whilst DTT
causes the disruption of the non-covalent inter- and intra-molecular associations i.e.
the protein no longer has a secondary or tertiary structure. Samples were either used
immediately for gel electrophoresis or stored at -80qC.
2.8.1.2 Gel Electrophoresis
Proteins were separated by electrophoresis using a polyacrylamide gel; depending on
the size of protein being investigated either a pre-cast 12% NuPAGE or 8-16% Tris-
glycine gel (Invitrogen) was used. Due to the uniform negative charge, the proteins
were separated according to molecular weight rather than charge. NuPAGE gels
have a neutral pH, rather than the highly alkaline pH used with Tris-glycine gels,
which increases the stability of not only the proteins but also the acrylamide matrix.
NuPAGE gels also allow a wider range of separation and are able to separate
proteins through both low and high molecular weight ranges. NuPAGE gels were
78
used to examine PTHrP protein expression, which has a low molecular weight,
whereas PTH1R expression was examined using Tris-glycine gels, which allow
analysis of a mid-range of molecular weights.
The polyacrylamide gels were inserted into an XCELL SureLock Mini-Cell
(Invitrogen). The inner portion of the cell was completely filled with running buffer
and the outer portion filled with enough running buffer (NuPAGE MES SDS
Running Buffer or Novex Tris-Glycine SDS Running Buffer; Invitrogen) to cover
the buffer inlet into the gel. The sample concentration was determined using a
NanoDrop ND-1000 spectrophotometer and approximately 20µg of each sample was
loaded into individual wells of the gel and a constant voltage of 200V applied to
NuPAGE gels for 35 minutes whereas 125V was applied to Tris-glycine gels for 90
minutes.
2.8.1.3 Blotting
Proteins separated using NuPAGE and Tris-glycine gels were transferred to a 0.2µm
nitrocellulose membrane or a 0.2µm polyvinylidene fluoride (PVDF) membrane
(Invitrogen), respectively to allow for antibody detection of the protein of interest.
A sandwich was assembled in an XCell Blotting Module (Invitrogen) using blotting
pads saturated with transfer buffer (NuPAGE Transfer Buffer or Novex Tris-Glycine
Transfer Buffer, Invitrogen), the polyacrylamide gel and an appropriate membrane.
The blotting apparatus included a cathode plate and an anode; with the gel positioned
towards the cathode plate and the membrane towards the anode plate the proteins
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transfer from the gel to the membrane following the application of an electrical
current.
The membranes were equilibrated in transfer buffer for 10-15 minutes prior to
sandwich assembly. As the PVDF membrane is hydrophobic it was also necessary
to soak this membrane in methanol (VWR, Poole, UK) for 30 seconds prior to
equilibration.
A constant voltage of 30V was applied to the blotting module containing NuPAGE
gels for 60 minutes and Tris-glycine gels for 90 minutes.
2.8.1.4 Antibody incubation
Prior to antibody incubation, non-specific binding sites on the membrane were
blocked using 5% dried milk in Tris buffered saline (TBS: pH 7.6, 20mM Tris-base,
127mM sodium chloride, Sigma Aldrich). To detect the target protein each primary
antibody was diluted as required in TBS and incubated with the membrane overnight
at 4°C. Information relating to the antibodies used in this study is given in Table 2.6.
The excess antibody was removed by washing the membranes with TBS+0.1%
Tween-20 (Sigma Aldrich) five times, with each wash lasting approximately five
minutes. The primary antibody-antigen complex was then detected by incubating the
membrane with a biotin conjugated secondary antibody directed against the species
in which the primary antibody was raised (see Table 2.6). Again excess antibody
was removed using TBS+0.1% Tween-20.
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2.8.1.5 Visualisation
In order to visualise the protein of interest, a streptavidin-biotin-peroxidase complex
(DAKO, Cambridgeshire, UK) was used. Figure 2.4 demonstrates the binding of the
complex to the biotin conjugated secondary antibody which provides a substrate for
the chemiluminescent solution ECL Advance (Amersham Biosciences).
Luminescence was visualised using GeneSnap software in conjunction with a Chemi
Genius
2
BioImaging System.
Figure 2.4 Illustration of the biotinylated secondary antibody binding to the
primary antibody, which is followed by binding of the streptavidin-biotin
complex to the secondary antibody.
An alternative method utilised 3,3’-diaminobenzidine (DAB), a horseradish
peroxidase (HRP) substrate. Hydrogen peroxide causes oxidative polymerization of
DAB by HRP which results in a brown insoluble precipitate at the site of the bound
antibody. The developing solution contained 100mL TBS, 0.05g DAB, 0.07g
imidazole and 150µL hydrogen peroxide (Sigma Aldrich). Membranes were
incubated with developing solution for approximately ten minutes or until the
appearance of the brown oxidation product. Peroxidase activity was quenched with
running water and membranes left to dry.
Primary
Antibody
Antigen
Biotinylated
Secondary
Antibody
Streptavidin-
biotin
Complex
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A SeeBlue Plus2 Pre-Stained Standard or MagicMark XP Western Protein
Standard (Invitrogen) was loaded into one well of each polyacrylamide gel and used
for band size comparison.
2.8.1.6 Densitometry
The intensity of the bands present on the membranes is proportional to the amount of
bound secondary antibody and hence the amount of target protein present in the
sample. Band intensities were calculated using the Chemi Genius
2
BioImaging
System and compared intra-gel.
2.8.2 Immunocytochemistry
Cells were harvested and counted as previously described and 5x10
4
cells seeded in
tissue culture-treated 8-well chamberslides (VWR) and incubated overnight. The
following day, cells were fixed for five minutes with 4% electron microscope grade,
methanol free paraformaldehyde (Science Services, Munich, Germany). The excess
aldehyde was quenched using 10mM diethylamine (Sigma Aldrich). Following a
five-minute incubation, cells were washed twice with PBS before permeabilisation
with 0.1% Triton X-100 (Sigma Aldrich) and a further two PBS washes. The cells
were incubated with primary antibody at room temperature for one hour (see Table
2.6).
The cells were washed twice in PBS before application of fluorescent secondary
antibody directed against the species in which the primary antibody was raised (see
Table 2.6) for one hour at room temperature.
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Cells were then washed twice in PBS and slides cover-slipped using Antifade with
DAPI mounting media (Molecular Probes at Invitrogen). DAPI (4'-6-Diamidino-2-
phenylindole) forms a fluorescent complex with DNA and thereby allows
counterstaining of the nucleus. Slides were sealed using clear nail varnish and
fluorescence was visualised using a Zeiss LSM510uv META combi confocal
microscope and 364nm ex/ 470-500BP, 488nm ex/505-530nm and 543nm ex/585-
615 emission filters were used to examine DAPI, FITC and TRITC respectively.
2.8.3 Flow Cytometry
Both intracellular and extracellular protein expression can be examined using flow
cytometry. For extracellular staining a cell pellet containing 2x10
5
cells was washed
twice in 1mL PBA (PBS containing 0.5% BSA and 0.1% sodium azide, Sigma
Aldrich). The presence of the BSA prevents non-specific antibody binding while
sodium azide inhibits antibody uptake during live cell staining.
For intracellular staining it was necessary to first fix cells in 4% formalin
(formaldehyde diluted in PBS, Sigma Aldrich) at room temperature for 15 minutes.
Fixed cells were then washed once with 1mL saponin solution (PBA containing
0.1% saponin, Calbiochem, and 0.9% glucose, Sigma Aldrich) in order to
permeabilise the cell membrane and allow antibody entry. This was followed by a
further two PBA washes.
When conducting both extracellular and intracellular staining, cells were incubated
first with 2µL of primary antibody (see Table 2.6), washed twice with 1mL PBA,
then incubated with 1µL of fluorescently labelled secondary antibody (Table 2.6)
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and again washed twice with 1mL PBA. Cells were then fixed with 1% formalin
before analysis using a Beckman Coulter FACS analysis machine. Both antibody
incubations were carried out in the dark for 30 minutes at 4°C.
Within the FACS analysis machine the cells are hydro-dynamically forced into a
stream of PBS before the fluorescently labelled cells are then excited one at a time
using a laser beam. The light emitted is then detected by a photomultiplier tube and
the level of fluorescence of each cell recorded (Figure 2.5). The resulting data was
analysed using WinMDI software (The Scripps Institute, La Jolla, CA, USA).
Figure 2.5 Diagrammatic representation of a flow cytometry flow chamber
(taken from biology.berkeley.edu/crl/flow_cytometry_basic.html).
Each of the antibodies used to examine protein expression in this study, both primary
and secondary, can be seen in Table 2.6, which also includes the optimal
concentration or dilution used, where relevant.
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Table 2.6 Antibodies used in the various methods of examining protein
expression, including supplier and working concentration
Primary Antibody Technique
§
Supplier
Concentration
(µg/mL) or
dilution used
PTHrP (1-34) WB/IHC/FC Aphton
a
3
PTHrP (38-64) WB, IHC, FC Oncogene
b
3
PTHrP (polyclonal) WB, IHC Aphton 3
PTH1R WB, IHC Oncogene 1
D2 FC BD Bioscience 12.5
D5 FC BD Bioscience 12.5
D6 FC BD Bioscience 12.5
ȕ1 FC BD Bioscience 12.5
ȕ3 FC BD Bioscience 12.5
ȕ4 FC BD Bioscience 12.5
E-actin WB Abcamc 1:5000
Secondary Antibody Technique Supplier Dilution
Biotin labelled rabbit
anti-mouse
WB DAKO 1:1000
Biotin labelled goat
anti-rabbit
WB DAKO 1:1000
AlexaFlour 488
labelled goat anti-
rabbit
IHC Molecular Probes
d
1:200
AlexaFlour 594
labelled rabbit anti-
mouse
IHC Molecular Probes 1:200
FITC labelled rabbit
anti-mouse
FC DAKO -
PE labelled rabbit anti-
mouse
FC DAKO -
§
WB=western blotting, IHC=immunohistochemistry, FC=flow cytometry
a - Aphton Corporation, Woodlands, CA, USA; b - Oncogene, Nottingham, UK;
c - Abcam, Cambridge, UK; d – Molecular Probes at Invitrogen, Paisley, UK
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2.9 MITOCHONDRIAL MEMBRANE POTENTIAL ASSAY
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Molecular Probes) is a cationic dye which exhibits potential-dependent accumulation
in mitochondria. A shift in fluorescence emission from red (~590nm) to green
(~525nm) represents mitochondrial membrane depolarisation, a characteristic of
apoptosis.
Cells were prepared as previously described and seeded in black 96-well plates
(Corning). On the day of assay growth medium was removed from each well,
replaced with growth medium containing 5µM JC-1 and incubated with cells for one
hour at 37°C, 5% CO2. Cells were washed three times with 100µL Hanks Buffered
Saline Solution (Sigma Aldrich) before fluorescent emission was examined using a
FlexStation II
384
(Molecular Devices, Wokingham, UK).
2.10 LUCIFERASE SINGLE REPORTER ASSAY
Firefly luciferase is an enzyme which catalyses mon-oxygenation of luciferin in the
presence of Mg
2+
, ATP and molecular oxygen to generate both oxyluciferin and
luminescence, Figure 2.6.
Figure 2.6 Catalysis of luciferin to oxyluciferin (taken from Promega Technical
Manual No. 051)
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Cells were transfected with the pGL3-Basic plasmid, which contains the coding
region for firefly luciferase (see Section 2.3.2). 24 hours after transfection, cells
were lysed at room temperature using 100µL of Lysis Buffer (Promega). Lysates
were transferred to a 1.5mL microcentrifuge tube and cell debris pelleted by
centrifugation. Steady-Glo Assay Reagent was prepared by mixing lyophilised assay
substrate with Steady-Glo luciferase assay buffer (Promega) and equal volumes of
this reagent mixed with cell lysates in a black solid 96-well plate (Corning).
Following a five-minute incubation at room temperature, luminescence was analysed
using a MicroLumi XS Microplate Luminometer (Harta, Guildford, UK).
2.11 STATISTICAL ANALYSIS
Parametric data (following a normal distribution) were analysed by Students
unpaired t-test (comparison of two means) or one-way analysis of variance
(ANOVA, comparison of more than two means). All statistical analysis was
performed using Prism statistical software package (GraphPad Software, San Diego,
USA), with p<0.05 considered to be significant.
Chapter 3:
Characterisation of PTHrP
Expression and Activity
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3.1 INTRODUCTION
The mature PTHrP protein undergoes post-translational processing resulting in
several daughter peptides (Orloff, Reddy et al. 1994). These have often been used to
manipulate cell growth but conflicting reports have emerged and exogenous PTHrP
has been shown to be both pro- and anti-mitogenic.
For example Massfelder et al added a variety of PTHrP peptides to vascular smooth
muscle cells and observed a dose-dependent decrease in proliferation with amino-
terminal containing peptides. Mid-region and carboxyl-terminal fragments had no
effect on proliferation (Massfelder, Dann et al. 1997).
Several studies by Luparello and colleagues have shown that exogenous PTHrP also
causes a decrease in breast cancer cell proliferation. For example using (38-94)-
amide they slowed MDAMB231 cell proliferation and accelerated cell death. In
another study PTHrP (1-34), (67-86) and (107-139) were shown to inhibit 8701-BC
proliferation (Luparello, Burtis et al. 1995; Luparello, Romanotto et al. 2001).
Conversely the addition of exogenous PTHrP (1-34) has been shown to stimulate
proliferation in a number of cell lines including those derived from prostate (Asadi,
Faraj et al. 2001) and pancreatic tumours (Villaneuva-Penacarrillo, Cancelas et al.
1999). However when Cataisson et al used exogenous PTHrP (1-34) and [
3
H]-
thymidine incorporation to examine proliferation in a breast cancer cell line their
initial studies failed to demonstrate any effect on breast cancer cell proliferation.
The authors attributed this to high levels of endogenous PTHrP so subsequently used
a PTHrP (1-34) neutralising antibody to demonstrate a dose-dependent decrease in
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[
3
H]-thymidine incorporation. The authors also examined the role of the PTHrP
receptor PTH1R, and through the use of an antagonist were again able to
demonstrate a dose-dependent decrease in proliferation. These results led the
authors to suggest that the autocrine effects of endogenous PTHrP are mediated via
PTH1R. Miyaji et al also used a monoclonal antibody directed against the (1-34)
region of PTHrP to induce a dose-dependent increase in apoptosis in
chondrosarcoma cells (Cataisson, Lieberherr et al. 2000; Miyaji, Nakase et al. 2003).
It has been suggested that PTHrP is involved in the propensity of primary tumour
cells to metastasise to one particular organ. For instance, bone is the primary
location for breast cancer metastases (Powell, Southby et al. 1991), whereas GI
tumours predominantly metastasise to the liver (Fidler 1990; Belluco, Mammano et
al. 2005). As yet, the mechanism by which PTHrP promotes this specificity is
unknown however it has been suggested that it is linked to PTHrP’s ability to alter
cell adhesion (Ye, Seitz et al. 2001).
A large portion of the research conducted on PTHrP has related to breast cancer; it
was therefore decided to give more emphasis to the role of PTHrP in GI cancer.
However as part of this project a breast cancer cell line stably transfected to over-
express PTHrP was obtained. By comparing this cell line with the corresponding
wild-type cells it was believed that this would provide a positive control for changes
in PTHrP expression and activity. Using this positive control cell line in conjunction
with several GI cell lines it was also hoped that it would be possible to investigate
potential tissue-specific differences in cell adhesion.
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As described above, there is a degree of inconsistency in the results obtained using
exogenous PTHrP peptides. It may be possible to attribute this disparity to the
different cell lines used or perhaps to variations in experimental approach. It was
therefore necessary to screen a panel of tumour-derived cell lines, characterise their
activity and explore ways in which it would be possible to manipulate PTHrP.
3.2 AIMS
x To characterise PTHrP gene and protein expression in a panel of tumour-
derived cell lines.
x To further examine the preliminary finding that there is a link between
PTHrP expression and cell adhesion and to consider possible mechanisms of
action.
x To explore the effects of exogenous PTHrP and neutralising antibodies on
proliferation and adhesion.
3.3 METHODOLOGY
3.3.1 RT-PCR Analysis of PTHrP Gene Expression
As described in Section 2.7, total RNA was extracted from approximately 1x10
6
sub-
confluent cells using RNA-Bee and cDNA generated by reverse transcription.
PTHrP expression was assessed using RT-PCR in conjunction with primers designed
to detect all forms of PTHrP. Gene expression was deemed not detectable if the Ct
of the test gene was >35 when the Ct of HPRT was <25. All RT-PCR assays were
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carried out in triplicate and results shown are expressed relative to the cell line
MDAMB231 and are average values from three replicate assays.
3.3.2 Analysis of PTHrP and PTH1R Protein Expression
PTHrP and PTH1R protein expression was detected by western blotting (Section
2.8.1) and immunocytochemistry (Section 2.8.2). For the former method, cells were
lysed, the sample concentration determined using a NanoDrop ND-1000
spectrophotometer and approximately 20µg of each sample loaded into individual
wells of the gel. Samples were then separated by electrophoresis before transfer to
either a nitrocellulose (PTHrP) or PVDF (PTH1R) membrane. Using the appropriate
monoclonal primary and biotin conjugated secondary antibody, PTHrP and PTH1R
expression were detected via chromogenic DAB visualisation.
Cells analysed by immunocytochemistry were first seeded into 8-well chamber
slides, fixed and stained for PTHrP and PTH1R using specific polyclonal and
monoclonal antibodies, respectively. Using a fluorescent labelled secondary
antibody (AlexaFlour 488 conjugated goat anti-rabbit or AlexaFlour 594 conjugated
rabbit anti-mouse) it was possible to directly visualise PTHrP and PTH1R expression
and co-localisation.
PTHrP protein expression was also examined by flow cytometry. The cells were
first fixed and the cell membrane permeabilised in order to allow staining of
intracellular PTHrP. Cells were then incubated with an anti-PTHrP monoclonal
antibody followed by a FITC conjugated rabbit anti-mouse secondary antibody.
Fluorescence was measured using a CoulterAltra flow cytometer and results
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analysed using WinMDI software (Section 2.8.3). The results shown are the average
values from three separate assays.
3.3.3 ECM Adhesion Assay
As outlined in Section 2.6, clear 96-well tissue culture plates were coated with
5Pg/mL of either collagen type I, fibronectin or laminin. [During optimisation
studies adhesion to increasing concentrations of ECM protein (0.1-100Pg/mL) was
examined and 5Pg/mL shown to be optimal. Incubation time was also investigated,
with adhesion found to be maximal after one hour (data not shown).]
Cells were harvested, added to pre-coated 96-well plates and incubated for one hour
at 37qC, 5% CO2. Non-adherent cells were removed and cell-ECM adhesion
assessed using MTT uptake. To examine the effect of exogenous peptides or
neutralising antibodies on adhesion, cells were seeded in a 24-well plate and after 24
hours growth medium removed and replaced with serum free medium containing
either 100nM of the relevant PTHrP peptide or 1Pg/mL of neutralising antibody.
Either a scrambled PTHrP peptide or IgG1-N murine ascites was used as the relevant
control. Following a further 48 hour incubation, cells were harvested and seeded
into 96-well plates coated with the appropriate ECM. The concentration of PTHrP
peptide used was based on previous in-house studies whereas the antibody
concentration was chosen following preliminary dose-response studies (data not
shown).
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MTT assays were carried out in quintuplicate and results shown are the average
values from three replicate assays.
3.3.4 Effect of Peptide Stimulation or Neutralising Antibodies on Proliferation
Proliferation assays were carried out to assess the effect of either PTHrP antibodies
or exogenous PTHrP peptides on cell proliferation. Cells were seeded into opaque
96-well tissue culture plates and the following day, growth medium replaced with
serum free medium containing 1µCi/mL [
3
H]-thymidine along with either 100nM
PTHrP peptide or 1Pg/mL neutralising antibody; again scrambled PTHrP peptide or
IgG1-N murine ascites were used as controls. Radioactivity was evaluated on
successive days, with an increase in radioactivity proportional to an increase in cell
number (Section 2.5.1 and 2.5.2). Proliferation assays were carried out in
quintuplicate and the results shown are the average values from three replicate
assays.
3.3.5 Analysis of Mitochondrial Membrane Permeability
Using the cationic dye JC-1, it was possible to examine the effect of PTHrP antibody
incubation on mitochondrial membrane depolarisation, an early stage of apoptosis.
Cells were seeded into black 96-well tissue culture plates and the following day the
growth medium was replaced with serum free medium containing either 1Pg/mL of
PTHrP neutralising antibody or IgG1-N murine ascites. After a further 48 hours, this
medium was replaced with JC-1 containing growth medium and incubated for one
hour. Excess JC-1 was washed off with Hanks Buffered Saline Solution, and the
fluorescent emission measured, with an increase in the ratio of green (~525nm) to
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red (~590nm) indicating an increase in apoptosis (Section 2.9). Each JC-1 assay was
performed in triplicate and the results shown are the average values from three
separate assays.
3.4 RESULTS
3.4.1 PTHrP Expression in a Panel of Tumour-Derived Cell Lines
3.4.1.1 Analysis of PTHrP gene expression
PTHrP gene expression was determined in a range of tumour-derived human cell
lines. These cell lines were established from colorectal (C170HM2, COLO205,
HT29), pancreatic (PAN1, PANC1) and gastric (AGS, MGLVA1 ascites) tissue.
Included in the panel were the breast cancer cell lines MDAMB231, and
MDAMB231 cells stably transfected with PTHrP cDNA encoding for amino acids
(1-141) were used as the positive control cell line (hereafter referred to as
MDAMB231 (1-141)).
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Figure 3.1 PTHrP gene expression in a range of tumour-derived cell lines.
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It can be seen in Figure 3.1 that of the nine cells analysed, PTHrP gene expression
was detected in six. It was identified in one of the three colonic cell lines, one of the
two gastric cell lines, both of the pancreatic cell lines and both of the breast cell lines
examined. Where PTHrP was detected, the expression levels varied, with the
highest expression identified in the gastric cell line MGLVA1 ascites, the pancreatic
cell line PANC1 and the PTHrP over-expressing cell line MDAMB231 (1-141).
3.4.1.2 Analysis of PTHrP protein expression
Translational regulation and post-translational processing may result in differences
between gene and protein levels. Therefore, PTHrP protein expression was
examined by western blotting using the PTHrP monoclonal antibody raised against
the amino-terminal of PTHrP. Three forms of PTHrP were detected; a representative
Breast Colon Gastric Pancreatic
96
blot can be seen in Figure 3.2. The weight of the 13 and 16kDa bands correspond to
amino-terminal proteins with different levels of post-translational processing. The
identity of the bands visible at approximately 28kDa in the AGS, HT29,
MDAMB231 (1-141) and MGLVA1 ascites cell lines are unknown, however the
size suggests that this band represents the entire PTHrP protein including the pre-pro
region.
Figure 3.2 PTHrP protein expression in a panel of tumour-derived cell lines
using a specific PTHrP antibody and visualised using a biotin conjugated
secondary antibody in conjunction with DAB.
All three bands were quantified by densitometry analysis, added together and total
PTHrP expressed relative to the MDAMB231 cell line (Figure 3.3). Although the
results partly correlate with the gene expression data shown in Figure 3.1 there are
some obvious differences; specifically it appears that the highest amount of protein
expression was found in the AGS cell line whereas gene expression was not detected
at all in these cells.
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Figure 3.3 Densitometry analysis of PTHrP western blot
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Flow cytometry analysis was subsequently used to corroborate the results obtained
by western blotting (Figure 3.4).
Figure 3.4 PTHrP protein expression a panel of tumour-derived cell lines,
measured by flow cytometry in conjunction with a specific PTHrP antibody.
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PTHrP expression was again found in all nine cell lines, which was consistent with
the results obtained with western blotting; however, the relative protein expression
varied with the highest amount of protein expression found in MGLVA1 ascites
rather than AGS. This high expression of PTHrP in MGLVA1 ascites and PANC1
cells, and low expression in AGS and COLO205 cells, is more consistent with the
gene expression results shown in Figure 3.1. As a result, the level of PTHrP
expression determined by flow cytometry was used to compare PTHrP expression
with the results obtained in subsequent assays. The hierarchy of increasing PTHrP
expression in the GI cell lines was therefore COLO205, AGS, PAN1, C170HM2,
PANC1 and MGLVA1 ascites.
3.4.2 PTHrP Receptor Expression in a Panel of Tumour-derived Cell Lines
As the effects of PTHrP (1-34) are mediated via PTH1R, it was important to first
check the presence of this receptor prior to peptide stimulation.
Western blotting with the PTH1R antibody displayed expression of an 80kDa
receptor monomer and a 160kDa receptor dimer. As with PTHrP protein expression
all nine cell lines exhibited presence of PTH1R (Figure 3.5). Densitometry analysis
was carried out on PTH1R monomer expression (Table 3.1), which revealed the
highest expression in the cell lines previously shown to express high amounts of
PTHrP i.e. MDAMB231(1-141), MGLVA1 ascites and PANC1 which may be
indicative of the autocrine/paracrine mechanism by which PTHrP functions as high
protein expression may lead to increased receptor expression or vice versa.
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Figure 3.5 PTH1R expression in a panel of tumour-derived cell lines, using a
specific PTH1R antibody and visualised via a biotin-labelled secondary
antibody in conjunction with DAB
Table 3.1 Densitometry analysis of PTH1R monomer expression
Cell Line
Densitometry analysis
(% of MDAMB231)
AGS 105
C170HM2 129
COLO205 114
HT29 87
MDAMB231 100
MDAMB231(1-141) 164
MGLVA1 ascites 188
PAN 78
PANC1 203
3.4.3 PTHrP and PTH1R localisation
Four cell lines were used to investigate co-localisation of PTHrP and its receptor.
These cell lines represented low (COLO205 and MDAMB231) and high (MGLVA1
ascites and MDAMB231(1-141)) PTHrP and PTH1R expression.
It has previously been reported that PTHrP translocates to the nucleus so the cellular
localisation of both PTHrP and PTH1R were examined using fluorescent
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visualisation with dual staining in order to examine co-localisation of the protein and
the receptor.
Figure 3.6 shows the presence of PTH1R in all four cell lines. PTHrP protein
expression was visible in three of the four cell lines. Although PTHrP was detected
in COLO205 cells by immunocytochemistry it was too low to visualise by
fluorescent microscopy suggesting that this technique is less sensitive than the other
two methods; however, these results do correspond with the gene expression data.
By overlaying the different fluorescent signals it was possible to identify co-
localisation of the protein and the receptor, indicated by a yellow signal. Distinct co-
localisation was observed, which although primarily located within the cytoplasm
was visible within the nucleus.
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Figure 3.6 Immunocytochemical detection of PTH1R (green) and PTHrP (red)
in four tumour-derived cell lines. Expression was detected using a polyclonal
PTHrP antibody, monoclonal PTH1R antibody and fluorescently labelled
secondary antibodies. The nucleus was visualised using DAPI.
a) COLO205 b) MGLVA1 ascites
c) MDAMB231 d) MDAMB231 (1-141)
3.4.4 Adhesion of a Panel of Tumour-derived Cell Lines to the Extracellular
Matrix
Having characterised PTHrP gene and protein expression, adhesion to collagen type
I, fibronectin and laminin was explored in an effort to highlight a link between
PTHrP expression and adhesion.
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By comparing PTHrP expression in these cell lines to their adhesion to the three
ECM components, Figure 3.7 demonstrates an apparent association between PTHrP
expression and adhesion to both collagen type I and fibronectin. However, although
it can be seen that overall an increase in PTHrP expression is associated with an
increase in adhesion, AGS cell adhesion to collagen type I is higher than would be
expected; similarly C170HM2 adhesion to fibronectin is lower than expected.
GI cell adhesion to laminin was generally poor and there was no obvious link with
PTHrP expression. The breast cancer cell lines did show relatively strong adherence
to laminin. However, while there was an increase in adherence of the over-
expressing cell line MDAMB231 (1-141) compared with the wild-type, this increase
was relatively small and not statistically significant. Similarly there was no apparent
increase in adhesion of MDAMB231 (1-141) cells to collagen type I or fibronectin,
compared with the wild-type.
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Figure 3.7 Adhesion of a panel of tumour-derived cell lines to the extracellular
matrix components collagen type I, fibronectin and laminin.
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b) Fibronectin
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3.4.5 Analysis of Integrin Expression in a Panel of Tumour-derived Cell Lines
The cell adhesion molecules integrins are important mediators of cell-ECM
interaction. Gene and protein expression was therefore examined in an effort to
elucidate the apparent link between PTHrP expression and cell adhesion. Only the
six cell lines which had demonstrated positive PTHrP expression at both the gene
and protein level were analysed.
When integrin gene expression is considered in the GI cell lines there also appears to
EHDQDVVRFLDWLRQEHWZHHQ37+U3DQGH[SUHVVLRQRIWKHLQWHJULQVXEXQLWVĮ1Į3Į5
DQG ȕ1 (Figure 3.8). When expression off the integrin subunits are similarly
compared with PTHrP expression in the two breast cancer cell lines, only a small
increase in integrin expression is detected and this increase was not statistically
significant. However this is consistent with the results obtained when adhesion of
these cell lines was analysed.
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Figure 3.8 Integrin gene expression in panel of tumour-derived cell lines.
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7KH LQWHJULQ VXEXQLWV Į2 Į5 Į6 ȕ1 ȕ3 DQG ȕ4 were chosen for analysis of protein
expression. As with the integrin gene expression data, an increase in PTHrP
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H[SUHVVLRQ LVDVVRFLDWHGZLWKDQ LQFUHDVHH[SUHVVLRQRIĮ5DQGȕ1 expression in the
*,FHOO OLQHVDQGĮ5Į6ȕ1DQGȕ4 expression in the breast cancer cell lines (Figure
3.9). As before the increase in integrin expression between the two breast cancer cell
OLQHV ZDV UHODWLYHO\ VPDOO DQG QRW VWDWLVWLFDOO\ VLJQLILFDQW  ȕ3 expression was not
detected in any of the cell lines examined, consequently the data is not shown.
Figure 3.9 Integrin protein expression in a panel of tumour-derived cell lines.
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3.4.6 Effect of PTHrP Manipulation on Cell Proliferation
As mentioned earlier, various exogenous peptides have been used in an attempt to
elucidate the role of PTHrP in cell growth, with varying results. It was therefore
decided to explore the effects of neutralising antibodies and exogenous PTHrP
daughter peptides on cell proliferation.
3.4.6.1 Effect of neutralising antibodies on cell proliferation
Two antibodies were used to neutralise the effects of PTHrP. One was used to
neutralise PTHrP (1-34) and the other PTHrP (38-64). Having carried out a titration
of both antibodies, the maximal effect was observed using 1µg/mL after 72 hours
(data not shown).
The PTHrP (1-34) antibody produced a modest, although significant decrease in
proliferation compared with control; however, the PTHrP (38-64) antibody had no
effect (Figure 3.10, One-way ANOVA * p<0.05, ** p<0.001). The greatest
decreases were observed in the cell lines expressing the most PTHrP: there was a
~16.5% decrease in proliferation in MGLVA1 ascites and MDAMB231 (1-141)
cells treated with the PTHrP (1-34) antibody compared with control. The
MDAMB231 and COLO205 cell lines demonstrated a decrease in proliferation of
only 14.9% and 10.4%, respectively.
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Figure 3.10 Effect of PTHrP antibodies and proliferation, after 72 hours.
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3.4.6.2 Effect of exogenous PTHrP peptides on cell proliferation
Various PTHrP daughter peptides were used to examine the effect on cell
proliferation over 72 hours. These included PTHrP (1-34), (67-86), (67-101) (107-
139) and (140-173), which correspond to amino-terminal, mid-region without NLS,
mid-region including NLS, osteostatin and carboxyl-terminal, respectively.
After 72 hours there was a significant increase in proliferation in cells treated with
PTHrP (1-34) (One-way ANOVA, p<0.05). None of the other peptides were able to
significantly affect proliferation in any of the four cell lines examined (Figure 3.11).
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Figure 3.11 Effect of peptide addition on proliferation.
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3.4.7 Assay of Anti-apoptotic Effects of PTHrP
The effect on apoptosis was subsequently examined using 1µg/mL antibody in
conjunction with the JC-1 assay. Again only the PTHrP (1-34) neutralising antibody
produced a response, with a significant increase in apoptosis compared with control
(Figure 3.12, One-way ANOVA, * p<0.0001).
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Figure 3.12 Effect of antibody addition on apoptosis, measured using JC-1
assay.
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3.4.8 Effect of PTHrP Manipulation on Cell Adhesion
Both the exogenous peptides and neutralising antibodies were assayed for their
impact on cell adhesion.
3.4.8.1 PTHrP neutralisation and adhesion
The PTHrP (1-34) neutralising antibody had previously been used to induce a
significant decrease in cell proliferation and was subsequently used to further
examine the role of PTHrP in cell adhesion. Despite not causing a significant
reduction in proliferation, the effect of the (38-64) antibody was also examined in
order to determine if mid-region PTHrP played a role in adhesion.
111
Figure 3.13 Effect of pre-incubation with PTHrP antibodies on ECM adhesion
as determined by MTT uptake. Results shown are expressed as percentage of
control.
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Again the antibodies produced modest results however Figure 3.13 demonstrates that
the PTHrP (38-64) antibody caused a significant reduction in adhesion to collagen
type I and fibronectin in all four cell lines examined. It was also able to reduce
adhesion of both breast cancer cell lines to laminin. The (1-34) antibody also caused
a significant reduction in breast cancer cell adhesion to laminin as well as a
significant reduction in MGLVA1 ascites adhesion to collagen type I and
fibronectin. This antibody also reduced MDAMB231 (1-141) adhesion to collagen
type I and MDAMB231 adhesion to laminin (One-way ANOVA, * p<0.05, **
p<0.005).
3.4.8.2 Effect of exogenous peptides on cell adhesion
Analysis of adhesion following antibody addition indicated that amino- and mid-
terminal PTHrP was involved. When the effect of exogenous peptide addition on
adhesion was examined, there was no effect on adhesion to collagen type I or
fibronectin (Figure 3.14); effects on adhesion to laminin were not investigated.
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Figure 3.14 Effect of peptide addition on ECM adhesion as determined by MTT
uptake. Results shown are expressed as percentage of control.
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3.5 DISCUSSION
Western blotting and flow cytometry were both used to examine protein expression.
Both assays demonstrated that although low gene expression does not always allow
detection of PTHrP, the protein is expressed by each of the cell lines used in this
study. Each of the methods has its drawbacks for instance as western blotting
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separates proteins by size, proteins with different levels of processing are detected
thereby making it more specific but also making it more difficult to fully quantify the
total level of PTHrP protein expression. Flow cytometry analysis on the other hand
appears to demonstrate lower sensitivity compared with western blotting, although it
did correlate well with the gene expression and cell adhesion data.
Immunocytochemistry also allowed the examination of PTHrP protein expression
and although it was not possible to quantify the data, the results did correspond with
the gene expression data. Following densitometry analysis it can be seen that the
results obtained by western blotting also correlated with the gene expression results,
with the exception of AGS and C170HM2, which showed relatively high protein
expression. Although protein levels were quantified so that equal amounts of protein
would be loaded, a loading control such as E-actin was not used. Therefore there
may have been differences in the amount of protein actually loaded onto the gel so
repeating the western blot protein characterisation using a loading control would
help to clarify the protein expression in each of these cell lines.
By comparing PTHrP expression (as determined by flow cytometry) and adhesion to
the ECM proteins collagen type I, fibronectin and laminin there was an indication of
a relationship between PTHrP and adhesion with an increase in PTHrP expression
parallel to an increase in cell adhesion to collagen type I and fibronectin. Adhesion
of the GI cell lines to laminin was generally poor and there was no indication of a
relationship between PTHrP expression and cell adhesion to this ECM protein.
Although it was possible to examine PTHrP expression in a panel of cell lines and
use this to investigate its relationship with cell adhesion, it was also considered
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important that a control cell line be included whereby changes in PTHrP expression
could be directly correlated to downstream effects, independent of possible
differences between cell lines. The breast cancer cell line MDAMB231 (1-141),
which contained the coding region for PTHrP (1-141), was used. Despite observing
a 10,000 fold increase in PTHrP gene expression, when adhesion of this cell line to
the ECM proteins was examined and compared with the corresponding wild-type
cell line although there was a small increase in adhesion to laminin when PTHrP was
over-expressed this was not statistically significant and there was no increase in
adhesion to either collagen type I or fibronectin. Taken in isolation, this result
suggested that PTHrP did not play a role in ECM adhesion. However, taking into
consideration the results obtained from the panel of GI cell lines, which did show a
positive correlation between PTHrP expression and cell-ECM adhesion, reservations
concerning this cell line’s role as a positive control arose.
A number of studies had suggested a role for PTHrP in cell growth, with exogenous
PTHrP daughter peptides shown to be mitogenic (Villaneuva-Penacarrillo, Cancelas
et al. 1999; Asadi, Faraj et al. 2001), anti-mitogenic (Luparello, Romanotto et al.
2001) and anti-apoptotic (Aarts, Davidson et al. 2001; Tovar Sepulveda, Shen et al.
2002). However, due to some apparent inconsistency in the published date it was
unknown how the panel of tumour cell lines used here would respond to peptide
stimulation.
Only PTHrP (1-34) was able to induce any change in cell proliferation, inducing a
significant increase in proliferation in all four cell lines examined. When antibodies
were used to neutralise endogenous PTHrP there was a significant decrease in
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proliferation in all four cell lines with the antibody directed towards PTHrP (1-34)
whereas the antibody directed towards PTHrP (38-64) had no effect on cell
proliferation. These results suggest that PTHrP (1-34) stimulates proliferation and it
can be hypothesised that this is mediated via PTH1R.
When cell-ECM adhesion was examined, none of the exogenous peptides induced
any significant effect; however, neutralisation of endogenous PTHrP resulted in a
decrease in cell adhesion. So proliferation appears to be mediated by both
exogenous and endogenous PTHrP suggesting an autocrine and/or paracrine
mechanism. Adhesion, on the other hand, appears to be mediated solely by an
intracrine mechanism.
The three ECM proteins used here are ligands for different integrin heterodimers and
the combination of the subunits determines the specificity. When integrin expression
was examined there were differences in endogenous integrin subunit expression
between the GI cell lines. Furthermore, several of these subunits showed a
connection to PTHrP expression with a correlation between integrin and PTHrP
expression. For example, higher PTHrP expression was associated with higher
H[SUHVVLRQ RI WKH LQWHJULQV Į1 Į3 Į5 DQG ȕ1  7KH LQFUHDVH LQ Į5 DQG ȕ1 gene
expression was also seen at the protein level. There were no changes in expression
RIĮ6DQGȕ4 DQGDVĮ6ȕ4 is a receptor for laminin this relates to the adhesion data.
6LPLODUO\DVĮ1ȕ1Į3ȕ1DQGĮ5ȕ1 are receptors for collagen type I, fibronectin or both
these results also tie in with the adhesion data for the GI cell lines.
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$OWKRXJKWKHUHZDVVOLJKWO\KLJKHUH[SUHVVLRQRIĮ3Į5ȕ1 DQGȕ4 in the PTHrP over-
expressing breast cancer cell line compared with the wild-type cell line this was not
statistically significant, therefore correlating to the lack of difference in adhesion
observed with these two cell lines.
The aim of these initial studies was to characterise PTHrP expression and to then
explore a role for this protein in cancer cell adhesion. The results described here
suggest a role for PTHrP in proliferation, apoptosis and adhesion however they also
show that the exogenous peptides do not mimic the effects of endogenous PTHrP
and that endogenous PTHrP is related to adhesion, the main focus of this study.
Furthermore, owing to the limited effects of the neutralising antibodies as well as the
costs involved, it was felt important to find an alternative means of regulating PTHrP
expression.
Although, using the panel of tumour-derived cell lines, it was possible to identify a
trend whereby PTHrP was linked to adhesion and integrin expression it was difficult
to come to any definitive conclusions as the endogenous levels of integrin expression
varied between tissues. For example, the two pancreatic cell lines exhibited lower
levels of integrin expression than the other GI cell lines. In addition, although it was
possible to compare endogenous integrin and PTHrP expression it was unknown
how manipulating PTHrP expression would affect integrin expression and unclear as
to the manner in which the two were linked. In order to further examine the
mechanism of PTHrP’s action on integrin expression an alternative means of
regulating PTHrP expression was sought.
Chapter 4:
Manipulating the Actions of
PTHrP
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4.1 INTRODUCTION
The results described in Chapter 3 suggested a link between PTHrP expression and
adhesion, which was mediated via the cell adhesion molecules, integrins. However
although there was evidence of an association, the results were by no means
definitive.
The use of two different antibodies directed towards the amino-terminal and mid-
region of PTHrP provided a successful means of reducing the PTHrP-mediated
effects on cell adhesion and proliferation. However, not only was this a costly way
of blocking the actions of PTHrP but the resultant effects were relatively minor.
Alternative methods were therefore considered in an effort to find a more effective
means of negating the effects of PTHrP.
Following the sequencing of the human genome, silencing gene expression has been
an effective and valuable tool in exploring the functions of previously
uncharacterised genes. Anti-sense oligodeoxynucleotides (As-ODNs) have
frequently been used in this capacity following their initial description in 1977
(Paterson, Roberts et al. 1977) and have to date been the method of choice for
regulating gene expression both in vivo and in vitro.
Anti-sense technology has previously been successfully used to inhibit PTHrP. For
example, furin cDNA, a proprotein convertase within the secretory pathway, has
been used in an anti-sense orientation to inhibit processing of PTHrP in rat leydig
tumour cells (Liu, Amizuka et al. 1995). Tsukazaki et al used anti-sense
oligonucleotides targeted against PTHrP directly and were able to decrease
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translation of PTHrP mRNA which resulted in inhibition of DNA synthesis
(Tsukazaki, Ohtsuru et al. 1996).
In spite of their wide-spread use, As-ODNs have a number of weaknesses which
have made their use problematic. For example, selecting a sequence within the
mRNA target is not an easy task as mRNA associated proteins and the tertiary
structure of mRNA often physically block binding of the As-ODN. A hit and miss
approach is commonly used which results in a low success rate. Delivery is another
problem area, as a result of degradation by endonucleases and exonucleases, and
passive diffusion across the cell membrane cannot occur as As-ODNs are
polyanionic. This necessitates As-ODN stabilisation through modifications of
phosphodiester bridges and sugar moieties. It has been demonstrated that As-ODN
uptake is time, energy, temperature and concentration dependent with Gewirtz and
colleagues showing that at lower concentrations a “receptor-like mechanism” is
responsible for uptake whereas other studies have shown that at higher
concentrations this switches to endocytosis (Beltinger, Saragovi et al. 1995). Once
an effective As-ODN has been found and successfully introduced into a cell, it is
often necessary to use high concentrations in order to induce a prolonged inhibition
of mRNA translation. So it can be seen that the use of As-ODNs can be both time-
consuming and expensive (Gewirtz, Sokol et al. 1998).
The discovery of RNA interference however has made gene silencing a much
simpler task and has revolutionised this area of research as it has quickly emerged as
a powerful tool for suppressing gene expression. As with most discoveries, RNA
interference was first stumbled upon by a group of researchers who were attempting
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to deepen the purple colour of petunias by over-expressing a key enzyme in plant
coloration (Napoli, Lemieux et al. 1990). What they found instead was that the
introduction of the cDNA for this enzyme actually caused 42% of the flowers to turn
either totally white or to contain white areas. Further study showed that the
introduction of this gene reduced expression of the homologous gene, a phenomenon
the authors described as “co-suppression” but one that they were unable to explain.
Napoli et al’s idea of “co-suppression” was further developed when the researchers
Guo and Kemphues used anti-sense RNA to inhibit par-1 gene expression in
Caenorhabditis elegans (C.elegans). They used the corresponding sense strand as a
control and to their surprise the sense strand was able to induce a similar reduction in
gene expression compared with the anti-sense strand (Guo and Kemphues 1995).
Fire et al expanded on this finding by demonstrating that the use of double-stranded
RNA (dsRNA) to silence gene expression in C.elegans was more effective than
using either the sense or anti-sense strand alone and were the first to label this event
RNA interference (RNAi). Their research also showed that only a few molecules of
dsRNA were required to induce a significant decrease in gene expression, that
dsRNA targeted against introns or promoter sequences were ineffective at reducing
gene expression, and that the gene silencing was also inherited by the offspring of
the targeted C.elegans (Fire, Xu et al. 1998). For their efforts Dr Andrew Fire and
Dr Craig Mello were awarded the 2006 Nobel Prize for medicine.
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4.1.1 RNAi Mechanism of Action
Double stranded RNA are generated in the nucleus and following transport to the
cytoplasm are cleaved by Dicer (a highly conserved RNase-III-like dsRNA-specific
ribonuclease) in an ATP dependent, processive manner to produce dsRNA 21-23
nucleotides (nt) in length. These dsRNA are known as small interfering RNA
(siRNA) and their processing, which is known as the initiator step, is illustrated in
Figure 4.1 (Timmons 2002; Lieberman, Song et al. 2003).
Figure 4.1 –Initiator step of siRNA production, whereby dsRNA moves from
the nucleus to the cytoplasm where it is cleaved by Dicer to produce small
interfering RNA
The siRNA then undergo further processing to produce an siRNA with a free 5’-
monophosphate and a 3’–hydroxyl group, which are necessary for incorporation into
the RNA-induced silencing complex (RISC) (Lipardi, Wei et al. 2001; Lieberman,
Song et al. 2003; Lieberman, Song et al. 2003). The presence of the two-base 3’
overhang has also been shown to increase the potency of the siRNA (Elbashir,
Harborth et al. 2001).
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+
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The introduction of chemically synthesised 21nt siRNA results in the bypass of this
initiator step and the siRNA are able to enter directly into RISC. When the siRNA
goes on to induce gene silencing this is known as the effector step, which can be
seen in Figure 4.2.
Figure 4.2 –Effector step of siRNA action
During this step, the duplex siRNA is unwound by an ATP-dependent helicase. One
strand is then incorporated into RISC, a multi-protein complex that includes an
effector nuclease. The siRNA strand then binds to the homologous target RNA and
RISC is then able to guide RNA cleavage. It is thought that RISC includes an
siRNAs bind to nuclease
complex
siRNA
3’OH
5’P
5’P
3’OH
Inactive RISC
RISC
Cleavage of target transcript
siRNA
mRNA
Active RISC associates with
target transcript
ATP
Active RISC 5’P3’OH
RISC
Unwinding of
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124
endonuclease which is responsible for cleaving the RNA in the middle of the
homologous sequence, ~12 nucleotides from the 3’ terminus of the siRNA
(Lieberman, Song et al. 2003).
Unlike As-ODNs, it is relatively easy to design an effective siRNA and various
guidelines have been developed based on previously verified effective siRNA.
Criteria taken into account when designing an siRNA include G/C content,
thermodynamic stability, an avoidance of internal repeats and the preferential use of
specific bases at known positions on the sense strand (i.e. positions 3, 10, 13 and 19).
However, it has also been shown that some siRNA which did not satisfy these
criteria were still functional siRNA; as such there are no absolute rules for siRNA
design. Nevertheless by using their general rules Reynolds et al were able to
increase their success rate at selecting an siRNA able to induce more than 80%
knockdown by 3.5 fold (Reynolds, Leake et al. 2004).
Not only are siRNAs now commonly used within the laboratory to induce gene
silencing but there are a number of siRNA currently undergoing clinical trials. For
example Cand5 has been developed to silence VEGF expression in macular
degeneration (Tolention, Brucker et al. 2004). Patient enrolment for a Phase II trial
was completed in early 2006 and so far the trial has produced positive results. Initial
results have shown it to be safe and there is evidence of dose-dependent efficacy
(www.acuitypharma.com).
Although siRNA have been shown to be an effective tool in silencing gene
expression, and are a valuable tool for examining the role of novel genes, they do
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have a number of disadvantages which require consideration. For example, a recent
study demonstrated that not all siRNA which have been shown to silence gene
expression also go on to silence protein expression. Whilst developing a method
whereby they could examine changes in protein expression in novel genes silenced
by siRNA, Wu et al examined the effects of a siRNA on both gene and protein
expression. Their initial study examined four genes and used three different siRNA
for each gene. When this was expanded to 30 genes they showed that in three cases
even though there was a decrease in mRNA levels there was no decrease in protein
expression. As such, it is ill-advised to make conclusions regarding the effects of
gene silencing without knowing that the corresponding protein has also been down-
regulated (Wu, Hodges et al. 2004).
Another factor which must be taken into account when using siRNA is the
observation that the introduction of dsRNA into mammalian cells can result in the
induction of an antiviral pathway. Interferons are cytokines which are involved in
the first line of defence during viral infection and as dsRNA are commonly
associated with viruses their introduction to the cell appears to inadvertently trigger
these cytokines. The innate interferon response appears to be mediated by the
protein kinase PKR, which phosphorylates several substrates including the
translation initiation factor eIF2D. Once phosphorylated, eIF2D initiates a cascade
leading to inhibition of protein synthesis (Stark, Kerr et al. 1998). It has been shown
that dsRNA >30nt in length are also able to bind and activate 2’,5’-oligoadenylate
synthetase which in turn activates RNaseL, a general ribonuclease that degrades
cellular RNAs and shuts down protein translation (Wang and Carmichael 2004).
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PKR activation is dependent on the length and concentration of dsRNA with the
minimum length required for PKR activation being 33bp. Elbashir et al
demonstrated that the use of 21bp siRNA circumvents induction of the interferon
pathway (Elbashir, Harborth et al. 2001).
As with ODNs, delivery of siRNA can also be problematic, however due to the
potency of siRNAs it is not necessary to deliver as much in order to be effective.
Indeed, when Bertrand et al compared As-ODNs and an siRNA, both directed
towards the coding region of GFP, they were able to show that the siRNA not only
induced a greater decrease in GFP expression but that this decrease lasted longer
than that induced by the ODN (Bertrand, Pottier et al. 2002).
Due to the numerous advantages of RNAi it was decided to use this technique as a
means to down-regulate PTHrP during the course of this study.
The breast cancer cell line MDAMB231 transfected with the cDNA encoding for
PTHrP (1-141) was intended to be used as a positive control for PTHrP over-
expression. However, there was no increase in adhesion compared with the wild-
type cell line and as a result it was also decided to either obtain or construct PTHrP
expression vectors in order to produce some alternative over-expressing cell lines.
Xiaoli Shen and Miriam Falzon have constructed several PTHrP over-expressing cell
lines and by deleting the nuclear localisation sequence have shown some noteworthy
intracrine effects. Upon application, Professor Miriam Falzon kindly agreed to
donate her PTHrP-containing vectors.
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It was hoped that both the siRNA and expression vectors would provide useful tools
for investigating the actions of PTHrP.
4.2 AIMS
x To develop an effective mechanism of silencing PTHrP expression.
x To use the PTHrP-containing expression vectors to stably transfect a GI and
breast mammalian cell line.
x To explore the effects of PTHrP on cell growth.
4.3 METHODS
4.3.1 siRNA Construction and Transfection
As described in Section 2.2.1, Ambion’s siRNA Design Centre was used to identify
over 30 possible targets within the PTHrP nucleotide gene sequence. These siRNAs
were checked for homology with other genes using the web based tool BLAST and
three siRNAs subsequently chosen. The sense and anti-sense oligonucleotides of
these targets were purchased and the siRNA constructed using the Silencer siRNA
Construction kit. Fluorescent siRNA were constructed using an NTP mix containing
fluorescein-12-UTP.
An siRNA specific to the house-keeping gene GAPDH was used as a control whilst
assessing the activities of the three PTHrP siRNA. Once the most effective of the
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three had been identified, a scrambled version was constructed for use as an
alternative positive control.
Cells were harvested and seeded into 24-well plates one day prior to transfection.
The following day the cells were transiently transfected with the appropriate
preformed siRNA/siPORT Amine complex (see Section 2.4.1). During optimisation
studies different volumes of siPORT Amine were tested (1, 2 and 4µL); 2µL was
found to induce the greatest decrease in gene expression and this volume was
subsequently used during all future siRNA transfections.
4.3.2 Analysis of Gene Expression
In order to analyse gene expression, RNA was extracted using RNA-Bee and reverse
transcribed to produce cDNA. This cDNA was then used to analyse gene expression
of PTHrP, OAS and STAT by RT-PCR, as described in Section 2.7. All RT-PCR
assays were performed in triplicate. Unless otherwise stated results shown are
expressed relative to the scrambled PTHrP siRNA or vector control, where
appropriate, and are the average values from three replicate assays.
4.3.3 Analysis of PTHrP Protein Expression
Following siRNA transfection, PTHrP protein expression was measured using both
flow cytometry and western blotting. For flow cytometry, cells were harvested,
fixed and stained with a primary antibody raised against PTHrP (1-34), followed by
a PE-conjugated secondary antibody. Fluorescence was measured using a
CoulterAltra flow cytometer and results analysed using WinMDI software (Section
2.8.3).
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Samples for western blotting were prepared by cell lysis, the proteins separated by
electrophoresis before transfer to a nitrocellulose membrane and the detection of
PTHrP protein using a primary PTHrP (1-34) antibody in conjunction with a biotin-
labelled secondary antibody. E-actin was used as a loading control to ensure that
equal amounts of protein were loaded per lane. Protein expression was visualised
using ECL in conjunction with a Chemi Genius
2
BioImaging System (Section 2.8.1).
4.3.4 Transfection Protocol
The pcDNA3.1 vectors containing a geneticin selection marker as well as cDNA
encoding for PTHrP were transfected into MDAMB231 and HT29 cells using
Lipofectamine 2000. Three vectors were used; one contained cDNA encoding for
amino acids (-5 to +139), one contained PTHrP encoding for cDNA with the nuclear
localisation sequence (residues 88-91 and 102-106) deleted, and an empty vector was
used as a negative control (Section 2.4.2).
Transfected cells were selected using 500µg/mL geneticin and resistant cells selected
in 96-well tissue plates and expanded into T75cm
2
tissue culture flasks. Over-
expression of PTHrP was assessed using RT-PCR and two clones from each cell line
chosen for further analysis.
4.3.5 PTHrP Silencing and Proliferation
The effect of PTHrP silencing was examined using [
3
H]-thymidine incorporation as
a measure of cell proliferation, as described in Section 2.5.3. Transfected cells were
re-plated into an opaque 96-well plate and incubated with 1µCi/mL [
3
H]-thymidine.
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Radioactivity was counted daily, with an increase being proportional to an increase
in DNA synthesis and therefore related to an assessment of proliferation.
4.3.6 Clonagenicity Assays
Cells transfected with either the pcDNA3.1 vector containing PTHrP cDNA (with
and without the NLS) or the empty vector control were seeded into opaque 96-well
plates and incubated with 1µCi/mL [
3
H]-thymidine. Radioactivity was counted
daily, where an increase in radioactivity was indicative of an increase in proliferation
(Section 2.5.4). Assays were carried out in quintuplicate and all results shown are
the average values of three replicate assays.
4.3.7 Mitochondrial Membrane Potential Assay
As described in Section 2.9, apoptosis was examined using the cationic dye JC-1,
which exhibits potential-dependent accumulation in mitochondria. Cells transfected
with either the PTHrP siRNA or scrambled control were seeded into black 96-well
plates and grown for 72 hours before a one hour incubation with 5µM JC-1 dye
diluted in 10% FBS growth medium. Excess JC-1 was then removed and fluorescent
emission examined with a shift in fluorescence emission from red (~590nm) to green
(~525nm) was indicative of a lack of mitochondrial membrane potential and,
therefore, apoptosis.
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4.4 RESULTS
4.4.1 PTHrP Small Interfering RNA
4.4.1.1 PTHrP gene expression following siRNA transfection
Three siRNAs were chosen for construction and transiently transfected into
MGLVA1 ascites. This cell line was chosen as it had previously demonstrated a
high level of PTHrP expression, both at the gene and protein level. All three siRNAs
target sequences within exon VI, which is present within all three PTHrP isoforms.
Each siRNA was serially diluted. In a final transfection volume of 250µL the
working concentration of neat siRNA (20µM) was equivalent to 80nM, with
successive dilutions equivalent to 8nM, 0.8nM and 0.08nM.
The level of PTHrP gene expression was measured 24 hours following transfection
and Figure 4.3 demonstrates that all three siRNAs were able to significantly reduce
PTHrP gene expression (Students t-test, p<0.0001). The siRNA designated Target
19 proved to be the most effective at down regulating PTHrP, followed by Target 4
and Target 28. Even at its lowest concentration, Target 19 produced a greater than
80% decrease in PTHrP gene expression and was consequently chosen for further
study.
For the remaining experiments the chosen siRNA was used at a working
concentration of 8nM as it was felt that this would bring about the most effective and
economical gene silencing. Upon selection of the chosen siRNA, a scrambled
version was constructed to replace the control GAPDH siRNA.
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Figure 4.3 PTHrP gene expression following siRNA transfection in MGLVA1
ascites. Results shown are expressed relative to GAPDH siRNA and are the
mean of two separate transfection assays.
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4.4.1.2 The temporal effect of PTHrP silencing
Twenty-four hours after the PTHrP siRNA had been transiently transfected into
MGLVA1 ascites there was a >90% decrease in PTHrP gene expression. The
temporal effect of siRNA transfection was then examined and the study expanded to
include a further three cell lines. The wild-type and over-expressing MDAMB231
cell lines used previously were included; however, as PTHrP gene expression was
undetectable in COLO205 cells, this cell line was replaced by another GI cell line,
HT29, which had previously demonstrated PTHrP gene expression similar to that of
MDAMB231.
Gene down-regulation was maximal at day one in all four cell lines when there was a
significant reduction in PTHrP gene expression of 80-90% compared with control.
On subsequent days PTHrP gene expression slowly increased which is consistent
with the transient nature of siRNA (Figure 4.4; Students t-test, p<0.0001).
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Figure 4.4 Duration of PTHrP gene silencing in four tumour-derived cell lines.
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4.4.1.3 Protein down-regulation
Protein expression following siRNA transfection was examined in order to confirm
that gene silencing translated into a decrease in protein expression.
Protein expression was first examined using flow cytometry. Used in conjunction
with a fluorescent siRNA this technique allowed the examination of PTHrP protein
expression as well as providing an indication of transfection efficiency.
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Fluorescent siRNA were constructed (see Section 4.3.1) in order to compare the
level of transfection obtained with the control and PTHrP siRNA. MGLVA1 ascites
were transfected with either fluorescent control or PTHrP siRNA and the
fluorescence emitted from the siRNA detected by flow cytometry. The overlay of
the histograms obtained from these cells can be seen in Figure 4.5a and there is no
apparent difference between the two siRNAs. Furthermore, the mean fluorescent
intensities obtained from the two siRNAs were similar. These results indicate that
the transfection efficiency of both siRNAs are comparable and therefore any changes
in protein expression can be attributed to PTHrP gene silencing rather than
differences in siRNA uptake.
When PTHrP protein expression was examined by flow cytometry following siRNA
transfection a decrease in protein expression was observed. This decrease is
illustrated by the shift in fluorescence between the control and PTHrP siRNA
transfected cells (Figure 4.5b). Figure 4.5b also demonstrates that two cell
populations were sometimes detected in PTHrP siRNA transfected cells. Population
one appears to represent cells in which the siRNA was taken up and PTHrP silenced:
population two contains cells where the siRNA was also taken up but was
ineffective. These two populations were not always detected as the two peaks often
merged into one.
When the temporal effect of siRNA transfection on protein expression was
examined, the decrease in expression was maximal five days after transfection
(Figure 4.5c). However, despite achieving a decrease in gene expression of more
than 90% a reduction in protein expression of only ~30% was detected.
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Figure 4.5 Flow cytometry analysis of siRNA transfected cells
a) Fluorescence emitted from fluorescent control or
PTHrP siRNA transfected MGLVA1 ascites
b) Fluorescence emitted from rabbit anti-mouse FITC
secondary antibody in MGLVA1 ascites transfected
with either scrambled control or PTHrP siRNA
c) Temporal effect of siRNA transfection on protein expression
in MGLVA1 ascites (mean results from three separate assays)
Day After Transfection
D1 D3 D5 D7
M
ea
n
F
lu
o
re
sc
e
n
t
In
te
n
si
ty
0
100
200
300
400
500
600 Control
PTHrP
Scrambled control
PTHrP siRNA
Scrambled control
PTHrP siRNA
Population 2
Population 1
136
When protein expression was examined in MGLVA1 ascites following siRNA
transfection using western blotting, the greatest decrease in protein expression was
observed five days after transfection, which correlated with the results obtained by
flow cytometry. However, a 45% decrease in PTHrP protein expression was
observed whereas only a 32% decrease was observed using flow cytometry.
Western blotting was therefore subsequently used to examine protein expression in
the other three cell lines. Again the greatest decrease in protein expression occurred
five days after transfection in these cell lines (Figure 4.6).
Figure 4.6 PTHrP and E-actin protein expression five days following
transfection with either the PTHrP siRNA or the scrambled control.
The results from densitometry analysis are summarised in Table 4.1 and show a
decrease in protein expression between 40 and 70% compared with the scrambled
control siRNA. E-actin was used as a loading control and Figure 4.6 shows similar
protein levels in both control and PTHrP siRNA samples, thereby demonstrating that
the differences in protein expression observed can be directly attributed to PTHrP
silencing.
MGLVA1 MDAMB231
ascites HT29 (1-141) MDAMB231
Control/siRNA Control/siRNA Control/siRNA Control/siRNA
PTHrP
18kDa
E-actin
44kDa
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Table 4.1 Densitometry analysis of western blots shown in Figure 4.6
Cell Line
Protein Expression
(% of scrambled control)
MGLVA1 ascites 55.85
HT29 56.2
MDAMB231 (1-141) 32.17
MDAMB231 59.03
4.4.1.4 Induction of the innate interferon response
Several groups have shown that siRNA are able to induce the innate interferon
response and thereby cause the cessation of protein translation. Interferon
expression was therefore examined in order to demonstrate that the siRNAs used in
this study did not induce such a response.
Using primers specific for the interferon subunits STAT and OAS all four cell lines
were examined for interferon expression. There was no apparent increase in
expression of either STAT or OAS in any of the four cell lines examined following
siRNA transfection which indicates that the innate interferon response was not
induced and therefore the decrease in protein expression observed was the result of
the specific actions of the PTHrP siRNA (Figure 4.7). Furthermore, as E-actin
expression did not change following siRNA transfection (Figure 4.6) this also
demonstrates that protein expression wasn’t affected.
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Figure 4.7 Effect of PTHrP siRNA transfection on interferon induction,
determined using primers specific for the interferon genes STAT and OAS.
Results shown are expressed relative to scrambled control siRNA and are the
mean values from two replicate assays.
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4.4.2 Construction of PTHrP Over-expressing Cell Lines
The breast cancer cell line MDAMB231 and the colonic cancer cell line HT29 were
transfected with either the empty expression vector or those containing cDNA
encoding for PTHrP. Figure 4.8 shows PTHrP expression in several of the selected
geneticin resistant clones. Varying levels of PTHrP expression were observed in the
transfected cells and two positive clones were selected for each plasmid. The HT29
cells over-expressing full-length PTHrP were designated PTHrP (2) and PTHrP (4).
Cells expressing PTHrP but lacking the NLS were designated NLS (1) and NLS (3).
Similarly the MDAMB231 cells were designated PTHrP (1), PTHrP (2), NLS (1)
and NLS (3).
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Figure 4.8 PTHrP expression in cells transfected with pcDNA3.1 vectors
containing cDNA encoding for PTHrP (with and without the NLS). Results
shown are expressed relative to cells containing the vector only and are the
mean values of two separate RT-PCR assays.
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4.4.3 PTHrP and Cell Proliferation
4.4.3.1 Effect of PTHrP silencing on proliferation
Using the siRNA targeted against PTHrP, protein expression had successfully been
reduced therefore, resulting effects on proliferation were examined.
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Figure 4.9 shows that there was a significant reduction in proliferation in each of the
four cell lines examined, which was maximal seven days following transfection
(Students t-test, * p<0.05, ** p<0.005). Table 4.2 shows the percentage decrease in
proliferation on day seven and demonstrates that MDAMB231 (1-141) was more
sensitive to gene silencing than the corresponding wild-type, although this was not a
significant difference. Similarly MGLVA1 ascites was more sensitive than the other
GI cell line HT29. The greater decrease in proliferation thus correlates with the
higher endogenous PTHrP expression found in MGLVA1 ascites and MDAMB231
(1-141) and is consistent with the greater decrease in gene and protein expression
previously demonstrated (See Figures 4.4 and 4.6).
Figure 4.9 Effect of transfection of either PTHrP siRNA or scrambled control
on proliferation.
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Table 4.2 Percentage inhibition of proliferation
Cell Line
Maximal Inhibition of Proliferation
(% of Control)
MGLVA1 ascites 29.03
HT29 26.9
MDAMB231 (1-141) 38.09
MDAMB231 33.75
4.4.3.2 Effect of PTHrP over-expression on proliferation
Proliferation was also examined in the PTHrP over-expressing cell lines and
compared with cells containing the vector only. Figure 4.10 demonstrates that after
72 hours the HT29 clones PTHrP (2) and (4) exhibited a significant 37% and 30%
increase in proliferation, respectively. When the MDAMB231 clones PTHrP (1) and
(2) were similarly examined there was an increase in proliferation of 61% and 49%,
respectively (One-way ANOVA, p<0.0001). Figure 4.10 also shows that despite
demonstrating a significant increase in PTHrP expression, the rate of proliferation in
all of the NLS mutant clones was not significantly different compared to vector
control.
Figure 4.10 Effect of PTHrP over-expression on cell proliferation, measured
using [
3
H]-thymidine.
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4.4.4 PTHrP Silencing and Apoptosis
Examination of cell proliferation revealed a significant decrease in [
3
H]-thymidine
incorporation in cells transfected with the PTHrP siRNA compared with scrambled
control. PTHrP has also been shown to be anti-apoptotic so the effect of PTHrP
silencing on apoptosis was investigated.
Apoptosis was examined five days subsequent to siRNA transfection, when the
decrease in PTHrP protein expression was known to be maximal. Figure 4.11 shows
that the silencing of PTHrP expression resulted in a significant increase in the
green/red fluorescent ratio of JC-1, an indicator of mitochondrial membrane
potential, in each of the four cell lines examined, indicative of an increase in
apoptosis (Students t-test, p<0.05). The increase in apoptosis was greater in siRNA-
treated MGLVA1 ascites compared with HT29 cells with an increase of 20% and
13%, respectively, and corresponds with the greater decrease in PTHrP expression
observed in MGLVA1 ascites. Conversely, transfected MDAMB231 (1-141) cells
displayed only a 12% increase in apoptosis vs. a 27% increase in MDAMB231 cells,
which is not consistent with the greater decrease in PTHrP expression detected in the
MDAMB231 (1-141) cell line.
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Figure 4.11 Mitochondrial membrane potential of cells transfected with either
PTHrP siRNA or scrambled control. Results shown are the average values of
three replicate assays.
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4.5 DISCUSSION
The results presented here demonstrate that using an siRNA homologous to PTHrP it
is possible to not only induce post-transcriptional gene silencing but this leads to a
reduction in protein expression and proliferation, and an increase in apoptosis.
Three siRNA were tested for their ability to induce post-transcriptional gene
silencing. Whilst all three were able to induce a significant decrease in PTHrP gene
expression, the siRNA designated Target 28 was noticeably less effective than
Targets 4 and 19. As mentioned previously, there are a variety of emerging
guidelines for the design of an effective siRNA, which although not conclusive have
been shown to increase siRNA potency. One of these guidelines recommends the
avoidance of internal repeats as these have been shown to promote the formation of
an internal fold-back structure (Reynolds, Leake et al. 2004). As the sequence of
Target 28 contains an internal repeat (AAGAAAAAACGGCGAACTCGC) it can be
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speculated that this is the cause of its relatively poor ability to silence PTHrP gene
expression.
The siRNA induced knock-down of gene expression is a transient effect, which is
generally believed to last between four and six cell doublings. It would therefore be
expected that the temporal effects of siRNA will depend on the rate of cell growth.
MGLVA1 ascites grow relatively slowly compared with the other three cell lines
used here and when the temporal effects of the PTHrP siRNA were examined gene
knockdown appeared to last longer in this cell line. However, when comparing the
breast cancer cell lines there was a greater inhibition of gene expression in the over-
expressing cell line, which lasted longer compared with the wild-type cell line. The
over-expressing cell line grows marginally faster than the corresponding wild-type
line so it can be speculated that the temporal effects of siRNA are not solely related
to growth rate. Indeed the longest duration of action, as well as the greatest gene
silencing, occurred in the two cell lines which demonstrate the greatest endogenous
PTHrP expression (MGLVA1 ascites and MDAMB231 (1-141)). A similar effect
was demonstrated when protein expression was examined: western blotting showed a
greater decrease in protein expression in the cell lines MGLVA1 ascites and
MDAMB231 (1-141) compared with MDAMB231 and HT29.
Protein expression was examined using both flow cytometry and western blotting.
There was a higher degree of sensitivity with western blotting which is consistent
with previous results (see Chapter 3). However the use of flow cytometry not only
provided a corroboration of the protein results obtained by western blotting but used
in conjunction with a fluorescent siRNA allowed the examination of the level of
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transfection and protein down-regulation. The fluorescence emitted by the control
siRNA-transfected cells was similar to that emitted by the PTHrP siRNA-transfected
cells, indicating a similar level of siRNA transfection. Cells transfected with the
PTHrP siRNA demonstrated a decrease in mean fluorescent intensity compared with
control and in addition it was sometimes possible to visualise two distinct cell
populations. These populations appear to represent cells where PTHrP had been
effectively silenced and cells where although there was uptake of the siRNA it was
ineffective i.e. no change in PTHrP protein expression. Sorting these two
populations by FACS would make it possible to determine if this is indeed the case.
PTHrP was manipulated in breast and GI cell lines both through over-expression and
gene silencing and the resultant effects on proliferation examined. Both mechanisms
resulted in a direct effect on cell proliferation: when PTHrP expression was silenced
there was a significant decrease in proliferation and when PTHrP expression was
increased the opposite effect was observed. Furthermore, the increase in
proliferation observed through PTHrP over-expression was reversed upon the
confinement of PTHrP to the cytoplasm. These results correspond with the results
obtained with the exogenous peptides and neutralising antibody (see Chapter 3),
where it was suggested that there was an autocrine and/or intracrine mechanism, and
also indicate that there is an important role for nuclear PTHrP in proliferation.
The results described here indicate PTHrP is mitogenic; however, PTHrP has also
been shown to be an anti-apoptotic factor. The significant increase in apoptosis
observed upon PTHrP gene silencing is therefore consistent with previous studies
(Aarts, Davidson et al. 2001; Tovar Sepulveda, Shen et al. 2002).
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When comparing the potency of the siRNA it appears that cell lines exhibiting
greater endogenous PTHrP are more sensitive to the effects of PTHrP silencing.
This is demonstrated by the greater decrease in gene expression (leading to a
similarly larger decrease in protein expression) as well as the greater decrease in
proliferation. However the levels of apoptosis observed are not completely
consistent with these earlier findings; although there was a 20% increase in apoptosis
observed in MGLVA1 ascites compared with only a 13% increase in HT29
apoptosis, there was only a 12% increase observed in MDAMB231 (1-141) cells
compared with a 27% increase in the corresponding wild-type cell line. It may be
possible to attribute this effect to an artefact associated with the breast cell lines as
the results obtained with the GI cell lines supports the earlier findings. It may also
be possible that there was a greater increase in apoptosis in MDAMB231 (1-141)
cells than was detected and that many of the dead cells may have been inadvertently
removed during the washing steps giving a somewhat misleading result. This second
scenario is much more likely as the JC-1 assay was carried out after 48 hours and
therefore the full effects of PTHrP on apoptosis could have been missed.
Consequently, repeating this assay over a number of time points and investigating
apoptosis using another assay would help to confirm that PTHrP is indeed anti-
apoptotic. For example Baskin et al used DAPI, which is excluded by viable cells,
in conjunction with a fluorescent microplate reader to examine apoptosis in both
attached and floating dead cells. Similarly Hauge et al simply quantified the number
of floating and adherent cells using a counting chamber and determined the level of
apoptosis using the number of floating cells as a percentage of total yield. They also
confirmed their finding using acridine orange, which stains both viable and dead
cells, and DNA laddering. Consequently, using an alternative method to detect
147
apoptosis would help to clarify these inconsistent findings and there are several
approaches which could be utilised in order to do so (Baskin, Ngo et al. 2003;
Hague, Hicks et al. 2005).
Clarification would also be required for some of the other results described here. For
example studies have shown that PTHrP localises to the nucleus in a cell-cycle
dependent manner (Lam, Olsen et al. 1997; Lam, House et al. 1999) so analysis of
any changes in the cell cycle following silencing of PTHrP may have correlated with
the significant decrease in [
3
H]-thymidine incorporation, i.e. proliferation, which was
observed.. Also, housekeeping genes were utilised for analysis of both gene and
protein expression using HPRT and E-actin, respectively and although no change in
expression of either one was observed following siRNA transfection, using the same
housekeeping gene for both techniques would have allowed consistency as well as
corroboration of the results obtained.
The establishment of PTHrP over-expressing cell lines as well as the development of
a PTHrP specific siRNA allowed effective regulation of PTHrP expression. Not
only were changes in gene and protein expression observed, but these led to
important biological effects which have previously been associated with PTHrP (i.e.
proliferation and apoptosis). Therefore it was felt that these two systems could be
used in conjunction to further examine the role of PTHrP in cell adhesion.
Chapter 5:
PTHrP Mediated Cell Adhesion
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5.1 INTRODUCTION
Several studies have demonstrated a link between PTHrP and adhesion. The first
study by Ye et al in 2001 showed that over-expression of PTHrP in HT29 cells
resulted in a significant increase in cell adhesion to collagen type I but not to
fibronectin or laminin. This led the authors to suggest that PTHrP may influence cell
adhesion to specific extracellular matrix proteins (Ye, Seitz et al. 2001).
A similar effect has been shown in a number of other cell lines. For example, upon
stable transfection of the prostate cancer cell line PC3 with cDNA encoding for
PTHrP amino acids (-5 to +139) Shen et al demonstrated an increase in adhesion to
collagen type I, laminin and fibronectin and an increase in cell surface expression of
WKHLQWHJULQVXEXQLWVĮ1Į5Į6DQGȕ4. This increase was ablated in cells when the
NLS was deleted (Shen and Falzon 2003). Using the breast cancer cell line MCF-7
DQLQFUHDVHLQWKHH[SUHVVLRQRIĮ6DQGȕ4 was again reversed by the NLS mutation
which led to an increase in cell adhesion to laminin but not to collagen type I (Shen,
Qian et al. 2004). Transfection of the colonic cell line LoVo led to an increase in
DGKHVLRQWRFROODJHQW\SH,ILEURQHFWLQDQGODPLQLQDORQJZLWKDQLQFUHDVHLQĮ2Į5,
ȕ1ȕ4 DQGȕ6 expression (Shen and Falzon 2005).
Shen et al’s use of different cell lines demonstrates that PTHrP’s effects on integrin
expression may be tissue specific and could provide an explanation for the
appearance of primary tumours to favour particular organs during the formation of
metastases.
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To date there have been 18 D and 6 E subunits discovered however it was beyond the
scope of this study to examine all of these. Following a review of the literature only
the subunits believed to be relevant were studied and are shown in Table 5.1
(Friedrichs, Ruiz et al. 1995; Zhang, Vuori et al. 1995; Gong, Want et al. 1997;
Wewer, Shaw et al. 1997; Giannelli, Astigiano et al. 2002).
Table 5.1 Integrin subunits examined during the course of this study and the
ligands associated with each heterodimer.
Beta Subunit Alpha Subunit Ligand
E1
D1 Collagens, Laminin
D2 Collagens, Laminin
D3 Collagens, Laminin, Fibronectins
D5 Fibronectin
E1 & E4 D6 Laminin
Over-expression of PTHrP has been used to demonstrate a link between PTHrP and
cell adhesion. However, the effects of down-regulating PTHrP have yet to be
explored. Using the siRNA to silence PTHrP expression it was hoped that it would
be possible to further explore the effects of PTHrP on both adhesion and integrin
expression.
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5.2 AIMS
x To manipulate PTHrP expression and examine the resultant effects on cell
adhesion.
x To determine if PTHrP effects adhesion by regulating integrin expression.
x To identify possible tissue-specific differences in PTHrP regulation of
integrin expression.
5.3 METHODOLOGY
5.3.1 siRNA Transfection
Following the optimisation steps described in Section 4.4.1.1 the PTHrP siRNA was
used at a final concentration of 8nM and cells were reverse transfected with either
the PTHrP siRNA or scrambled control (see Section 2.4.1).
5.3.2 Assay of Extracellular Matrix Adhesion
Cell adhesion was examined as described in Section 2.6 using collagen type I,
fibronectin and laminin and cells subjected to either PTHrP silencing or over-
expression.
Following siRNA transfection the decrease in PTHrP protein expression was
maximal five days after transfection (see Section 4.4.1.3). Thus, cells were
harvested at this time point and the effect on cell adhesion examined (Section 2.6.4).
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The number of viable adherent cells were determined via MTT uptake with each
assay carried out in quintuplicate (Section 2.6.4 and 2.6.5). All results shown are
expressed relative to the scrambled control siRNA and are the average values from
three individual transfection assays.
5.3.3 Analysis of Integrin Gene Expression
RNA was extracted, reverse transcribed and gene expression examined using RT-
PCR and primers designed to detect specific integrin subunits (Section 2.7) with
each RT-PCR assay carried out in triplicate. Results shown are expressed relative to
scrambled control or vector control, where appropriate, and are the average values
from three separate assays.
5.3.4 Analysis of Integrin Protein Expression
&HOOVXUIDFHH[SUHVVLRQRI WKHLQWHJULQVXEXQLWVĮ2Į5Į6ȕ1DQGȕ4 was examined
using flow cytometry (Section 2.8.3). Results shown are mean results from three
replicate assays.
5.4 RESULTS
5.4.1 Effect of PTHrP Manipulation on ECM Adhesion
5.4.1.1 Silencing of PTHrP and adhesion
The effect of decreasing PTHrP expression on cell adhesion was examined using the
PTHrP siRNA. In the breast cancer cell lines there was a significant reduction in
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adhesion to collagen type I, fibronectin and laminin (Figure 5.1, One-way ANOVA,
** p<0.05, *** p<0.0001). When the GI cell lines were transfected, whilst there was
a significant decrease in adhesion to collagen type I and fibronectin there was no
decrease in MGLVA1 ascites or HT29 cell adhesion to laminin (One-way ANOVA,
** p<0.005 *** p<0.0001). Table 5.1 summarises the percentage decrease in cell
adhesion.
Figure 5.1 Effect of siRNA transfection on ECM adhesion.
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Table 5.2 Percentage decrease in ECM-cell adhesion
Cell Line % Decrease in Cell Adhesion
Collagen Fibronectin Laminin
MGLVA1 ascites 51.90 46.50 4.06
HT29 24.82 19.84 8.71
MDAMB231 (1-141) 18.34 15.77 20.25
MDAMB231 14.93 15.36 13.41
5.4.1.2 Adhesion of cells over-expressing PTHrP
When PTHrP expression was down-regulated there was a decrease in ECM-cell
adhesion however, there was no decrease in adhesion to laminin observed in the two
GI cell lines. Adhesion in the breast and GI cell lines transfected to over-express
PTHrP was compared to see if a similar effect was detected.
In over-expressing HT29 cells there was a significant increase in adhesion to
collagen type I and fibronectin but not to laminin (Figure 5.2, One-way ANOVA,
*** p<0.0001). This increase in adhesion was reversed in cells where the NLS had
been deleted.
MDAMB231 cells over-expressing PTHrP demonstrated a significant increase in
adhesion to collagen type I, fibronectin and laminin (One-way ANOVA, * p<0.05,
** p<0.001, *** p<0.0001). Again this increase was reversed in cells where the
NLS had been deleted.
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Figure 5.2 Effect of PTHrP over-expression on cell adhesion to collagen type I,
fibronectin and laminin, with and without NLS.
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5.4.2 Integrin Expression
The results presented above suggest that there is a functional difference between the
breast and GI cell lines which results in the variation in laminin adhesion. Previous
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results suggested a link between PTHrP and integrin expression, so integrin
expression was subsequently examined to determine if there were also cell-specific
differences in the effect of PTHrP on integrin subunit expression.
5.4.2.1 PTHrP siRNA and integrin expression
The effect of PTHrP silencing was examined on integrin expression at both the gene
and protein level.
(i) Gene expression
Cells were transfected with the PTHrP siRNA and integrin expression examined five
days later, when the decrease in protein expression and adhesion was maximal.
Silencing of PTHrP induced a decrease in gene expression of several integrin
subunits. The results presented in Figure 5.3 show that in MGLVA1 ascites there
ZDVDVLJQLILFDQWGHFUHDVHLQH[SUHVVLRQRIWKHVXEXQLWVĮ3, Į5 and ȕ1, whilst in HT29
FHOOVWKHUHZDVDGHFUHDVHLQH[SUHVVLRQRIĮ1, Į3, Į5 and ȕ1. In the breast cancer cell
OLQHV WKHUH ZDV D VLJQLILFDQW GHFUHDVH LQ H[SUHVVLRQ RI Į1 Į3, Į5, Į6, ȕ1 DQG ȕ4
(Students t-test, * p<0.0001).
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Figure 5.3 Effect of PTHrP silencing on integrin subunit gene expression.
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(ii) Protein expression
Protein expression of five integrin subunits were examined: the subunits which were
selected included integrins which had shown no link with PTHrP expression as well
as those which appeared linked to PTHrP in breast and/or GI cell lines. Analysis of
protein expression of these integrin subunits using flow cytometry revealed a
VLJQLILFDQWUHGXFWLRQLQH[SUHVVLRQRIRQO\Į5 DQGȕ1 in the GI cell lines while in the
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EUHDVWFHOO OLQHV WKHUHZDVDVLJQLILFDQW UHGXFWLRQ LQH[SUHVVLRQRIĮ5, Į6, ȕ1 DQGȕ4
(Figure 5.4; Students t-test, * p<0.0001).
Figure 5.4 Effect of PTHrP silencing on integrin subunit protein expression.
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5.4.2.2 PTHrP over-expression and integrin expression
Likewise, the effect of PTHrP over-expression was also examined, again at both the
gene and protein level.
(i) Gene expression
When integrin expression was then examined in the cell lines transfected to over-
H[SUHVV37+U3WKHUHZDVDVLJQLILFDQWLQFUHDVHLQĮ1, Į3, Į5 DQGȕ1 expression in the
HT29 cells while the MDAMB231 over-expressing cells demonstrated a significant
LQFUHDVH LQĮ1 Į3, Į5, Į6, ȕ1 DQGȕ4 (Students t-test * p<0.0001). The increase in
integrin expression was reversed in cells where the NLS had been deleted (Figure
5.5).
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Figure 5.5 Effect of PTHrP over-expression on integrin subunit gene
expression.
a) HT29
Integrin Subunit
Alpha1 Alpha2 Alpha3 Alpha5 Alpha6 Beta1 Beta4
R
el
a
ti
v
e
G
en
e
E
x
p
re
ss
io
n
(L
o
g
)
0.1
1
10
100
1000
10000
Vector Control
PTHrP (2)
PTHrP (4)
NLS (1)
NLS (3)
*
*
*
*
b) MDAMB231
Integrin Subunit
Alpha1 Alpha2 Alpha3 Alpha5 Alpha6 Beta1 Beta4
R
el
a
ti
v
e
G
en
e
E
x
p
re
ss
io
n
(L
o
g
)
0.1
1
10
100
1000
10000
Vector Control
PTHrP (1)
PTHrP (2)
NLS (1)
NLS (3)
* *
* *
* *
* *
* *
* *
(ii) Protein Expression
When protein expression was subsequently examined, there was a significant
LQFUHDVH LQ H[SUHVVLRQ RI Į5, Į6, ȕ1 DQG ȕ4 in the MDAMB231 cell line and an
LQFUHDVH LQ H[SUHVVLRQ RI RQO\ Į5 DQG ȕ1 in the HT29 cells (Students t-test, *
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p<0.0001). Again this increase was reversed in cells where the NLS had been
deleted (Figure 5.6).
Figure 5.6 Integrin cell surface in cells over-expressing PTHrP.
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*
*
Integrin Subunit
Alpha 2 Alpha 5 Alpha 6 Beta 1 Beta 4
M
e
a
n
F
lu
o
re
sc
e
n
t
In
te
n
si
ty
0
100
200
300
Vector Control
PTHrP (2)
PTHrP (4)
NLS (1)
NLS (3)
* *
* *
b) MDAMB231
*
*
Integrin Subunit
Alpha 2 Alpha 5 Alpha 6 Beta 1 Beta 4
M
e
a
n
F
lu
o
re
sc
e
n
t
In
te
n
si
ty
0
50
100
150
200
250
300
350
Vector Control
PTHrP (1)
PTHrP (2)
NLS (1)
NLS (3)
* *
* *
* *
* *
162
5.5 DISCUSSION
Following the construction of HT29 and MDAMB231 over-expressing cell lines as
well as the use of the PTHrP siRNA it was possible to obtain a clearer picture of the
role of PTHrP in cell adhesion. By directly comparing up- and down-regulation of
PTHrP in the same cell lines and observing the resultant effects it was possible to
determine that PTHrP positively regulates cell adhesion i.e. a significant increase in
cell adhesion was observed upon over-expression whereas silencing of PTHrP
induced the opposite effect. By utilising cell lines derived from two different tissues
(breast and colon) it was also possible to observe some phenotypic differences i.e.
PTHrP regulated adhesion of both cell lines to collagen type I and fibronectin but
only breast cancer cell adhesion to laminin.
In contrast to these results however, the MDAMB231 (1-141) over-expressing cell
line used in the earlier studies showed no apparent increase in adhesion to any of the
ECM proteins (see Section 3.4.4). Although the results from this study provide no
definitive explanation for these differences in adhesion the most obvious difference
between the cell lines is the vectors used to induce PTHrP over-expression. The
cells obtained from Teresa Guise’s laboratory were created using a vector encoding
for PTHrP (1-141) whilst the vector obtained from Miriam Falzon encodes for
PTHrP (1-139). It is therefore possible that PTHrP’s effects on adhesion are
mediated by the (1-139) isoform and not the (1-141) isoform. The PTHrP siRNA
was able to decrease adhesion of these cells to the ECM, however although these
cells over-express PTHrP (1-139) they also endogenously express the other two
isoforms therefore the observed decrease in adhesion can be attributed to the siRNA
decreasing expression of the endogenous PTHrP.
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This hypothesis is supported by a study by Bouizar et al who examined the
expression of the different PTHrP isoforms and correlated this expression with the
formation of bone metastases from primary breast tumours. They found no
expression of the (1-173) isoform in breast tumours but did demonstrate that
expression of (1-139) was greater than (1-141) in breast tumours. They went on to
show that expression of (1-139) was also greater in patients who developed bone
metastases compared with non-metastatic tumours. Expression of (1-141) on the
other hand was similar in both metastatic and non-metastatic tumours (Bouizar,
Spyratos et al. 1999).
Bouizar et al’s study suggests that PTHrP (1-139) but not (1-141) plays a role in
breast cancer progression. Although this would be consistent with the adhesion
results obtained with both of the MDAMB231 PTHrP over-expressing cell lines
there is no evidence in this thesis to support such a hypothesis.
When Ye et al examined PTHrP over-expression and adhesion using HT29 cells they
demonstrated an increase in adhesion to collagen type I but not fibronectin or
laminin, which is in contrast to the results described here where an increase in
adhesion to both collagen type I and fibronectin was observed. There are a number
of differences between the two studies which may explain this disparity. Firstly Ye
et al used crystal violet staining to quantify adhesion rather than MTT uptake, which
was used during this study. Secondly the authors do not state where they obtained
their ECM proteins therefore it is possible that the fibronectin used in their study
differs from the fibronectin used here. Thirdly, there may be phenotypic differences
between the HT29 clones used here and the clone used by Ye et al i.e. following
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propagation different clonal populations may have arisen following mutations in
individual cells. This may have resulted in the gain, loss or mutation of individual
genes and proteins and thereby affected the observable behaviour of the cell
population.
Shen et al used the breast cancer cell line MCF-7 (Shen, Qian et al. 2004) rather than
MDAMB231; therefore, it is not possible to directly compare and contrast their
results with those described here. However if PTHrP does affect adhesion in a
tissue-specific manner then similar results would be expected. Whilst Shen et al
described an increase in adhesion to only laminin, over-expression of PTHrP in
MDAMB231 cells led to an increase in adhesion to collagen type I, fibronectin and
laminin. The same expression vector was used in both studies so any differences
between the studies cannot be attributed to isoform differences or to differences in
ECM proteins as Shen and colleagues also obtained their ECM proteins from BD
Biosciences. As with the comparison of Ye et al’s study it may be possible to
explain the discrepancy through differences in quantification of adhesion which Shen
et al determined by acid phosphatase activity. In spite of this it is more likely that
the differences in adhesive properties can be attributed to the establishment of these
cell lines from different sources, as this has almost certainly led to a number of
phenotypic differences between the two cell lines.
Such phenotypic differences may be especially relevant when considering integrin
expression, due to the high degree of redundancy with these receptors i.e. it is not
necessary for each subunit to be expressed as others are often able to perform the
same function. When Shen et al observed only an increase in cell adhesion to
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ODPLQLQWKH\DOVRREVHUYHGDFKDQJHLQH[SUHVVLRQRIRQO\WZRLQWHJULQVXEXQLWVĮ6
DQGȕ4. As these subunits form a heterodimer which mediates adhesion to laminin
this correlates with their cell adhesion results. Similarly, during this study when
integrin expression in MDAMB231 cells was examined following regulation of
37+U3H[SUHVVLRQWKHUHZDVDVLJQLILFDQWFKDQJHLQH[SUHVVLRQRIĮ1, Į3Į5Į6ȕ1
DQGȕ4 which correlates with the changes in adhesion to collagen type I, fibronectin
and laminin as these subunits form heterodimers responsible for adhesion to these
ECM proteins.
By comparing the GI and breast cell lines it was hoped that it would be possible to
elucidate some tissue-specific differences. When adhesion was examined following
regulation of PTHrP expression there was a significant change in adhesion to laminin
in the breast cell lines whilst neither GI cell line demonstrated any change in
adhesion to this ECM protein. When integrin expression was subsequently
examined following both PTHrP silencing and over-expression one of the common
REVHUYDWLRQVZDVWKHFKDQJHLQH[SUHVVLRQRIĮ6 DQGȕ4 in only the breast cancer cell
lines. As previously mentioned this integrin mediates adhesion to laminin and
therefore correlates with the aforementioned changes in laminin adhesion.
Another important finding was the reversal of the increase in adhesion and integrin
expression upon confinement of PTHrP to the cytoplasm. Not only does this
correlate with Shen et al’s findings but also suggests that there is an intranuclear
mechanism responsible for PTHrP’s role in integrin expression. Furthermore, as
both integrin gene and protein expression were examined it appears that the changes
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observed at the gene level are translated to parallel changes in protein expression
which suggests that PTHrP regulates integrin expression at the transcriptional level.
It is therefore possible to make a number of conclusions from these results. Firstly,
expression of PTHrP is related to cancer cell adhesion. Secondly, this link is indirect
and is mediated through changes in integrin expression. Furthermore, PTHrP’s
control of integrin expression is regulated in a tissue-specific manner and finally this
is mediated via an intranuclear mechanism.
Chapter 6:
Silencing Integrin Expression
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6.1 INTRODUCTION
By correlating PTHrP and integrin interactions through genetic manipulation of
PTHrP expression levels (gene knock-in and knock-down), there was strong
evidence suggesting that PTHrP and integrin expression were inter-related in
mediating cell adhesion. By using cell lines where the NLS had been deleted, it was
also confirmed that the actions of PTHrP were dependent on its presence within the
nucleus.
To further support these findings and to confirm PTHrP’s indirect role in cell
adhesion it was decided to design siRNAs targeted against two different integrin
subunits for use in conjunction with the PTHrP over-expressing cell lines.
The integrin subunits D5 and D6 were chosen for investigation since nuclear PTHrP
appears to affect D5 expression in both the breast and colon cancer cell lines whereas
D6 expression is only affected in the breast cancer cell line.
Studies by Elbashir and colleagues resulted in the use of a double-stranded 21nt
siRNA with a two base over-hang as the use of longer siRNA was believed to induce
the interferon response. However, recent work by Kim et al has refined this
approach following their observation that increasing siRNA length also increases
potency (Elbashir, Harborth et al. 2001; Elbashir, Lendeckel et al. 2001; Kim,
Behlke et al. 2005).
169
Kim et al examined a range of RNA duplexes of different lengths and observed that
the optimal siRNA length was 27nt. The authors also examined Dicer cleavage in
their range of duplexes and demonstrated that the 21nt duplex was the only siRNA
not cleaved indicating that the 27nt siRNA is cleaved to produce a 21nt siRNA. The
authors went on to propose that Dicer may cleave the 27nt siRNA in several different
places thereby producing a range of different 21nt products, increasing the number
of siRNA homologous to the target sequence and thereby increasing potency.
However when they tested this theory by synthesising each possible 21nt siRNA that
could be produced from the 27nt siRNA, none were as effective as the longer siRNA
either when used individually or when pooled.
Another interesting finding was the observation that increasing the length of an
ineffective 21nt siRNA to 27nt resulted in a significant decrease in gene expression.
Additionally, the use of the longer siRNA increased the temporal effect with gene
suppression lasting for up to ten days compared with a suppression of around four
days using the corresponding 21nt siRNA.
Due to the number of advantages associated with the 27nt siRNA it was decided that
this new design would be applied to the integrin siRNA designed in this study.
6.2 AIMS
x To design and construct an effective siRNA targeted against the integrin
subunits D5 and D6.
x To compare the efficiency of 27nt siRNA to a classical 21nt siRNA in gene
down-regulation.
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x To examine the effect of PTHrP over-expression on siRNA-induced D5 and
D6 gene silencing and the subsequent effect on cell adhesion.
6.3 METHODOLOGY
6.3.1 siRNA Construction and Transfection
Using Dharmacon’s siRNA Target Finder, several different siRNA for both D5 and
D6 were designed and then constructed using the Silencer siRNA Construction Kit,
as described in Section 2.2. Cells were forward transfected, as previously described
(see Section 2.4.1).
6.3.2 Analysis of Gene Expression Following siRNA Transfection
Changes in gene expression were examined following RNA extraction, reverse
transcription and RT-PCR analysis using primers designed to detect D5, D6, STAT
and OAS gene expression (Section 2.7). Each RT-PCR assay was carried out in
triplicate. Unless otherwise stated results shown are expressed relative to D5
scrambled control and are the average values from three separate transfection assays.
6.3.3 Analysis of Protein Expression Following siRNA Transfection
Integrin cell surface expression was examined by flow cytometry using specific D5
and D6 primary antibodies and PE labelled rabbit anti-mouse secondary antibodies
(Section 2.8.3). Results shown are mean results from three replicate transfections.
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6.3.4 Assay of ECM Adhesion
Adhesion to the ECM components collagen type I, fibronectin and laminin following
siRNA transfection was measured as previously described in Section 2.6.4.
6.4 RESULTS
6.4.1 Comparison of siRNA Length
When searching for potential D5 siRNA targets, two of the proposed siRNA
overlapped and provided an ideal opportunity for investigating the potential of a 27nt
siRNA. Gene expression was examined 24 hours after transfection and Figure 6.1
shows that both the 21nt and 27nt siRNA were able to significantly reduce D5 gene
expression using 20nM siRNA (Students t-test p<0.0001). However, unlike the 21nt
siRNA, the longer siRNA was able to induce a significant decrease in gene
expression at even the lowest concentration examined (50pM).
Figure 6.1 Comparison of gene silencing induced by D5 siRNA in MDAMB231
cells. Results are expressed relative to the PTHrP scrambled control siRNA
and are average values from two separate transfection assays.
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When designing the D6 siRNA it was also hoped to construct a 27nt siRNA, however
it was initially necessary to construct and test several 21nt siRNA in order to find the
most effective one prior to modification. The three siRNA chosen for analysis were
designated D6A, D6B and D6C.
Figure 6.2 shows that each of the siRNA were able to significantly reduce gene
expression compared with the scrambled control (Students t-test, p<0.0001),
however D6A was the most effective, inducing a significantly greater reduction in
gene expression compared with either D6B or D6C (Students t-test, p<0.005). D6A
was therefore subsequently altered to create a 27nt siRNA.
Figure 6.2 Gene silencing in MDAMB231 cells transfected with three different
D6 siRNA. Results shown are expressed relative to PTHrP scrambled control
siRNA and are average values from two replicate assays.
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When the corresponding 21nt and 27nt D6 siRNA were both titrated, there was a
dose-dependent increase in gene silencing. However the 27nt siRNA was much
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more effective at silencing gene expression and was able to induce gene silencing of
more than 60% even at the lowest concentration used (Figure 6.3).
Figure 6.3 Titration and comparison of D6 siRNA length in MDAMB231 cells.
Results shown are expressed relative to PTHrP scrambled control siRNA and
are the mean values from two replicate assays.
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Both the D5 and D6 siRNA were most effective at a final concentration of 5nM and
were subsequently used at this concentration in all future studies. A scrambled form
of the 27nt D5 siRNA was also constructed and used as a control in each of the
subsequent experiments.
6.4.2 Effect of Gene Silencing on Protein Expression
The 21nt and 27nt siRNA were also compared for their ability to reduce protein
expression. Similar to the gene expression results, there was a significant decrease
in protein expression with all four integrin siRNA compared with scrambled control
(Students t-test, * p<0.01, ** p<0.001, *** p<0.0001). As with gene silencing the
27nt siRNA were more effective at reducing protein expression compared with the
corresponding 21nt siRNA. Figure 6.4 demonstrates that the 21- and 27nt D5 siRNA
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produced a 14% and 32% decrease in protein expression, respectively, whilst the D6
siRNA induced a 22% and 44% reduction in protein expression. Comparison of the
corresponding 21- and 27nt siRNA revealed that the longer D5 and D6 siRNA
induced a significantly greater decrease in protein expression compared with the
corresponding 21nt siRNAs (Students t-test * p<0.01, ** p<0.001).
Figure 6.4 Protein downregulation in MDAMB231 cells transfected with either
21- or 27nt siRNA.
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6.4.3 Integrin siRNA and the Innate Inteferon Response
The expression of two interferon genes, STAT and OAS were examined in order to
determine if the innate interferon response had been induced as a result of siRNA
transfection.
Figure 6.5 shows that there was no significant difference in expression of either
interferon gene following siRNA transfection (STAT D5 p=0.5580, D6 p=0.072;
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OAS D5 p=0.3601, D6 p=0.9307), so it can be surmised that the innate interferon
response was not induced following integrin siRNA transfection.
Figure 6.5 Induction of innate interferon response in MDAMB231 cells
transfected with integrin siRNA. Results shown are expressed relative to D5
scrambled control and are average values from two separate transfection
assays.
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6.4.4 Effect of D5 and D6 Silencing on ECM Adhesion
It can be seen in Figure 6.6 that following transfection with the D5 siRNA there was
a significant reduction in cell adhesion to fibronectin compared with the scrambled
control but no decrease in cell adhesion to either laminin or collagen type I (One-
way ANOVA, p<0.0001). Similarly using the D6 siRNA, adhesion to laminin
significantly decreased with transfection of the target siRNA compared with
scrambled control (One-way ANOVA, p<0.0001), whilst there was no decrease in
adhesion to collagen or fibronectin. These results indicate that the downstream
effects of silencing either integrin siRNA were specific to the targeted ligand only.
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Figure 6.6 Effect of integrin siRNA transfection on MDAMB231 cell adhesion
to the ECM.
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6.4.5 Duration of Action of Integrin siRNA
Following siRNA transfection, integrin gene and protein expression were both
examined at several time points in order to assess the duration of action of both
siRNA.
6.4.5.1 Gene expression
As with the PTHrP siRNA both integrin siRNA produced maximal gene silencing at
day one and then proceeded with a gradual decrease in silencing (Figure 6.7).
The duration of action appears to last longer compared with the 21nt PTHrP siRNA;
however it is not possible to make an accurate comparison due to differences not
only in the target but also in the potential transfection efficiency caused by the use of
different transfection reagents and this was not investigated.
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Figure 6.7 Duration of action of integrin siRNA.
a) HT29
Integrin siRNA
Alpha5 Alpha6
R
e
la
ti
v
e
G
en
e
E
x
p
re
ss
io
n
0.0
0.2
0.4
0.6
0.8
1.0
Day 1
Day 3
Day 6
b) MDAMB231
Integrin siRNA
Alpha5 Alpha6
R
el
a
ti
v
e
G
e
n
e
E
x
p
re
ss
io
n
0.0
0.2
0.4
0.6
0.8
1.0
Day 1
Day 3
Day 6
6.4.5.2 Protein expression
When protein expression was examined the decrease in protein expression was
maximal three days after transfection in both cell lines and with both siRNA (Figure
6.8).
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Figure 6.8 Integrin cell surface expression in cells transfected with integrin
siRNA.
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6.4.6 Effect of PTHrP Over-expression on Silencing of Integrin Expression
It was predicted that over-expression of PTHrP would reduce the degree of integrin
siRNA-induced silencing by being ‘out-competed’ by enhanced mRNA levels and
that the absence of nuclear PTHrP would reverse this effect.
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The decrease in protein expression was maximal at day three and as this translates
into a comparable effect on adhesion this time point was subsequently chosen for
simultaneous examination of adhesion, gene and protein expression.
6.4.6.1 Integrin gene expression
When D5 and D6 gene expression were examined following integrin siRNA
transfection there was a significant decrease in gene expression in each of the cell
lines examined when compared with cells transfected with scrambled control siRNA
(Figure 6.9, Students t-test, p<0.0001). However Figure 6.9a demonstrates that in
the cells over-expressing wild-type PTHrP there was less down-regulation of D5
gene expression compared with vector control containing cells. In the MDAMB231
vector control cells, D5 expression was reduced to ~40% of that seen in the
scrambled control-transfected cells, whereas in the cells over-expressing wild-type
PTHrP D5 expression was reduced to ~60%. Similarly, in the HT29 PTHrP over-
expressing cells, D5 expression was reduced to ~50% compared with a reduction to
only ~20% in vector control and NLS deleted cells. Similarly, Figure 6.9b
demonstrates that D6 expression was reduced to only ~20% in MDAMB231 vector
control cells whereas in cells expressing wild-type PTHrP D6 expression was
reduced to 50-60% of that seen in scrambled control-transfected cells. In
MDAMB231 cells where the NLS had been deleted there was a similar level of gene
down-regulation as vector control cells in D5 and D6 siRNA-transfected cells. The
decrease in D6 gene expression was similar in each of the HT29 cell lines examined,
thus providing further evidence of the cell-specific actions of PTHrP.
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Figure 6.9 Effect of PTHrP over-expression on siRNA induced D5 and D6 gene
silencing three days following transfection.
a) HT29 and MDAMB231 cell lines transfected with D5 siRNA.
Results expressed relative to scrambled control-transfected cells.
Cell Line
HT29 MDAMB231
R
el
a
ti
v
e
G
en
e
E
x
p
re
ss
io
n
0.0
0.2
0.4
0.6
0.8
1.0
Vector Control
PTHrP (2)/(1)
PTHrP (4)/(3)
NLS (1)
NLS (3)
b) HT29 and MDAMB231 cell lines transfected with D6 siRNA.
Results expressed relative to scrambled control-transfected cells.
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6.4.6.2 Protein expression
The same effect was observed when protein expression was examined i.e. there was
a significant decrease in protein expression in each of the cell lines examined (Figure
6.10, Students t-test, p<0.0001). Over-expression of wild-type PTHrP in HT29 cells
resulted in a reduction in the degree of D5 knockdown in these cells compared with
vector control and NLS deleted cells but had no effect on silencing of the D6 subunit.
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Figure 6.10a shows that in HT29 vector control cells there was a ~50% knockdown
in protein expression in D5 siRNA-transfected cells compared with scrambled
control-transfected cells whereas there was only a ~20% knockdown in wild-type
expressing cells. Likewise, in MDAMB231 cells expressing wild-type PTHrP there
was a knockdown of D5 expression of only ~30% compared with a knockdown of
~50% in vector control cells. Figure 6.10b demonstrates that the protein knockdown
following D6 siRNA transfection was similar in all of the HT29 cell lines whereas in
the MDAMB231 cells there was a knockdown of ~50% in vector control cells and
only a knockdown of ~20% in wild-type over-expressing cells. (Students t-test,
p<0.0001).
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Figure 6.10 Effect of PTHrP over-expression on siRNA induced D5 and D6 cell
surface expression, three days following transfection.
a) HT29 and MDAMB231 cell lines transfected with D5 siRNA.
Results expressed relative to scrambled control-transfected cells.
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b) HT29 and MDAMB231 cell lines transfected with D6 siRNA.
Results expressed relative to scrambled control-transfected cells.
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6.4.6.3 Cell Adhesion
Figure 6.11 shows that when the effect of D5 and D6 siRNA transfection on cell
adhesion was examined, whilst there was a significant decrease in adhesion in each
of the cell lines examined, the nuclear translocation of PTHrP caused a smaller
reduction in adhesion of D5 transfected HT29 cells to fibronectin (~15% decrease
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compared with a 30% decrease in adhesion in vector control cells), whilst adhesion
to laminin was similar in each of cell lines examined. Both integrin siRNA caused a
significant reduction in MDAMB231 cell adhesion to fibronectin and laminin and
again the presence of PTHrP within the cell nucleus appears to diminish the
reduction of siRNA induced adhesion. Both siRNA reduced adhesion to fibronectin
and laminin by ~15% in wild-type over-expressing cells, whereas adhesion to
laminin was reduced by up to 40% in vector control cells (One-way ANOVA,
p<0.0001).
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Figure 6.11 Effect of integrin siRNA transfection on ECM-cell adhesion.
a) Cell adhesion to fibronectin following transfection with D5 siRNA.
Results expressed relative to scrambled control-transfected cells.
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b) Cell adhesion to laminin following transfection with D6 siRNA.
Results expressed relative to scrambled control-transfected
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6.5 DISCUSSION
During the course of this study a link between PTHrP and cell adhesion has been
shown. The results have also suggested that this link is mediated via changes in
integrin expression. In order to confirm this indirect mode of action it was decided
to examine the effect of PTHrP over-expression on silencing of the integrin subunits
D5 and D6. If PTHrP plays a direct role in cell adhesion then it was predicted that its
over-expression would have no effect on integrin silencing.
Following the successful design and construction of siRNA homologous to either D5
or D6, gene suppression was induced and there was a decrease in protein expression
which led to a decrease in cell adhesion. D5 forms a heterodimer with E1 to act as a
receptor for fibronectin while D6 forms a heterodimer with either E1 or E4 and
interacts with laminin (Hynes 2002). When cell adhesion to the ECM proteins
collagen type I, fibronectin and laminin was examined following gene silencing of
either D5 or D6 there was a significant decrease in adhesion to only fibronectin or
laminin, respectively. The downstream effects of integrin silencing were therefore
specific and consistent with expectations.
When the effect of PTHrP over-expression was subsequently examined, both the
MDAMB231 and HT29 cells over-expressing full length PTHrP demonstrated a
smaller decrease in D5 silencing compared with both the vector control cell lines and
the cell lines lacking the NLS. When D6 silencing was similarly examined, whilst
the MDAMB231 cell lines also demonstrated a smaller decrease in silencing
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compared with the vector control cell lines, there was no discernable difference
between the HT29 clones upon D6 silencing. As subsequent examination of protein
expression and cell adhesion demonstrated a similar effect it can be seen that PTHrP
counter-acts the effects of the integrin siRNA.
Consequently, these results provide further evidence of PTHrP’s indirect role in cell
adhesion. They also correlate with the previous findings that PTHrP’s regulation of
integrin expression is dependent on nuclear localisation and the observations
regarding the absence of a relationship between D6 and PTHrP expression in the
HT29 cell line and thereby support the hypothesis that there is tissue-specific
regulation of integrin expression by PTHrP.
The use of siRNA to induce post-transcriptional gene silencing is a relatively new
discovery and a rapidly expanding field. As such it is not known how Kim et al’s
study examining the use of longer siRNA will fit into the RNAi story and if it will be
applicable to a wide range of targets. However, the results described in this thesis
support Kim et al’s findings and as 27nt siRNA are less reliant on adherence to the
siRNA design ‘rules’ and are significantly more potent than the corresponding 21nt
siRNA this will not only increase siRNA usability but will also enhance their
potential as therapeutic agents (Kim, Behlke et al. 2005).
Chapter 7:
PTHrP and Integrin
Transcription
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7.1 INTRODUCTION
The results previously described demonstrate that PTHrP regulates integrin
expression at the transcriptional level which is then translated to changes in protein
expression. Gene expression can be regulated through a variety of mechanisms
including transcription, translation and mRNA stability.
7.1.1 Transcription
The NLS of PTHrP is homologous to the NLS of the transcription factors c-jun, c-fos
and p53, which has led to suggestions that PTHrP may be a transcription factor. It
has also been suggested that as PTHrP is able to move between the cytoplasm and
nucleus, PTHrP may act as a nuclear export factor for mRNA whereby it would help
to transport mRNA between the nucleus and cytoplasm (Fiaschi-Taesch and Stewart
2003).
7.1.2 Translation
PTHrP has previously been shown to interact with RNA by Aarts et al. They
demonstrated the interaction of PTHrP with RNA within the nucleolus of COS-1
cells and went on to show that PTHrP down-regulates ribosomal RNA (rRNA)
synthesis. rRNA is involved in translation; therefore, by decreasing synthesis,
PTHrP is able to prevent translation and arrest the cell cycle. Aarts et al
demonstrated that in doing so PTHrP was able to protect serum-deprived cells from
apoptosis (Aarts, Levy et al. 1999; Aarts, Davidson et al. 2001).
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However, although this would explain the effects of PTHrP on proliferation and
apoptosis it does not explain the ability of PTHrP to affect adhesion and integrin
expression.
7.1.3 mRNA Stability
The steady-state concentration of mRNA within a cell is dependent not only on
transcription but also on mRNA degradation. As mentioned earlier PTHrP has been
shown to interact with RNA, and RNA-binding proteins are known to protect mRNA
from degradation. Similarly several hormones have shown an ability to regulation
gene expression, a good example being oestrogen. Oestrogen is able to stabilise and
destabilise the same mRNA in the same cell type in different species. For example
in avian liver oestrogen destabilises vitellogenin mRNA, whilst in amphibian liver it
stabilises this mRNA. Oestrogen is also able to stabilise different mRNA within the
same cell e.g. ovalbumin and conalbumin in chick oviduct (Ing 2005).
Hence, it can be seen that there are a variety of mechanisms whereby PTHrP can
have an effect on gene expression, with the most likely being manipulation of
transcription or mRNA stability.
Calculating mRNA half-life is a difficult task as mRNA translation and degradation
is not entirely stochastic. It was therefore decided to first explore the possibility that
PTHrP is a transcription factor of integrin gene expression. The integrin subunits D2,
D5 and D6 were chosen for analysis; D2 demonstrates no apparent link with PTHrP
expression in the cell lines examined here and therefore provided a suitable negative
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control, expression of both D5 and D6 was related to PTHrP expression in the breast
cancer cell lines, and D5 but not D6 appeared to be linked to PTHrP in the GI cell
lines. Consequently using all three integrin subunits it was hoped that it would be
possible to identify whether PTHrP was a transcription factor and provide further
evidence of a tissue-specific mechanism of action.
7.2 AIMS
x To create reporter constructs containing the promoter sequences of the
integrin subunits D2, D5 and D6.
x To determine if PTHrP increases integrin gene transcription.
7.3 METHODOLOGY
7.3.1 PCR Amplification of the Integrin Promoter Regions
The promoter region of the integrin subunits D2, D5 and D6 were amplified from
genomic DNA using specific primers in conjunction with PCR (See sections 2.3.2,
2.7.3 and 2.7.4). Primers for amplifying the D2 promoter region were designed using
Primer3, while the D5 and D6 promoter regions were amplified using primers
previously published by Klein et al and Lim et al, respectively (Klein, Bikfalvi et al.
1996; Lim, Lee et al. 2001).
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7.3.2 DNA Extraction and Purification from Agarose Gel
Using a 2% agarose gel, PCR products were examined and visualised using ethidium
bromide staining. The DNA was then excised and purified using the reagents
provided with the QIAquick Gel Extraction Kit, as described in Section 2.3.5. The
purified products were then sent for sequencing at the School of Biomedical
Sciences, University of Nottingham (see Section 2.3.9).
7.3.3 Ethanol Precipitation
DNA was concentrated by ethanol precipitation, by incubating the DNA with two
volumes of 100% ethanol and 1/10
th
volume of sodium acetate. Following a one
hour incubation at -20°C the DNA was pelleted by centrifugation and washed twice
with 70% ethanol. Once dry the pellet was re-suspended in RNase and DNase free
water (Section 2.3.4).
7.3.4 DNA Digest and Ligation
To allow ligation of the promoter sequences into the reporter vector, the primers
used for PCR amplification contained restriction sites for the relevant restriction
enzymes and these enzymes were incubated with either the promoter DNA or the
pGL3-Basic vector over-night to allow digestion (Section 2.3.3).
The digested vector and promoter DNA were combined with a T4 ligase enzyme and
incubated overnight at 4°C to promote ligation (Section 2.3.6).
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7.3.5 Bacterial Transformation and Plasmid DNA Extraction
The ligated promoter DNA and vector were transformed into XL-1 Supercompetent
bacterial cells by heat-shock. The transformed bacteria were then grown overnight
on LB Agar plates containing 50µg/mL ampicillin. The resultant colonies were then
selected and grown further in NZY LB medium (Section 2.3.7).
A GenElute Plasmid Mini-prep kit was used to extract the plasmid DNA from the
overnight bacterial culture (Section 2.3.8).
7.3.6 Plasmid Transfection
Cells were seeded into 6-well plates one day prior to transfection. The plasmid DNA
was then combined with Lipofectamine 2000 and the resultant complex added to the
cells, which were then incubated over-night to promote transfection (Section 2.4.2).
7.3.7 Luciferase Reporter Assay
The pGL3-Basic vector contains the cDNA of firefly luciferase (Figure 7.1).
Coupling the promoter sequence to this indicator allows quantification of promoter
activity as transcription of the promoter also results in transcription of the luciferase
cDNA. Changes in promoter/luciferase activity can consequently be measured
following addition of luciferin substrate, with an increase in luminescence indicating
an increase in transcription.
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Figure 7.1 pGL3-Basic vector circle map, with multiple cloning sites.
24 hours following plasmid transfection, cells were lysed, and the cell debris pelleted
by centrifugation. The supernatant was transferred to a black solid 96-well plate and
mixed with an equal volume of luciferase assay substrate. Luminescence was then
detected following a 5-minute incubation at room temperature (Section 2.10).
7.4 RESULTS
7.4.1 Amplification of Promoter Sequence
Following PCR amplification, the sequences of the PCR products were verified by
the automatic sequencing service provided by the School of Biomedical Sciences,
University of Nottingham. The DNA sequence for D2 and D5 matched the
information from the Entrez Nucleotide database (Appendix 1).
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Lim et al’s 2001 paper described the construction of an D6 promoter/luciferase
reporter, and the published primers were used for amplification of the D6 promoter
region. However, despite obtaining a PCR product of approximately the correct size,
when analysed the sequence did not match the information within the Entrez
Nucleotide database. Upon further analysis of the reverse primer, there was no
homology with any sequence within the human genome.
A reverse primer for the D6 promoter region was subsequently designed using the
information within the Entrez Nucleotide database and the promoter region amplified
by PCR. The PCR products of all three promoter regions can be seen in Figure 7.2.
Figure 7.2 D2, D5 and D6 PCR products following PCR amplification, visualised
by ethidium bromide staining.
D2 D5 D6
7.4.2 Cloning and Transformation
In order to allow cloning into the pGL3-Basic vector, forward primers contained
sequences for the restriction site Mlu I while the reverse primers for D5 and D6
included sequences for the restriction site Bgl II. The promoter sequence for D2
contained a restriction site for Bgl II therefore the reverse primer for this subunit was
designed to contain the restriction site for Bam HI as Bgl II and Bam HI have
compatible cohesive ends.
1093o
949o 830o
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The promoter DNA was subsequently digested and ligated with the pGL3-Basic
vector. However, following bacterial transformation none of the resultant bacterial
colonies contained promoter DNA.
The restriction enzyme Mlu I has very low cleavage activity, with a percentage
cleavage of approximately 50%. It was suspected that this may result in insufficient
cleavage of the promoter DNA and vector to allow ligation. To investigate whether
this was indeed the situation, the D5 forward primer was redesigned and the Mlu I
restriction site replaced with Kpn I, which has a cleavage of >90%. Following
digestion, ligation and bacterial transformation a number of bacterial colonies were
produced which contained the D5 promoter DNA (Figure 7.3).
Figure 7.3 D5 promoter and pGL3 vector following restriction digest with Kpn I
and Bgl II restriction enzymes.
7.4.3 Promoter Activity
Once the D5 promoter DNA had been successfully cloned into the pGL3-Basic
vector, the plasmid was then transfected into HT29 and MDAMB231 cells over-
expressing PTHrP and the level of D5 promoter activity examined by measuring
luciferase activity.
m ~4800
m 949
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196
Figure 7.4 shows a significant increase in promoter activity in the cells over-
expressing PTHrP, compared with vector control cells. Cells expressing PTHrP
where the NLS had been deleted exhibited a level of luminescence similar to control
cells (One-way ANOVA, p<0.0001).
Figure 7.4 Promoter activity in cells transfected with pGL3-Basic vector
containing D5 promoter DNA. Results shown are average values from three
replicate assays.
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7.5 DISCUSSION
It was hoped that using reporter vectors containing the promoter regions for integrins
D2, D5 and D6 it would be possible to verify that not only does PTHrP regulate
integrin gene transcription but that it does so in a tissue-specific manner.
Although it was not possible to create reporter constructs containing the promoter
regions for D2 or D6, using the D5 construct, a significant increase in promoter
activity was demonstrated in the cell lines over-expressing PTHrP. This increase
was reversed in the cell lines where the NLS had been deleted and therefore supports
the other findings described in this study.
The multiple cloning sites included in the pGL3 vector allow a degree of choice
when selecting the sites to be used during cloning; Mlu I and Bgl II were
subsequently chosen as these restriction enzymes could be used with all three
integrin subunits. However the low cleavage by Mlu I caused difficulties during
cloning and one of the alternative cloning sites was therefore sought and successfully
used in the cloning of the D5 construct.
Although Kpn I could also be used during cloning of the D2 construct, the promoter
region of the D6 promoter contains a restriction site for Kpn I thus preventing its use
during the cloning of this vector. Consequently it would be necessary to choose an
alternative cloning site and both Xho I or Hind III could be utilised as each of these
enzymes have a cleavage of >75% and neither site can be found within the D6
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promoter region. Unfortunately time limitations prevented such a course of action
being pursued.
Although the PTHrP-induced increase in D5 promoter activity indicates an increase
in transcriptional activity it does not necessarily support the hypothesis that PTHrP is
a transcription factor. PTHrP may increase integrin transcription indirectly by
stimulating a known transcription factor such as Sp1, NF-NB or the ets family of
proto-oncogenes (Birkenmeier, McQuillan et al. 1991; Nishida, Kitazawa et al.
1997), rather than interacting with the promoter region directly. It would be possible
to examine the interaction of PTHrP with the integrin promoter DNA by using a
protein-DNA interaction assay such as DNase I footprinting or electrophoretic
mobility shift (Fried and Crothers 1981; Garner and Revzin 1981; Brenowitz, Senear
et al. 1986) and thereby conclusively ascertain whether or not PTHrP is indeed an
integrin transcription factor.
Chapter 8:
Discussion
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8.1 INTRODUCTION
PTHrP is emerging as a multi-functional protein. Even after almost 20 years and
numerous studies into its expression and function, neither its role or mechanisms of
action have been fully elucidated (Philbrick, Wysolmerski et al. 1996; Lam, Thomas
et al. 2000; Clemens, Cormier et al. 2001; Fiaschi-Taesch and Stewart 2003).
In spite of this it is clear that PTHrP plays a major role in tumour biology and is
involved in various facets of cancer. Whether as a mitogen or an anti-apoptotic
factor or by manipulating cell adhesion it is evident that targeting this protein
presents an invaluable opportunity in the treatment of multiple tumour types (Asa,
Henderson et al. 1990; Wysolmerski and Broadus 1994; Nishihara, Ito et al. 1999;
Deftos 2000; Akashi, Fuse et al. 2002; Richard, Luchin et al. 2003). Further
examination of the regulation of PTHrP expression as well as its mechanism of
action would help to refine the targeting of this protein and thereby enhance its
potential as a therapeutic target and this has been the main goal of this thesis.
Tumour progression leads to numerous complications in cancer patients and is a
major obstacle to effective therapy; many primary tumours can be removed by
surgery and remaining tumour cells eradicated by chemo- or radiotherapy. The
establishment of secondary tumours however significantly reduces patient survival
with the majority of cancer deaths attributed to the development of metastases. For
example, a 2001 study used immunohistochemistry analysis to detect the presence of
occult tumour cells in lymph nodes and bone marrow aspirates obtained from breast
cancer patients deemed to be metastases-free. The disease free survival and overall
survival rates in patients where occult tumour cells were present were significantly
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lower compared with patients where occult tumour cells were not detected (Gerber,
Krause et al. 2001). Similarly 70% of patients with colorectal cancer liver
metastases have a median survival of only 15 months, even with chemotherapy
(Belluco, Mammano et al. 2005).
Tumour progression is a multi-step process with adhesion of tumour cells to the
ECM and the exchange of biological information one of the key steps (Fidler 1990).
It has often been observed in cancer patients that primary tumours have a partiality
for one particular organ during metastasis, for example breast tumours metastasise to
bone (Powell, Southby et al. 1991) while GI tumours predominantly metastasise to
the liver (Fidler 1990; Belluco, Mammano et al. 2005). PTHrP has previously been
associated with tumour progression and linked to tissue-specific metastasis (Ye,
Seitz et al. 2001), however the mechanism by which this occurs has not yet been
elucidated. This present study examined the role of PTHrP in both breast and GI
cancer cell adhesion and investigated the role of this molecule in cell adhesion to
various components of the ECM and the role that integrins play in this process.
8.2 EXPRESSION OF PTHrP
Ye et al’s 2001 study indicated that PTHrP was an important factor in GI cell
adhesion and numerous other studies have demonstrated that PTHrP plays an
important role in breast cancer progression (Southby, Kissin et al. 1990; Powell,
Southby et al. 1991; Wysolmerski and Broadus 1994). It was thus decided to
initially examine PTHrP expression in a number of GI cell lines to further define the
role of PTHrP in this tumour type and to use a breast cancer cell line induced to
over-express PTHrP (Guise, Yin et al. 2002) in conjunction with the corresponding
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wild-type cell line in order to allow direct correlation between PTHrP expression and
downstream effects in breast and GI tumour cells (Ye, Seitz et al. 2001).
Initial investigations used a panel of tumour-derived cell lines and examined PTHrP
expression at both the gene and protein level. The panel included gastric, colorectal
and pancreatic cell lines. Although PTHrP gene expression was not detected in all of
the cell lines examined, protein expression was detected in the entire panel
suggesting wide-spread PTHrP expression.
Post-transcriptional and translational regulation (e.g. gene transcription rate,
transcript stability, translational regulation, protein degradation) often results in
differences between gene and protein expression (Paradet-Balade, Boulme et al.
2001). Such disparities between mRNA and protein expression have been
previously described, for example Gygi et al examined the correlation between
mRNA and protein expression in yeast and although they showed a general trend
whereby increased mRNA expression resulted in increased protein expression they
also found cases where similar mRNA levels resulted in a variation in protein
expression of up to 30-fold (Gygi, Rochon et al. 1999).
8.3 PTHrP AND CELL GROWTH
8.3.1 Mitogenic actions of PTHrP
Post-translational processing results in the production of various PTHrP peptides,
with the main three believed to be PTHrP (1-36), (38-94) and (107–139) (Fiaschi-
Taesch and Stewart 2003). These peptides are subsequently packaged and secreted
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from the cell and are more commonly expressed by cells than the unprocessed
peptide (Philbrick, Wysolmerski et al. 1996).
There have been a number of studies examining the effects of exogenous PTHrP on
cell proliferation and this has resulted in conflicting views as to the role of PTHrP.
For instance PTHrP (1-34) has been shown to be both mitogenic (Villaneuva-
Penacarrillo, Cancelas et al. 1999; Asadi, Faraj et al. 2001) and anti-mitogenic
(Luparello, Romanotto et al. 2001), with other studies demonstrating that exogenous
PTHrP has no effect on proliferation (Ye, Seitz et al. 2001). One of the objectives of
the present study was to compare the effects of different post-translational fragments
of PTHrP on proliferation and down-stream signalling events.
Of the various peptides used as part of this study only PTHrP (1-34) increased cell
proliferation in GI tumour-derived cell lines. Similarly when antibodies directed
towards different regions of PTHrP were used to neutralise PTHrP, the antibody
directed towards PTHrP (1-34) resulted in a significant reduction in cell proliferation
whereas the antibody directed towards PTHrP (38-64) had no effect. These results,
therefore, suggest that only amino-terminal PTHrP is involved in cell proliferation
and are consistent with Asadi et al and Villaneuva-Penacarrillo et al studies which
demonstrated that PTHrP (1-34) caused an increase in proliferation in a prostate and
pancreatic cell line, respectively. Similarly Cataission et al demonstrated that a
PTHrP neutralising antibody directed against amino acids (1-34) caused a dose-
dependent decrease in proliferation. However, these results are in contrast to several
studies including those led by Claudio Luparello where PTHrP (1-34), (38-94)-
amide, (67-86) and (107-139) have all been shown to decrease breast cancer cell
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proliferation (Luparello, Burtis et al. 1995; Cataission, Lieberherr et al. 2000;
Luparello, Romanotto et al. 2001).
For example, Luparello et al’s 1995 study demonstrated a decrease in 8701-BC cell
proliferation using PTHrP (1-34), (34-68), (67-86) and (107-138) at concentrations
similar to those used in the present study: all four peptides induced a decrease in
proliferation at 100nM. In a later study Luparello and colleagues (2001) used a
panel of different breast cancer cell lines to examine the effect of mid-region PTHrP
on growth, invasion and tumourigenesis. Two of the six cell lines used (Hs578T and
T47D) demonstrated a biphasic response to PTHrP (38-94)-amide whereby at lower
concentrations (0.01nM) there was an increase in proliferation but at higher
concentrations (1nM) this switched to a decrease. The authors were unable to
explain this response but suggested that it could be the product of activation of
different signalling pathways at different peptide concentrations. Although a
receptor for the mid-region of PTHrP has not yet been identified, it is known that
PTH1R is linked to both the adenylyl-cyclase/PKA and PLC/PKC pathways and
Fortino et al demonstrated that activation of the PKA pathway in human skin
fibroblasts results in a decrease in proliferation whereas activation of the PKC
pathway increases proliferation (Luparello, Burtis et al. 1995; Luparello, Romanotto
et al. 2001; Fortino, Torricelli et al. 2002).
A disparity in results obtained between different studies is not uncommon. For
example when Hoey et al examined the role of PTH1R in breast cancer cell
proliferation using exogenous PTHrP and the breast cancer cell line MCF-7 their
results conflicted with a similar study by Maioli and Fortino who questioned their
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results in a letter to the British Journal of Cancer. Hoey et al’s study used MCF-7
cells induced to over-express PTH1R and using 125nM of PTHrP (1-34) they
induced an increase in cAMP production and proliferation in the over-expressing cell
line whereas the vector control cells were unresponsive to PTHrP. In their study,
Miaoli and Fortino induced an increase in wild-type MCF-7 cell proliferation using
640nM PTHrP (1-34) and led them to suggest that the concentration Hoey et al used
was too low to induce a response in their wild-type cells. Hoey et al replied and
suggested that the disparities were the result of “differences in experimental
approach” (Hoey, Sanderson et al. 2003; Hoey, Sanderson et al. 2004; Maioli and
Fortino 2004).
The peptide concentration used during the present study was 100nM and could
therefore be the cause for the differences in results obtained here and those described
elsewhere. A previous in-house study had shown a reduction in proliferation of
other breast cancer cell lines at this peptide concentration and repeating this assay
using a range of concentrations may induce a greater, or biphasic response, not only
to PTHrP (1-34) but also to the other peptides.
Examining the activity of the two different PTH1R transduction pathways following
peptide stimulation would allow the cellular actions of PTHrP to be linked to these
pathways, and allow clarity on this complex issue. For instance there may be a
threshold where the transduction pathway switches from the PKC to PKA signalling
pathways and if receptor density differs between cell lines, and indeed different
clones, this could result in the previously observed disparities between studies (Hoey
et al & Maioli and Fortino) and would also be consistent with Luparello et al’s
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findings. Using a radioligand binding assay to examine the number and affinity of
receptors in different cell lines would help to explain differences in the cellular
response to exogenous PTHrP. Similarly investigating PKC and PKA signalling and
the resultant downstream effects at various peptide concentrations would also help to
clarify the role of exogenous PTHrP on cell proliferation. Similarly, even though a
mid-region receptor has not yet been cloned, analysis of second messenger signalling
upon peptide stimulation would allow a similar study to be carried out for mid-
region PTHrP.
It has also been shown that PTHrP localises to the nucleus in a cell-cycle dependent
manner (Lam, Olsen et al. 1997; Lam, House et al. 1999). Investigation into whether
the PTHrP siRNA affected the cell cycle was not part of this study but should be
conducted in order to assess what effects, if any, PTHrP had on the cell cycle.
When clonagenicity assays were carried out using PTHrP over-expressing cell lines,
elevated PTHrP expression resulted in a significant increase in proliferation which
was reversed in cells where the NLS had been deleted. This is consistent with other
studies where intranuclear PTHrP has also been shown to affect proliferation (Tovar
Sepulveda and Falzon 2002; Shen and Falzon 2005). It is not, however clear
whether the autocrine/paracrine PTH1R pathway is distinct from the intranuclear
mechanisms: PTHrP may be released, internalised after binding to PTH1R before
translocation towards the nucleus. It is clear that further investigation is necessary in
order to clarify which mechanisms are involved.
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8.3.2 PTHrP as an anti-apoptotic factor
Aarts and colleagues demonstrated that PTHrP binds to RNA within the nucleus and
that this is dependent on the NLS. They went on to show this action protects
chondrocytes from apoptosis induced by serum starvation and consequently
suggested an anti-apoptotic role for intranuclear PTHrP. Similarly, Tovar Supulveda
and Falzon demonstrated that not only does intranuclear PTHrP increase mitosis but
it also protects cells against apoptosis. As growth rate is a balance between
proliferation and apoptosis it can therefore be speculated that the pro-proliferative
effects of intranuclear PTHrP are mediated by both an increase in proliferation as
well as a decrease in apoptosis (Aarts, Levy et al. 1999; Aarts, Davidson et al. 2001;
Tovar Sepulveda, Shen et al. 2002).
Apoptosis is a complex process and a simple representation of the intrinsic Bcl-2
regulated pathway can be seen in Figure 8.1. Briefly, a change in the ratio of the
pro- and anti-apoptotic proteins in the Bcl-2 family of apoptotic proteins can result in
mitochondrial membrane permeabilisation. This not only disrupts key cellular
functions but also results in the release of apoptotic proteins including caspases,
proteases responsible for the cleavage of cellular proteins and the ultimate cause of
cell death (Jin and El-Deiry 2005).
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Figure 8.1 Bcl-2 regulated apoptosis (adapted from (Jin and El-Deiry 2005)
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When apoptosis was examined following antibody neutralisation during this study
there was a significant increase in apoptosis observed with the PTHrP (1-34)
antibody, as measured by mitochondrial membrane potential. Similarly when the
effect of PTHrP silencing was examined there was a significant increase in apoptosis
in cells treated with the PTHrP siRNA compared with the scrambled control. These
results therefore suggest that PTHrP is an anti-apoptotic factor and are consistent
with several other studies investigating PTHrP and apoptosis.
For example, Miyaji et al also used an anti-PTHrP monoclonal antibody raised
against amino acids (1-34) and demonstrated a dose-dependent increase in
chondrosarcoma cell apoptosis, measured using the TUNEL assay. They also
detected decreased levels of procaspase-3 which they attributed to cleavage of the
procaspase to the active form, as well as a dose-dependent decrease in Bcl-2 and an
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increase in Bax expression. Similarly, Tovar Sepulveda et al demonstrated that
PTHrP over-expression caused a decrease in serum deprivation induced apoptosis in
breast cancer cells, which was dependent on the NLS, and went on to demonstrate
that this was mediated through changes in the Bcl-2 and Bcl-xL to Bax ratio (Tovar
Sepulveda, Shen et al. 2002; Miyaji, Nakase et al. 2003).
Apoptosis was measured in the present study using an indicator of early stage
apoptosis (mitochondrial membrane permeabilisation). The results obtained are
consistent with both Miyaji et al and Tovar Sepulveda et al’s studies which also
demonstrated that PTHrP acts at an early stage in the apoptosis pathway. The
present study has also demonstrated that PTHrP regulates expression of certain
integrins. Integrins are known to regulate the activity of members of the Bcl-2
family, for example ligation of D5ȕ1 increases transcription of the bcl-2 gene in CHO
cells (Matter and Ruoshlahti 2001). As such rather than acting on Bcl-2 directly,
PTHrP’s anti-apoptotic effects may instead be mediated through modulation of
integrin expression. Further study will be required in order to determine if this is
indeed the case and could be carried out through the use of RNAi of integrin subunit
expression and examination of any resultant changes in apoptosis, in particular Bcl-2
expression.
8.4 PTHrP AND ADHESION
8.4.1 Changes in cell adhesion
The main focus of the present study was to investigate the role that PTHrP plays in
adhesion. The exogenous PTHrP peptides (1-34), (67-86), (67-101), (107-139),
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(140-173) had no effect on cell adhesion, which is consistent with other studies by
Ye et al and Shen and Falzon. Ye et al used exogenous PTHrP (7-34), (67-86) and
(107-139) during their investigation but did not demonstrate any effect on HT29 cell
adhesion. Similarly Shen and Falzon examined the effect of PTHrP (1-34) on PC-3
cell-surface integrin expression and PTHrP (1-34), (67-86), (107-139) and (141-173)
on MCF-7 cell adhesion, migration, invasion and cell surface integrin expression but
demonstrated no significant effects (Ye, Seitz et al. 2001; Shen and Falzon 2003;
Shen, Qian et al. 2004).
Both the PTHrP (1-34) and (38-64) neutralising antibodies used in this study caused
a significant reduction in adhesion to collagen type I and fibronectin in both the
breast and GI cell lines and a reduction in breast cell adhesion to laminin. To date no
one has examined the effect of antibody addition on cell adhesion so it is not
possible to compare these results. However the results obtained did indicate that
PTHrP was involved in adhesion and it was decided to further investigate the
mechanism whereby PTHrP regulated adhesion.
Although statistically significant, the reduction in adhesion obtained with the PTHrP
antibodies was modest and proved to be an inefficient means of inhibiting the
biological actions of PTHrP. It was therefore felt necessary to find a system
whereby PTHrP could be more effectively regulated. As RNAi has been shown to
be an effective yet simple way of inducing post-transcriptional gene silencing
(Bertrand, Pottier et al. 2002; Ramaswamy and Slack 2002) it was decided to design
an siRNA specific for PTHrP.
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Three siRNAs (all targeted within exon VI of the PTHrP gene, which is common to
all three PTHrP isoforms) were initially tested for their ability to reduce PTHrP gene
expression and the most effective of the three was chosen for further study. Once it
had been established that this siRNA (Target 19) was able to significantly reduce
both gene and protein expression, the resultant effects on adhesion were investigated.
Following gene silencing, there was a significant reduction in adhesion to collagen
type I and fibronectin in each of the breast and GI cell lines examined. However,
whilst there was a reduction in adhesion to laminin in the breast cancer cell lines
there was no alteration in GI cell adhesion to this ECM protein.
The pattern of changes in adhesion was consistent when either siRNA or antibodies
were used i.e. there was no change in GI cell adhesion to laminin with either
approach. However, compared with the antibodies, the siRNA was able to induce a
much greater decrease in adhesion. For example, whereas the anti-PTHrP antibodies
induced a ~15% decrease in MGLVA1 adhesion to collagen type I, the siRNA
caused a ~52% decrease.
When PTHrP was over-expressed in a GI and breast cell line there was an increase in
adhesion to both collagen type I and fibronectin whereas only breast cancer cells
demonstrated an increase in adhesion to laminin, again consistent with previous
observations. This selective regulation of adhesion by PTHrP may relate to
differences between the sites of metastases for cells of GI and breast origin during
cancer progression.
Paget’s “seed and soil” hypothesis proposes that cancer cells metastasise to an area
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which has a favourable microenvironment. Primary tumours appear to exhibit a
partiality for one particular organ during metastasis, for example breast cancer cells
predominantly metastasise to bone (Powell, Southby et al. 1991) whilst
gastrointestinal tumours tend to establish secondary tumours in the liver (Fidler
1990; Belluco, Mammano et al. 2005). PTHrP expression in MDAMB231 cells
demonstrated a correlation with adhesion to collagen type I, fibronectin and laminin,
which may be linked to the composition of bone which is comprised of 95%
collagen type I and contains fibronectin and laminin within the bone marrow ECM
(Vituri, Alvarez-Silva et al. 2000), with laminin also a key component of the
sinusoidal basement membrane (Gu, Kortesmaa et al. 2003). Hepatic sinusoidal
endothelial cells do not possess a basement membrane but both fibronectin and
collagen type I are prevalent in the space of Disse, which separates hepatocytes from
sinusoids (Martinez-Hernandez and Amenta 1995), so cells which have an increased
ability to adhere to fibronectin and collagen type I but not laminin (i.e. GI cells), may
exhibit preferential metastasis to the liver rather than bone (Shah, Haddad et al.
1997).
8.4.2 Regulating Integrin Expression
The cell adhesion receptors, integrins, are the largest group of adhesion molecules
(Hynes 2002) and were considered to be the best target for elucidating the pathway
linking PTHrP to cell adhesion, an idea supported by Shen and Falzon’s studies.
Integrin expression was therefore examined in relation to PTHrP expression and
comparisons of endogenous PTHrP and integrin expression revealed a parallel
increase in integrin expression alongside an increase in PTHrP expression (Shen and
Falzon 2003; Shen and Falzon 2003; Shen, Qian et al. 2004; Shen and Falzon 2005) .
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Subsequent manipulation of PTHrP expression (over-expression and silencing)
supported these early findings and several subunits were identified as potential
targets (specifically D1, D3, D5, D6ȕ1 DQGȕ4). The results shown in Chapter 5 also
suggested that PTHrP was able to selectively regulate integrin expression i.e. D6 and
ȕ4 expression was affected in the breast but not the GI cell lines. As D6 combines
ZLWKHLWKHUȕ1RUȕ4 to form a laminin receptor these results are consistent with the
previously described changes in cell adhesion where only breast cancer cell adhesion
to laminin was affected following manipulation of PTHrP.
These findings are also consistent with those described by Shen and Falzon who
examined MCF-7 cell adhesion and only detected an increase in adhesion to laminin
in association with an increase in expression of D6DQGȕ4 expression. Although the
MDAMB231 cells used in the present study also demonstrated changes in adhesion
to collagen type I and fibronectin these results suggest that adhesion to laminin is a
key aspect of PTHrP’s role in breast cancer metastasis to bone (Shen, Qian et al.
2004).
Some of the results described in the present study are comparable with those
previously described in the literature, specifically the increase in adhesion and
integrin expression as a result of PTHrP over-expression. However there are some
disparities. For example Ye et al’s 2001 study used HT29 cells over-expressing
PTHrP and, whereas they demonstrated an increase in adhesion to collagen type I
and no change in adhesion to laminin, they did not detect any change in adhesion to
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fibronectin which is in contrast to the results described here. Ye et al used the same
cDNA encoding PTHrP (-36-136) but measured the increase in PTHrP expression by
the level of immunoreactive PTHrP secreted into the culture medium, the transfected
cells demonstrating an 80% increase in PTHrP secretion compared with vector
control. PTHrP expression in this study was measured by RT-PCR and not PTHrP
secretion and it is therefore not possible to directly compare the fold increase in
PTHrP expression between the two studies (Ye, Seitz et al. 2001).
It may be possible to explain the discrepancy between Ye et al’s study and the
results shown here by differences in experimental protocol, as Ye et al used crystal
violet to quantify cell adhesion compared with MTT uptake used in the present
study. Similarly Shen and Falzon also used a different method to quantify cell
adhesion (alkaline phosphatase activity) and their examination of integrin expression
correlated with their observed changes in cell adhesion which was also demonstrated
here. This therefore suggests that the method used to quantify cell adhesion may not
significantly affect the results obtained.
Although Shen and Falzon used different cell lines to the ones used in the present
study they did use cell lines derived from breast and colon tissue. Therefore, a
similar adhesion profile would be expected, but was not observed. Consequently
these disparities may be indicative of a more general problem in the varied integrin
expression in immortalised cell lines. Kiefer and Farach-Carson noted this
possibility in their 2001 study; using the prostate cancer cell line PC-3 to examine
integrin expression in PC-3 cells they compared their results to the findings from
another group and found different expression levels of certain integrins.
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6SHFLILFDOO\ZKHUH.LHIHUDQG)DUDFK&DUVRQIRXQGFHOOVXUIDFHH[SUHVVLRQRIĮ1ȕ1,
Į2ȕ1DQGĮ3ȕ1 Kostenuik et alIRXQGRQO\ORZH[SUHVVLRQRIĮ1ȕ1DQGĮ3ȕ1. Kiefer
and Farach-Carson attributed these inconsistencies to either “subtle phenotypic
differences” in the different PC3 cell clones used or the different monoclonal
antibodies used in the two studies. If phenotypic differences exist between clones
derived from the same parental cell line then there will certainly be phenotypic
differences between distinct cell lines (Kostenuik, Singh et al. 1997; Kiefer and
Farach-Carson 2001).
Such phenotypic differences are especially relevant when examining integrin
expression as even a small difference in integrin subunit phenotype may significantly
DOWHU WKH DGKHVLRQ SURILOH RI FHOOV GXH WR WKH QXPHURXV LQWHUDFWLRQV WKDW HDFK Į
subunit can have with each E VXEXQLW HJ Į1ȕ1 binds to collagens and laminin
ZKHUHDVĮ4ȕ1 DQGĮ4ȕ7 both bind to fibronectin (Hynes 2002).
8.4.3 PTHrP as a Transcription Factor
In their 2003 review on the intracrine actions of PTHrP, Fiaschi-Taesch and Stewart
suggested a number of possible roles for PTHrP within the nucleus, including a role
as a nuclear export factor for mRNA, whereby PTHrP would shuttle mRNA between
the nucleus and cytoplasm. They also suggested that PTHrP may bind to other
nuclear or cytoplasmic proteins in order to carry out its nuclear actions as well as
indicating that PTHrP may be a transcription factor due to the homology of PTHrP’s
NLS to the NLS of several transcription factors that are known to bind directly to
DNA (e.g. c-jun, c-fos and p53) (Fiaschi-Taesch and Stewart 2003).
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The results described in Chapters 5 and 7 of this study suggest that PTHrP plays a
role in transcriptional regulation of integrins. As both integrin gene and protein
expression were altered following PTHrP silencing and over-expression this suggests
that PTHrP regulates integrin expression at the transcriptional level which is then
translated to similar changes in protein expression. In addition the increases in both
adhesion and integrin expression upon PTHrP over-expression were reversed when
the NLS of PTHrP was deleted, suggesting that PTHrP must locate to the nucleus to
carry out this role.
It was therefore decided to explore the role of PTHrP in integrin transcription by
examining integrin promoter activity. As discussed in Chapter 7 it was not possible
to construct an D2 or D6 reporter vector, however using the D5 vector it was possible
to demonstrate a significant increase in promoter activity in the cell lines over
expressing PTHrP, but not in those cell lines lacking a NLS. This is consistent with
the previous results demonstrating that intranuclear PTHrP increases expression of
specific integrins and in turn, affects cellular adhesion.
To further define the role of PTHrP as a transcription factor a number of additional
studies are required. Transcription factors bind directly to specific sites within the
promoter or enhancer region to regulate transcription; consequently analysing
whether PTHrP directly interacts with the integrin promoter region would help to
conclusively determine the nature of PTHrP’s role in integrin expression.
Employing a DNA footprinting assay or electrophoretic mobility shift assay to
demonstrate that PTHrP binds directly to the integrin promoter region would clarify
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the nature of PTHrP’s role in integrin transcription. Alternatively PTHrP may act
indirectly by regulating a known transcription factor and as the promoter regions of
the majority of integrins have been characterised (e.g. D5 (Birkenmeier, McQuillan
et al. 1991; Nishida, Kitazawa et al. 1997) and D6 (Nishida, Kitazawa et al. 1997)),
investigation of the interaction of PTHrP with transcription factors which bind to
these promoters would be another possible approach.
PTHrP has also been shown to affect different integrin subunits in different cell
types which suggests that PTHrP is able to selectively regulate integrin expression
Similarly, PTHrP isoform expression is selectively regulated by the growth factors
7*)ȕDQG(*)ZKLFK DUH DEOH WR LQFUHDVH H[SUHVVLRQRI WKH37+U3 LVRIRUPV 
141) and (1-139), respectively (Sellers, Luchin et al. 2004).
Alternative splicing of the PTHrP gene results in the transcription of three different
isoforms and varied expression levels have been shown in different cancers. For
example Sellers et al (2004) demonstrated that while PTHrP (1-141) was the only
isoform expressed in normal lung tissue, all three isoforms were detected in adjacent
neoplastic samples suggesting that PTHrP expression is altered during
carcinogenesis. The PTHrP gene contains three different promoters, suggesting a
degree of transcriptional control and a complex regulation of expression. The use of
alternative promoters may therefore allow tissue-specific gene transcription. For
example, Richard et al demonstrated a change in the ratio of promoter-initiated
transcripts in carcinoma samples compared with healthy tissue; the ratio of P1:P2:P3
changed from 3:74:23 to 21:39:40 (Richard, Luchin et al. 2003; Sellers, Luchin et al.
2004).
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Similarly Bouizar et al’s study of PTHrP isoform expression in relation to the
formation of bone metastases in primary breast tumours also examined the usage of
the three promoter sites and found that the P3 promoter was used more frequently in
patients who developed metastases. This study also demonstrated greater expression
of PTHrP (1-139) than (1-141) in breast tumours as well as showing that (1-139)
expression was greater in patients who developed bone metastases compared with
non-metastatic tumours (Bouizar, Spyratos et al. 1999).
During the early stages of this study the breast cancer cell line MDAMB231 induced
to over-express PTHrP was used as a positive control for PTHrP expression. The
cells were obtained from Dr Guise’s laboratory where they had been stably
transfected with cDNA encoding for PTHrP (1-141). During this study despite
demonstrating a marked increase in gene expression there was only a small increase
in adhesion and integrin expression. In comparison, when the same wild-type cell
line was stably transfected with cDNA encoding for PTHrP (1-139) there was not
only a significant increase in integrin expression, but this resulted in a significant
increase in adhesion to the extracellular matrix. These differences may therefore be
indicative of isoform-specific regulation of cell adhesion. For example Bouizar et
al’s study suggested that whereas PTHrP (1-139) played an important role in breast
tumour progression PTHrP (1-141) was less important. Based on their study and the
results presented here it can be hypothesised that each PTHrP isoform may
selectively regulate transcription of different integrin subunits. For example, if
PTHrP (1-139) is expressed at higher levels in breast cancer than the other two
isoforms and it selectively regulates transcription of either D6RUȕ4 this would in turn
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increase adhesion to laminin and thereby aid metastasis to bone (Guise, Yin et al.
2002).
7*)ȕDQG(*)KDYHQRWRQO\EHHQVKRZQWRPRGXODWH37+U3H[SUHVVLRQEXWWKH\
have also been linked with integrin expression. For example Kostenuik et al found
WKDW 7*)ȕ LQFUHDVHV ELQGLQJ RI 3& FHOOV WR D W\SH , FROODJHQRXV PDWUL[ E\
LQFUHDVLQJ LQWHJULQ Į2 expression whilst Adelsman et al stimulated EGF receptor
activation in a breast cancer cell line using EGF and HRGE and revealed an increase
in integrin E1 activity resulting in an increase in cell adhesion and migration. A link
EHWZHHQ(*)7*)ȕ37+U3DQGLQWHJULQH[SUHVVLRQFDQWKXVEHSURSRVHG)LJXUH
,I7*)ȕDQG(*)FDQVHOHFWLYHO\UHJXODWH37+U3H[SUHVVLRQWKLVPD\WKHQ
result in selective regulation of individual integrin subunits. Such a hypothesis could
EH WHVWHGE\VLOHQFLQJ(*)RU7*)ȕDQG WKHQDQDO\VLQJ WKH UHVXOWDQWFKDQJHV LQ
both PTHrP and integrin expression (Kostenuik, Singh et al. 1997; Adelsman,
McCarthy et al. 1999).
Figure 8.2 Tentative model describing the pathway which could lead to tissue-
specific regulation of PTHrP and in turn integrin expression
7*)ȕ(*)
(1-141) (1-139)
Integrin X Integrin Y
(GI?) (Breast?)
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8.5 PTHrP AND THERAPY: ANTIBODY vs. SMALL INTERFERING RNA
Following its initial discovery, several studies targeted PTHrP in an attempt to treat
HHM. For example Kukreja et al used antibodies to block the biological activity of
PTHrP, producing a significant decrease in serum and urine calcium levels as well as
urine cAMP. However, serum calcium levels did not normalise in all animals which
the authors attributed to an insufficient concentration of antibody to fully neutralise
PTHrP activity. In a similar study Talon et al also used antibodies to neutralise the
effects of PTHrP in vivo and following an initial study found it necessary to increase
the frequency of the treatments in order to induce a response. Both of these studies
support the results presented here where only a modest decrease in PTHrP activity
was induced by the anti-PTHrP antibodies (Kukreja, Shrevin et al. 1988; Talon,
Lindner et al. 2005). Several other in vivo studies using anti-PTHrP agents have
been described including antibody based approaches (Guise, Yin et al. 1996;
Massfelder, Lang et al. 2004) and a recent study published by Chugai
Pharmaceutical Company described the effective use of an anti-PTHrP monoclonal
in a human xenograft model of bone metastasis where the antibody, directed against
PTHrP (1-34), reduced osteolytic bone metastasis. This led the authors to conclude
that the anti-PTHrP antibody could be used as an effective new treatment for bone
metastasis in breast cancer (Saito, Tsunenari et al. 2005).
Other more novel approaches have also been used. For example, nucleotide
analogues of guanine have been used to target PTHrP (Gallwitz, Guise et al. 2002)
and PTHrP peptides have also been used to vaccinate mice against PTHrP. Another
alternative approach was described by Arima et al who used PTHrP (102-111) or
(110-119) peptides to generate cancer-reactive cytotoxic T lymphocytes from
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peripheral blood mononuclear cells derived from patients with different tumour
types, including gastric, colon and renal cancer. The authors suggested that PTHrP
could be targeted in specific immunotherapy (Arima, Matsueda et al. 2005).
However, despite numerous in vivo studies there have yet to be any human clinical
trials with an anti-PTHrP agent and it remains to be seen whether an effective anti-
PTHrP therapeutic can be developed.
RNAi is a relatively new discovery; however, siRNA have been shown to be
powerful tools for the induction of posttranscriptional gene silencing. Use of the
PTHrP siRNA described in this thesis resulted in significant reduction in
proliferation, apoptosis and cell adhesion. In all cases the effects were greater than
those observed with neutralising antibodies. These results therefore suggest that
siRNA could be an effective therapeutic tool. As RNAi is a relatively new field the
mechanisms of action are being further investigated and continually deduced so it is
therefore unlikely that the therapeutic potential of siRNA has yet been fully
exploited. Indeed, although a number of weaknesses associated with siRNA have
been identified, as many of the problems are similar to those encountered in anti-
sense technology (e.g. uptake) most have been addressed and quickly overcome. For
instance siRNAs have a relatively short period of action and unmodified duplex
siRNA are quickly degraded by nucleases within the body and filtered through the
kidneys (Lieberman, Song et al. 2003) but cationic polymers and liposomes have
been shown to increase siRNA half-life in vivo and chemical modifications to siRNA
have been shown to prevent nuclease degradation. In general the RNAi process is
more efficient than anti-sense; for example, the RISC complex is recycled thereby
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allowing it to target further RNA molecules and lower concentrations are needed in
order to induce an effective response (Kurreck 2004).
The use of RNAi for therapeutic purposes is still in its infancy however there are a
number of promising RNAi-based therapeutics currently in development. The first
RNAi-based drug filed with the US Food and Drug Administration for clinical trials
was Cand5, developed by Acuity Pharmaceuticals to treat age-related macular
degeneration (a form of blindness). Cand5 decreases VEGF in human retinal
pigment epithelial cells thereby reducing the growth and leakage of abnormal blood
vessels. It has been successfully used in a primate model of age-related macular
degeneration (Tolention, Brucker et al. 2004) and with Phase I trials completed,
Phase II trials began early in 2006 (www.acuitypharma.com). To date the trial has
produced positive results and Cand5 has shown “dose dependent efficacy without
discernable adverse effects” (http://www.acuitypharma.com/press/release13.pdf).
Other companies are using RNAi to target diseases such as HIV
(www.internationaltherapeutics.com; www.benitec.com.au), Parkinson’s disease
(www.alnylam.com) and diabetes/obesity (www.benitec.com.au, www.cytrx.com).
A number of companies are also using RNAi to target cancer. For example Atugen
AG are exploring the use of siRNA to target hepatocellular, prostate, pancreatic and
lung cancer (www.atugen.com). Since PTHrP is a mitogen and an anti-apoptotic
factor, silencing PTHrP could also be used to both reduce tumour growth and induce
apoptosis as part of a multi-pronged attack.
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However, the transient effects of siRNA result in gene knock-down rather than
knock-out. Consequently, combining a PTHrP siRNA with another established
treatment designed to kill cells may produce a more effective, synergistic effect. For
example Stoeltzing et al used a novel inhibitor of D5E1 (ATN-161) in conjunction
with continuous 5-FU infusion and was able to significantly reduce the size and
number of colorectal liver metastases in mice, as well as increasing apoptosis and
overall survival. Neither ATN-161 or 5-FU achieved this individually (Stoeltzing,
Liu et al. 2003).
A selective but effective delivery mechanism will also prove vital; the success of
Cand5 can be attributed to the local delivery mechanism whereby it is injected
directly into the eye.
8.6 FUTURE RESEARCH DIRECTIONS
An increase in transcription of the D5 subunit was demonstrated but time constraints
prevented the construction of a reporter vector containing the promoter region of the
D6 subunit. Demonstrating an increase in promoter activity of the D6 subunit in
breast but not colon cell lines would add weight to the suggestion that PTHrP is able
to selectively regulate integrin expression and thereby adhesion. As such exploring
the transcriptional activity of this subunit in the PTHrP over-expressing cell lines
would provide further evidence for the tissue-specific effects of PTHrP. Similarly
co-transfecting cells with the reporter vectors and PTHrP siRNA would also support
the previous results regarding the role of PTHrP in integrin transcription.
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In order to determine if PTHrP is a transcription factor it would first be necessary to
isolate the region responsible for mediating the effects of PTHrP on transcription by
cloning smaller sections of the promoter region into the reporter vector. It would
then be possible to conduct a DNA footprinting assay to determine if PTHrP
interacts directly with that region.
The possibility that the tissue-specific effects of PTHrP are mediated via the three
different PTHrP isoforms could be explored by not only examining isoform
expression in a panel of tumour-derived cell lines from different tissues and then
comparing this with the endogenous levels of integrin expression but also by
VWLPXODWLQJFHOOVZLWKHLWKHU(*)RU7*)ȕDQGREVHUYLQJDQ\UHVXOWDQWFKDQJHVLQ
isoform expression.
Similarly transfecting cells encoding for PTHrP (1-141) and (1-173) would also
allow a further exploration of the PTHrP’s regulation of cell adhesion. Alternatively
siRNA could be used to selectively silence each of the three isofoms. The PTHrP
siRNAs used here were targeted against exon VI as this encodes for all three PTHrP
isoforms. Targeting siRNA against exons VII, IX and VIII would allow the
silencing of the (1-139), (1-141) and (1-173) isoforms, respectively, and make it
possible to elucidate any isoform specific activities of PTHrP (Figure 8.3).
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Figure 8.3 Gene structure of PTHrP, highlighting the different exons which
could be silenced to selectively decrease isoform expression
Unfortunately it would not be possible to examine protein expression of the different
isoforms due to the small differences in length i.e. there is only a two amino acid
difference in length between the (1-139) and (1-141) isoforms, however it would be
hoped that examination of gene expression would provide sufficient insight.
Reports from different groups have used the same cell lines but obtained small yet
significant differences compared with previously published data (Kiefer and Farach-
Carson 2001; Maioli and Fortino 2004). Such reports imply phenotypic differences
between cell lines and suggest that these groups are using different clonal
populations of the same cell line. These different populations have likely arisen after
years of propagation following immortalisation. As such, the use of immortalised
cell lines may be an unreliable tool when investigating protein function and
VLJQDOOLQJ SDWKZD\V  &RQVHTXHQWO\ FRQWUDVWLQJ (*)7*)ȕ 37+U3 DQG LQWHJULQ
expression in tumour and normal tissue may provide a more accurate picture of the
role of these proteins in tumour progression as well as an indication of a possible
pathway connecting these proteins. The use a tissue array would allow us to
LQYHVWLJDWHZKHWKHU H[SUHVVLRQRI(*) 7*)ȕ RU WKH LQWHJULQ VXEXQLWV FRUUHODWHV
with that of PTHrP.
P1 P2 P3 +1 ATG 139 aa 173 aa 141aa
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The results described here show for the first time that an siRNA can be used
effectively to silence PTHrP expression. RNAi is an ever expanding field and with
several siRNA currently being tested in clinical trials there is increasing evidence for
their potential as effective therapeutic agents. As such an in vivo study using the
PTHrP siRNA would allow the examination of the therapeutic potential of a PTHrP
siRNA as an inhibitor of metastasis and tumour growth. Increasing the length of the
PTHrP siRNA to 27nt may also increase the potency of the PTHrP siRNA (Kim,
Behlke et al. 2005) and should consequently be tested in vitro prior to embarking on
such a study.
In order to establish if the composition of bone and liver helps to dictate which
tumour types metastasise to which organs it would be necessary to use an invasion
assay using a chemoattractant (e.g. collagen, fibronectin or laminin) and examining
whether the cells invade into the Matrigel and also whether regulation of PTHrP
expression (i.e. knock-in or knock-down) affects any resulting invasion.
8.7 SUMMARY
The data presented here demonstrate that PTHrP is not only a mitogen and anti-
apoptotic factor but is also a key protein in facilitating cell adhesion. Additionally it
has been shown that this may be mediated via changes in integrin expression and
more importantly has demonstrated the mechanism by which this occurs - through
transcriptional activation of the cell adhesion molecules integrins.
Chapter 9:
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10.1 APPENDIX 1
DNA sequence for integrin subunit D2
(Accession Number L24121)
GGTTTCAGCAATGTGCTGGAAATTTGTGGCCAAACTTTTGGATAAAACAT
AAGATTCAGACAAGAAAAATTAATATCCTATTTCTTAGGTTTTTAACTAA
AAATCTCGGATATAGAATGTTCTCTTTCCAGATGTGAGACTGAAATAATG
GAAGAAAATGGTCACAGTCTATGTCACGGTGTAATGTAGACAGGGAGAG
TCACAAGTGCATGTATGGGCTCTCAGCCTTTTCTCTGGCCTTGAAGTTAA
TCTCCTAAACTCAGTCATTAAATCAGCTCTTAATTATCTCGGAGGAGAGG
AAGTAATGATGATTTCTCTCTCTCTGTCTCTCTGTCACACACACACACAC
ACACACACAGCTCTTGCAGCAGGTATTGCTTAAATATCACCTTGGATAAT
CATAACTTGTGAGCAGATCTTCTTTCCTGATGAGTTAGTTTCTAACCTGGT
CATTCTGCGCTTATTTTTGTCCCTTTCTCCACCCACTTAGGAAAAACAGAG
AAAGGGACGCACCGCGCAGCCCCTAGGCACTGTGGTTTAGGGCTAGTGC
CCTCGGACCCCGCTGCCAGGAGCCGGGCGCTGCCAAGGGCTGCGGAGGG
GCCACGTTCTCCCGGGGACTGGGGCATCTCCTGCGTACTGGCGACAGGCT
CGCGGGGGCGGAGTGGTGCCAGGGCGGGCGCTCGCCCGTCCGGATATGC
CCACCCGTCCCGTCCAGGGCAGGAAAGCCTGCCAGGGCGCCATCCCCAT
CCCCACCGCCTCCAGGCTGCCGGGGCTGGGCCGCTGTACGGGAGCCAAG
GTCGGTGCCCCGCGTGTGGACGAGCCGAGGTGCAGCCCGCGGGGCCGCA
GGGCCGGGGTGGGGCGGGCGCGGCCGGAGCAGATCCGGTGTTTGCGGAA
TCAGGAGGGGCGGGCCGGGGCGGGCCCTCGGCGCTGCAGGAGCTGCCCA
GAAACTTTTCCCTGCTCTCACCGGGCGGGGGAGAGAAGCCCTCTGGACA
GCTTCTAGAGTGTGCAGGTTCTCGTATCCCTCGGCCAAGGGTATCCTCTG
CAAACCTCTGCAAACCCAGCGCAACTACCGTCCCCCCGTCAGACCCAGG
ATGGGGCCAGAACGGACAGGGGCCGCGCCGCTGCCGCTGCTGCTGGTGG
TAGCGCTCAGTCAAGGTAAGCGGGGATTTC
10.2 APPENDIX 2
DNA sequence for integrin subunit D5
(Accession Number U48214)
GTTTACACCGATTAGGAGCTGAAGGTTTGGGTCCCTTTCGAAGACTTTCC
ACCACCACCACCACCTCTCACAATTCTCCAGGTTTGTAGGAACCCGGCCA
GTTTAATCAAGCAGGTACTGAGGGGCCAGCCACTCGCAGGCTTTTGGTCA
ACTGTCAGATCCAAGGAAGGGGCTCAGCAGAGGTTTACATACCCTAGGA
CCAAGAAGGGGGCAAACTGGAGGAGAATCCTCCTGATGAATGACCCCAA
ACTCCTGGGTTTTCAATACTGAAGAAGCTTGGAGGAGGAAGCAGCGGAA
CTTGAGGAGCCCGTGTAGGTCCTCTAGCAAGCTGACTGCGAACGCTGTCT
CTGTACCTCAACTGTTGTGTCCCAAATCCAGCTGGCCAGAACCCAGGCAC
CCGGCGGCCCCGGAAGGCAAGGGGGAATCCCAGTTGGCCGGACGCCAG
AGGAGTCTCCTGTCTCTTTAGACCCCAAAGTCTCCTCCCTAAAGCACTGA
GGGAGACCCCACACACATATACAGGCTTCCTCCGCCCACCAGAGGTGAT
TCCTTTCCTCATTAGGAAATTCTCCGCTCCCTTTTCCGACTCGTTTTCCGA
GCGTTTACGTTGTACATCTGGAAAGGAATGGGGAGGAAGGAGGGGGAA
242
GCAGAGAGGAGGGGGAAGAACCCAAACCCGCCCAGTCTAACCCAGTCC
AGACAACCGGCTTCCAGCTGGGGCTGGGGAAAGGGGGTTGGAGGGGTGC
GCCCCCCCCCCACGCCCCTTAGGGGTGGGGGACGCGGGCTCAGAGTTTC
CAGGGACCCAGGAATGCCCCCCCGCCAGCCCCCTCGGCAGGCGGGGGGA
GGGCTCAGCCGGGAGTTTGGCAAACTCCTCCCCGCGTTGAGTCATTCGCC
TCTGGGAGGTTTAGGAAGCGGCTCCGGGTCGGTGGCCCCAGGACAGGGA
AGAGCGGGCGCT
10.3 APPENDIX 3
DNA sequence for integrin subunit D6
(Accession Number AF078694)
CCCGGGTTAAGAACCCTGCAGGATAAGGTTGCCCCTAGGGCCAACACCT
CACTGGAGCCCCGCCTCATGTCCTGGAGGCAGGAGCCTTCATGCCACCTA
CACAGAACTCGGAGCTGTCTCTTGGCCCAGCAGTTCTCCCCACAACTAGT
TCTGAAAGTCCGGGGCTAGGAAAGAACGGCATCGTCGCCTGAGCTCCTG
GCGCCACTTTAAACAACCCATCCTTGACTTGCGTGACTTCTTCCACAAGC
TCTCCTGGTCACCTGGGCAAAATCCTAGGTGATCTGGGGACAAGGCGGA
ACTTCGGTTTTCTGATCTGCAAAAAGAAACACCTACCTCATAGGACTGTT
AGGATGAATTGAGGTAATGGCTGGGTTGTGTACATTATACAGCACTATCA
AGGTGTGCGCTGTGATCATTTTGAGGGTTGTTAGGTGTTTGAGGACCCAG
AACAGTCTACACAGCTGTAGTCCCCAAGTGTTGGGCACGCCTTAAGCGCT
CCATAAACACCTGTAGAAATGAATGAATGACGTATGCATCTGCACGTGG
GCCCACATCTGCAAGAACAGGCTGCTCAGGCCATGAGGCCCGGTGCATC
ACCTGCACTTCTCTTTATAACGGGTAGTAAAGTCTCCCTCGCTCTGTGCTA
CTCGGCAACCACAATTCTGTCCACAGAGGGCGGCGCAGTGGGGCTGCTT
CGCCGCGAGCTCGCCTCCGGGGCTCCCACGTCGTGGCTTCCGGGCAGGTA
CCGGGCAGCTGGAGACGCCAGAGCCGGCGGGTAAGGTGCGGGCGGTGC
GCCGGGCCGCGGGCGCGCAAGGAGGGGCGAGAGGGTGGGGAGGGGCGG
GGCCGGCGTCCTCGTCACTTGATAAAACGCCTGCGAGTCTCCAGAGAAC
AACGGGCTCATTCAGCGGTCGCGAGCTGCCCGCGAGGGGGAGCGGCCGG
ACGGAGAGCGCGACCCGTCCCGGG
